Understanding and managing fear of cancer recurrence by Wal, M.A. van de
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/173266
 
 
 
Please be advised that this information was generated on 2018-07-07 and may be subject to
change.
Understanding and managing fear of cancer recurrence 
Marieke van de Wal 2017
Understanding 
and managing 
fear of cancer 
recurrence
Marieke van de Wal
Understanding and Managing
Fear of Cancer Recurrence
Marieke van de Wal
The work presented in this thesis was carried out within the Radboud Institute for Health 
Sciences (RIHS), at the Department of Medical Psychology of the Radboud university 
medical center in Nijmegen, the Netherlands.
This PhD research was funded by a grant from the Dutch Cancer Society.
ISBN: 978-94-92380-37-1
Cover design: M.A. van de Wal / istockphoto.com
Design and printing: Optima Grafische Communicatie, Rotterdam
Copyright © 2017 M.A. van de Wal
All rights reserved.
Understanding and Managing
Fear of Cancer Recurrence
Proefschrift
ter verkrijging van de graad van doctor
aan de Radboud Universiteit Nijmegen
op gezag van de rector magnificus prof. dr. J.H.J.M. van Krieken,
volgens besluit van het college van decanen
in het openbaar te verdedigen op maandag 12 juni 2017
om 12.30 uur precies
door
Maria Antonia van de Wal
geboren op 30 augustus 1988 
te Tilburg
Promotoren
Prof. dr. J.B. Prins
Prof. dr. A.E.M. Speckens
Copromotoren
Dr. B. Thewes
Dr. M.F.M. Gielissen
Manuscriptcommissie
Prof. dr. M.W.G. Nijhuis-van der Sanden (voorzitter)
Prof. dr. W.R. Gerritsen
Prof. dr. G.M. Humphris (University of St Andrews, Verenigd Koninkrijk)
“My philosophy is that worrying means you suffer twice.”
– Newt Scamander (2016).
TAble of ConTenTs
1. General introduction 11
PART I: Understanding FCR in cancer survivors and partners.
2. Does fCR differ between cancer types? 29
Does Fear of Cancer Recurrence Differ Between Cancer Types? A Study 
From the Population-based PROFILES Registry.
Psycho-Oncology (2016).
3. fCR in prostate cancer survivors 45
Fear of Cancer Recurrence in Prostate Cancer Survivors.
Acta Oncologica (2016).
4. fCR in partners of prostate cancer survivors 61
Fear of Cancer Recurrence: a Significant Concern Among Partners of 
Prostate Cancer Survivors.
Psycho-Oncology (2017).
PART II: Managing FCR in cancer survivors.
5. sWoRD: trial design 77
Study Protocol of The SWORD-study: a Randomised Controlled Trial
Comparing Combined Online and Face-to-face Cognitive Behaviour
Therapy versus Treatment as Usual in Managing Fear of Cancer
Recurrence.
BMC Psychology (2015).
6. sWoRD: case study 99
Cognitive Behavior Therapy for Fear of Cancer Recurrence - a Case 
Study.
Revised & resubmitted.
7. sWoRD: effect study 127
Efficacy of Blended Cognitive Behavior Therapy for High Fear of 
Recurrence in Breast, Prostate and Colorectal Cancer Survivors; the 
SWORD-study, a Randomized Controlled Trial.
Journal of Clinical Oncology (2017).
8. General Discussion 151
9. summary 175
English summary
Dutch summary
10. Appendices 187
List of publications 189
PhD Portfolio 195
Dankwoord 201
Curriculum vitae 207

 CHAPTER 1
General Introduction
General introduction
13
1
Improved methods for early cancer detection and innovations in cancer treatment have 
led to increasing numbers of people surviving this disease. Over the past 20 years, the 
5-year survival rate of adult cancers has increased and it is anticipated that by 2020 there 
will be 666.000 people living with a diagnosis of cancer in the Netherlands [1]. One of 
the most common long-term problems cancer survivors face is fear of cancer recurrence 
(FCR). In a recent study of unmet needs amongst Dutch cancer survivors FCR was found 
to be the most frequently reported disease-related concern, with 23% reporting FCR to 
be their main concern [2]. International studies report similar numbers, whereby more 
than 1 out of 5 patients reports to have an unmet need for professional help with FCR 
[3-5].
PART I. UnDeRsTAnDInG fCR In CAnCeR sURvIvoRs AnD PARTneRs.
Defining fear of cancer recurrence
FCR was initially defined by Vickberg (2003) as “the fear that the cancer will return or 
progress in the same organ or in another part of the body” [6]. Given that all cancers 
are associated with a chance of recurrence, almost everyone diagnosed with cancer will 
at some point experience FCR [3]. FCR is a concern which ranges on a continuum from 
mild and transitory to debilitating and persistent. Whilst a consensus definition on what 
constitutes clinical or pathological FCR is still under development [7], the current litera-
ture variably describes high, severe or clinical FCR to indicate survivors who experience 
FCR at the upper range of the continuum. When referring to studies conducted in this 
thesis, we use the words “high” and “low” FCR. Quotation marks are used when referring 
to terms used by other authors to indicate FCR severity.
In itself, FCR is not pathological and can be adaptive in certain situations. FCR prompts 
appropriate self-protective responses, such as staying alert for early signs of recurrence, 
positive lifestyle adjustment, and it promotes adherence to medical regimes [3,8-9]. 
FCR becomes maladaptive when it starts to interfere with normal functioning. For 
instance, highly fearful breast cancer survivors may perform breast self-exams multiple 
times a day or fearful prostate cancer survivors might avoid testing for prostate-cancer 
specific antigen (PSA) due to FCR. So, while it is normal for persons treated for cancer to 
experience some FCR, a subgroup of patients experience FCR as a chronic, severe and 
debilitating problem that interferes with daily activities and significantly impacts quality 
of life [3,8,10,11-13]. Not surprisingly, FCR is also referred to as the “Damocles Syndrome” 
by survivors, because worrying about a recurrence “hangs over the heads of survivors and 
their families like a sword of Damocles for the rest of their lives” (figure 1) [14].
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figure 1. Patient experiences with FCR. Excerpts from Mutsaers et al., 2016 [15] and Thewes et al., 2016 
[16].
Assessment of fear of cancer recurrence
Thewes et al., (2012) provided a systematic review on all current multi-item self-report 
questionnaires and subscales that assess FCR in cancer survivors. A total of 20 instru-
ments were identified [17]. In a later review by Simard et al.,(2013) an additional 13 FCR 
instruments were identified resulting in 32 available multi-item questionnaires that can 
be subdivided in: FCR-specific subscales within a quality of life (or needs) questionnaire 
(n=11), brief FCR questionnaires (≤10 items, n=17) and longer FCR questionnaires (>10 
items, n=4) of which three have developed short forms useful for screening [3,17]. Ad-
ditionally, seven studies have assessed FCR with single items in longer questionnaires 
[3]. Both reviews were published a few years ago and in recently more questionnaires 
have emerged, such as the 8-item Cancer Worry Scale that was validated by our research 
group [18]. Relatively few of the identified measures have data on both internal and 
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external forms of validity, and only a few questionnaires have information available on 
their psychometrics properties [3,17]. There is no consensus on which questionnaire is 
best to assess FCR and no gold-standard measure of FCR exists.
Furthermore, few efforts have been made to define clinical cut-off scores for FCR ques-
tionnaires. The Fear of Cancer Recurrence Inventory (FCRI) and Cancer Worry Scale (CWS) 
are the only scales that have determined a cut-off point to differentiate between low and 
high levels of FCR in cancer patients [19,20]. Whereas the CWS was validated against a 
two-item FCR questionnaire (CAS), the FCRI established its clinical cut-off scores using a 
face-to-face semi-structured interview of FCR as a gold-standard measure [17,19], which 
is the preferred method. Cut-off points for the FCRI and CWS were thereby established 
against non-validated gold-standard instruments. In short, most researchers that aim 
to differentiate between high and low FCR, do this by: 1) using the CWS or FCRI and 
their established cut-off scores; 2) by using statistical considerations taking into account 
the distributional characteristics of the measure, or; 3) use theoretical considerations to 
guide their choice of cut-off score [9].
Structured psychiatric interviews are now the diagnostic gold standard in both 
research and daily clinical work in order to diagnose patients with a DSM-V disorder. 
In 2015 a clinical interview for FCR was published. This structured interview for FCR, 
the SI-FCR, is the first to introduce clinical judgment in classifying high versus low FCR 
and diagnosing patients with clinical FCR [21]. As it was published very recently, it has 
only been used in one study and very little information is available on its psychometric 
properties and usefulness in clinical practice.
Theoretical models of fear of cancer recurrence
Theoretical models offer unique and informative perspectives on causal and perpetuat-
ing factors of FCR and pathogenic mechanisms that may form targets for treatment. A 
review by Fardell et al., (2016) identified six different ways to understand FCR, of which 
Lee-Jones’s adaptation of the Self-Regulation of Illness or Common Sense Model is the 
most comprehensively evaluated one. Other conceptual models identified in the review 
had only limited evidence supporting their application to FCR [22].
The model by Lee-Jones (1997) is a FCR-specific formulation of the Self-regulation of 
illness model (SRI)[8]. According to the SRI an illness representation (or belief ) is activated 
when an individual is confronted with a serious health threat, such as cancer. This illness 
representation consists of two parallel motivational processing systems (cognitive and 
emotional) that trigger an individual’s emotional response. In this thesis, we propose 
an adapted version of FCR-specific model (figure2)[23]. According to this model FCR is 
a distressing emotion maintained by dysfunctional cognitive patterns, such as recurring 
unhelpful thoughts, negative beliefs, intrusive images, or persistent rumination [8,23]. 
These cognitions cause a person to interpret events or internal stimuli as potentially 
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threatening to their health and wellbeing, thereby triggering FCR. Behavioral strategies 
that may provide short-term alleviation of fear, such as avoidance, or safety-seeking 
behaviors, may actually sustain FCR in the end by preventing changes in cognitive ap-
praisal and/or by providing further exposure to triggers of FCR. Cognitions, appraisal of 
health outcomes, coping responses and exposure to triggers are affected by self and 
social context.
figure 2. FCR model.
This theoretical model of FCR shares some similarities with the Health Anxiety Model by 
Salkovskis (2001) [24]. For instance, both conceptualizations share the elements of fear 
producing stimuli and behavioral or emotional consequences of this fear. However, while 
to date there is not a lot of data on overlap between FCR and psychiatric conditions, first 
evidence seems to suggest health anxiety is not identical to FCR. Previous studies have 
shown that cancer survivors with high FCR report intrusive thoughts and symptoms that 
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are specifically related to the cancer experience. Furthermore, they do not worry about 
their general health but tend to worry specifically about the possibility of a recurrence 
[21,25]. While some overlap has been found between FCR and DSM anxiety disorders, 
only a minority of those with high FCR met the criteria for hypochondriasis, illness 
anxiety disorder or generalized anxiety disorder [21,25,26-27]. However, these findings 
also suggest that for some patients their health worries are more widespread and not 
just cancer-related.
In the DSM-V, the condition hypochondriasis has been replaced with two new catego-
ries: the somatic symptom disorder and the illness anxiety disorder. In simplified terms, 
core features of both DSM-V categories show some overlap with symptoms as seen in 
patients with FCR. For instance, patients with the somatic symptom disorder tend to 
have very high levels of worry about illness whereby there is often a misinterpretation 
of bodily symptoms. The Illness anxiety disorder is characterized by high levels of worry 
about health and the performance of excessive health-related behaviors or maladaptive 
avoidance [28]. Both features can also be present in those with high FCR. FCR therefore 
appears to be related to some psychiatric conditions, sharing a.o. the enhanced bodily 
awareness and health worry. However, the main distinctive feature between FCR and 
above mentioned conditions is that FCR has a strong realistic base: the threat of a recur-
rence is an undeniable real threat for persons who have had cancer [9].
fear of cancer recurrence: scope of the problem
Due to lack of consensus on a definition of FCR, a multitude of screening measures for 
FCR, absence of an optimal cut-off point to estimate “clinical” or “high” FCR, there is wide 
variability in reported prevalence [3,29]. Consequently, the differentiation between low 
and high FCR can be rather challenging. Overall, the current literature seems to sug-
gest that moderate to high levels of FCR – defined by scores above established cut-off 
points on FCR questionnaires - affect approximately 49% of cancer survivors with mixed 
diagnosis [3,19,25,26,27,29], and up to 70% of those in the more vulnerable groups (e.g. 
young female breast cancer survivors) [12,30-31]. In studies amongst Dutch breast and 
colorectal cancer survivors, the prevalence of moderate to high FCR has been reported 
to be slightly lower; 31% and 38% respectively [20,32].
Partners, informal caregivers and significant others may also fear a potential disease 
recurrence, but as FCR has often been regarded as a patient concern it remains an 
understudied and underserved problem in partners. The few studies that did address 
FCR in partners or caregivers found that FCR was as much a concern for them as for the 
cancer survivor himself [33-35] and in order to get a better understanding of the scope 
of the problem, more research is needed.
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High levels of fear of cancer recurrence
Reported characteristics of high FCR are: chronic worry, rumination, excessive bodily-
checking and/or reassurance seeking, avoidance of cancer reminders, the presence of 
intrusive thoughts or images and the limited ability to plan future activities [3,13,29,36-
37]. Furthermore, high FCR is associated with increased psychological distress, a poorer 
quality of life, functioning impairment and stress response symptoms [3,11,13,37].
FCR can also affect the delivery of medical care. There is evidence that cancer sur-
vivors with high FCR report more unmet supportive care needs [11,38-39], wonder if 
their medical follow-up is carried out thoroughly enough [40], are more likely to refuse 
discharge from follow-up [41] and express poorer health care satisfaction [42]. More-
over, they may have increased use of healthcare services, such as: more frequent use of 
alternative complementary medicine, higher medicine intake, higher number of visits to 
the general practitioner and more frequent visits to the emergency room [3,12,13,36]. 
Furthermore, high FCR has also been associated with lower activity levels and smoking 
behavior in colorectal cancer survivors and smoking behavior in premenopausal breast 
cancer patients: two behaviors that may actually increase the objective risk for a recur-
rence [43-44].
When no intervention is offered, high FCR tends to be stable over time. A review by 
Simard et al. found that 18 (out of 22) longitudinal studies did not find a spontaneous 
change of FCR over time (range 3 months – 6 years) [3]. For instance, in a sample of long-
term testicular cancer survivors – on average 11 years post diagnosis - where objective 
risk of recurrence is relatively low, one fourth (24%) reported that FCR still bothered 
them ‘quite a bit ’and 7% reported that FCR had bothered them ‘very much’ the past 
week [45]. A longitudinal study by Mehnert et al., (2013) monitored FCR during a 1-year 
period and reported similar percentages of “low”(15%), “moderate”(67%) and “high” 
(18%) fearful cancer survivors across multiple time points [46].
Demographic and medical correlates of fear of cancer recurrence
Studies on predictive factors of FCR have provided inconclusive results [3,11-13]. Regard-
ing demographics, there is consistent evidence that younger survivors report more FCR, 
whereas inconsistent evidence has been found for the relationship between FCR and 
education, marital status, ethnicity and income [3,11-13]. Despite the high prevalence 
of FCR in young women, gender’s association with FCR is also still inconclusive [12,30]. 
Studies found no evidence that family-history of cancer or psychiatric history is associ-
ated with FCR [45-47], whereas there is evidence to suggest a positive relationship be-
tween FCR and greater use of complementary and alternative medicine [48,49]. Finally, 
there is limited evidence that objective disease markers (e.g. disease stage, cancer type, 
time since diagnosis) or treatment-related variables play a role in FCR, whereas more 
subjective factors, such as the presence of physical symptoms (e.g. fatigue, pain, somatic 
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side-effects) has more consistently been associated with higher FCR [3,11-13]. Therefore, 
instead of focusing on the objective disease characteristics and behavioral correlates 
of FCR, more recent studies have also addressed the subjective disease experience. For 
instance, it was found that illness representations, such as symptom attribution and 
perceived consequences were more strongly associated with FCR than objective disease 
characteristics [50].
PART II: MAnAGInG feAR of CAnCeR ReCURRenCe In CAnCeR sURvIvoRs.
Despite being a well-documented problem in clinical practice and remaining one of 
the most common unmet needs by cancer survivors [2,4], very few interventions for 
FCR have been proposed. Previous research has shown that over 40% of psychosocial 
staff and clinical staff find helping patients with FCR challenging [51]. One of the main 
reasons why patients with high FCR are not referred for psychosocial care is a lack of 
evidence-based psychological therapies. Psychosocial workers and therapists employ 
multiple therapy strategies and approaches based on their own experience and prefer-
ence, thereby lacking consensus in their approach [51]. Evidence-based strategies to 
manage FCR are therefore urgently needed.
Psychosocial interventions for cancer survivors
Meta-analyses and literature reviews have found that psychosocial face-to-face inter-
ventions for cancer survivors have beneficial effects on anxiety, depression, emotional 
distress and quality of life [52-54]. Effect sizes were significantly higher in studies that 
preselected participants with heightened problem scores (e.g. distress), with a longer 
therapy duration (≥12 weeks) and an individual (medium effects) rather than group 
format (small-to-medium effects) [52-54]. While none of these interventions addressed 
FCR, psychological therapies targeting anxiety demonstrated effect sizes ranging from 
0.24 (“small”) to >1.00 (“large”). CBT does not only seem to be effective, but cost-effective 
as well. A recent systematic review by Dieng et al., (2016) concluded that CBT is the best 
value for money intervention for psychosocial problems in cancer survivors [55].
eHealth and blended therapy
Although face-to-face CBT is effective, it has some limitations. CBT is time-consuming, 
costly, resource intensive and health care institutions often do not have enough person-
nel capacity to treat all those with unmet needs using face-to-face therapy. Furthermore, 
it requires frequent hospital visits from patients and is associated with indirect costs (e.g. 
time off work, away from caregiver roles, travel costs) [56]. A possible solution to over-
come these problems is the use of internet health interventions (eHealth). Numerous 
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studies have investigated the efficacy of eHealth interventions for healthy individuals 
or those with a chronic (somatic) condition. Literature reviews suggest efficacy/cost-
effectiveness of internet-delivered interventions in achieving behavioral change or 
reducing symptoms such as anxiety or depression [57-59], whereby online delivered 
cognitive behavior therapy is one of the most promising interventions [60-61].
There is some evidence that eHealth interventions are able to improve the psycho-
logical wellbeing in cancer survivors. However, while feasible and acceptable to users, 
early studies found mixed evidence for its effectiveness [62]. A recently conducted RCT 
reported small-to-moderate effects of an unguided self-management intervention on 
distress in breast cancer survivors [63]. This study demonstrated a moderate effect size 
on FCR as well. Most systematic reviews found that online therapies are more effective 
when guidance from a care provider is included [64-65]. Therefore, blended therapy may 
be a good approach.
Blended therapy is a combination of online and face-to-face therapy. Online and 
offline components play an equally important role when they are integrated and in-
terconnected with each other [66]. For instance, some patient-therapist consultations 
may take place via (video) chat rather than face-to-face only. Activities on the website 
make it possible for patients to facilitate skill acquisition and learning between sessions, 
and therapists can monitor therapy progress online. Delivering parts of therapy over the 
internet (e.g. via email or videoconferencing) seems to result in a similar patient therapy 
satisfaction and working alliance as regular face-to-face therapy does [67]. Blended 
therapy has advantages of both online and offline guidance and treatment, which 
makes it a promising option that capitalizes on the advantages of both face-to-face-
therapy and eHealth, yet it is less resource intense to deliver than face-to-face therapy.
Why is a specific intervention for fear of cancer recurrence needed?
Psychotherapeutic treatment of realistic problems does not have many predecessors 
in therapeutic literature. Most traditional CBT interventions have been developed for 
neurotic or psychosomatic disorders and hold the premise that highly anxious individu-
als have unrealistic beliefs or irrational concerns [9]. However, cancer, with its related 
symptoms, treatment side effects and realistic threat of recurrence, is a disease that 
may cause functional impairment disability and even death. For cancer survivors, FCR 
is a very realistic threat and their FCR related thoughts are not irrational. Thus, many 
psychosocial professionals may find that classic CBT techniques are inadequate or inap-
propriate for patients with realistic fears related to their disease, such as FCR. Secondly, 
given the realistic nature of FCR and the fact that normal levels of FCR are adaptive, the 
aim of CBT for cancer survivors is not to eliminate all worries or concerns, but rather to 
reduce FCR severity to a level that no longer causes distress or impairs daily functioning. 
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Thereby, acceptance of uncertainty also plays a role and acceptance based approach 
should be incorporated in CBT for FCR.
existing interventions for fear of cancer recurrence
Several trials of FCR interventions are being conducted by research groups in Australia 
[68,69], Canada [70], Germany [71], the UK [72] and the Netherlands [73]. Three of them 
have already published their first results. The first is a controlled trial by Herschbach 
et al. (2010) which compared the efficacy of two face-to-face group interventions (CBT 
versus support-experiential therapy) and usual care on reducing “fear of progression” 
(FOP) [71]. Both interventions proved effective in reducing FOP. All participants were 
inpatients of a rehabilitation clinic and 20% had experienced a recurrence (or metasta-
ses), which limits the generalisability of findings to those with early-stage disease. The 
second intervention targeted FCR in oral and oropharyngeal patients with an individu-
ally delivered nurse-led intervention [72]. Participants were in their first year following 
diagnosis, not screened for high FCR and attrition was high. Hence, only small benefits 
on FCR were found [74]. The third study found that a psycho-educational intervention 
was capable in reducing FCR in high risk melanoma patients. Their sample included both 
patients with high and low FCR [69]. All three above mentioned trials were delivered in 
face-to-face format.
The remaining three trials have already published a study protocol and two of them 
conducted a pilot study/feasibility study of which the first results appear promising 
[75-76]. One study includes only female (breast or gynaecological) cancer survivors [75]. 
The remaining study although open to both male and female cancer types, the final 
sample included predominantly women with breast cancer (>90%) and therefore the 
effectiveness of FCR treatment amongst men is understudied [68,76]. Aforementioned 
two interventions were delivered in face-to-face format and did not incorporate aspects 
of eHealth. The third intervention is an online self-management intervention for high 
FCR in breast cancer survivors [73]. At the moment, no pilot results or preliminary find-
ings have been published.
In 2012, the plan to design a blended therapy to target high FCR in Dutch cancer 
survivors was formed at the Radboud University Medical Center (Department of Medical 
Psychology): resulting in the SWORD-study [77].
The sWoRD-intervention: blended therapy for fear of cancer recurrence
To address high FCR in Dutch cancer survivors an expert committee of researchers, psy-
chologists and a psychiatrist developed a blended cognitive behavior therapy (bCBT): 
the SWORD-intervention (“Survivors’ Worries Of Recurrent Disease”). The intervention 
is to be delivered as a three-month blended care program; combining individual face-
to-face therapy with ehealth support. Five individual face-to-face sessions and three 
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electronic or telephonic consultations with a registered health care psychologist take 
place following a fixed format and manualized intervention. The SWORD-intervention 
aims to reduce FCR severity by 1) identifying and modifying predisposing and perpetuat-
ing factors of FCR as specified in the FCR model (Figure 2) (e.g. unhelpful cognitions and 
dysfunctional behaviors) and 2) to equip cancer survivors with skills to better manage 
their own FCR.
oUTlIne of THe DIsseRTATIon
This dissertation contains of nine chapters. The main objectives of the studies presented 
in this thesis were to get a better understanding of FCR in cancer survivors and partners 
(e.g. characteristics associated with FCR) and to test the efficacy of bCBT in managing 
high FCR.
PART I: Understanding fCR in cancer survivors and partners
The first part of this dissertation concerns the prevalence, characteristics and de-
terminants of FCR in cancer survivors and their partners. In chapter 2, differences in 
FCR by cancer diagnoses were investigated using cross-sectional data from the Dutch 
PROFILES-registry. This study distinguished itself by its large sample size and inclusion 
of several understudied cancer types, such as thyroid carcinoma and endometrial carci-
noma. Medical and demographic associates of FCR were identified and the relationship 
of FCR with quality of life domains was investigated. Prostate cancer survivors remain an 
understudied population in terms of psychosocial functioning and FCR. Clinical practice 
suggests that FCR is a common problem for prostate cancer survivors as well. Therefore, 
in chapter 3, the prevalence, correlates and features of high FCR in persons treated for 
prostate cancer were investigated. Furthermore, because research in partners of cancer 
survivors is still limited, the role of FCR in their partners was examined as well. Chapter 
4 reports on the results of this study.
PART II: Managing fCR in cancer survivors
In the second part of this dissertation the potential efficacy of bCBT in reducing FCR 
severity is addressed. Chapter 5 describes the study protocol of SWORD (‘Survivors 
Worries Of Recurrent Disease’): a randomized controlled trial (RCT) investigating the 
superiority of bCBT over care as usual in managing high FCR in Dutch breast, colorectal 
and prostate cancer survivors. This chapter presents a short literature overview on inter-
ventions for FCR, the SWORD-study design, and a description of the SWORD treatment 
content. Chapter 6 describes a classical case study to illustrate how bCBT can be carried 
out in clinical practice and which challenges can be encountered along the way. Finally, 
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in chapter 7, the results of the RCT on the efficacy of bCBT for FCR are described and 
discussed.
Concluding this thesis, in chapter 8, the main findings from this thesis are placed in 
broader perspective and are discussed according to their clinical relevance and implica-
tions for further research. Chapter 9 summarizes the most important findings.
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AbsTRACT
objective: Knowledge of factors associated with fear of cancer recurrence (FCR) may 
inform intervention development and improve patient care. Aims were to (1) compare 
FCR severity between cancer types and (2) to identify associations between FCR, de-
mographics, medical characteristics, information provision and health-related quality 
of life.
Methods: Cross-sectional data were obtained from the PROFILES registry. We included 
stage I and II survivors diagnosed with melanoma (n=469), colorectal cancer (n=861), 
endometrial cancer (n=688), thyroid cancer (n=218), Hodgkin (n=103) or non-Hodgkin 
lymphoma (n=276). Cancer survivors completed questionnaires on FCR (Impact Of Can-
cer scale – Health Worries subscale), satisfaction with information provision (EORTC-QLQ 
INFO25, satisfaction scale) and health-related quality of life (EORTC-QLQ C30, SF-36).
Results: 2615 survivors completed the IOC-Health Worries subscale. No significant 
differences in FCR severity were found between any of the cancer types (p=0.063). A 
younger age, female gender, stage II disease, a shorter time since diagnosis, scheduled 
follow-up appointments and comorbidity were associated with higher FCR (p<0.01). 
Satisfaction with information provision was negatively correlated with FCR severity (r=-
0.16, p<0.05). Demographic and medical factors accounted for 6% of explained variance 
in FCR. The full model, also including health related quality of life, explained 15% and 
19% respectively.
Conclusion: FCR seems to be a universal concern of cancer survivors rather than a cancer 
type specific problem. Gender, age and medical factors were identified as risk factors.
FCR in different cancer types
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InTRoDUCTIon
Fear of cancer recurrence (FCR), the fear or worry that cancer will return or progress 
in the same organ or a different part of the body [1], has been identified as a major 
concern for cancer survivors [2,3]. While FCR is an understandable and rational response 
some survivors report heightened levels of fear that may negatively affect health status, 
quality of life, and increase health-care costs [2-4]. Due to missing cut-offs for high FCR, 
different percentages have been reported in studies (ranging between 39 – 97%)[2,3].
One area that needs further exploration is the relationship between FCR severity and 
cancer type. Because of the variation in objective risk of recurrence between cancer 
types, a recurrence is for some survivors more probable than for others. It seems logical 
that type of cancer diagnosis may influence fear. FCR severity would be expected to 
be higher in cancer types associated with a worse prognosis. Only four studies have 
investigated FCR between cancer types and those demonstrated inconclusive findings.
Higher FCR was found in head and neck cancer survivors compared with survivors of 
other cancer types (i.e. breast, prostate, urinary and gastro-intestinal, gynaecological 
cancer)[5]. Prostate cancer survivors experienced the lowest FCR, whereas FCR levels in 
breast, colorectal and lung cancer survivors were comparable [6,7]. Two other studies 
did not find a relationship between FCR and cancer type. Prostate, breast, colorectal and 
uterine cancer survivors reported similar proportions of FCR[8][9].
Other medical characteristics and demographics in relation to FCR have also been 
studied. Younger age, female gender and lower education have almost consistently 
been associated with higher FCR [2-3,10]. Only limited evidence was found for medical 
factors such as disease stage, treatment modality and physical comorbidity [2-3,10]. 
Still unexplored is information provision in relation to FCR. Information provision, that 
is congruent with a survivor’s need, may increase perceived control and thereby reduce 
feelings of threat or worry [11], ensuing lower FCR.
Knowledge of factors associated with FCR may help to better understand the nature 
of fear and is essential to inform intervention development and improve patient care. 
Findings may help clinicians to adequately identify cancer survivors that are at risk for 
high FCR. The majority of studies focused on FCR in one cancer type, most often breast 
cancer [10] and on short-term survivors (<5 years post-diagnosis),
In this study FCR was explored in a large mixed sample of cancer survivors up to 10 
years post-diagnosis. Survivors were diagnosed with colon cancer, rectal cancer, or one 
of five understudied cancer types: endometrial cancer, melanoma, thyroid cancer or 
(non-) Hodgkin lymphoma. The main study objectives were to compare FCR severity 
between these cancer types, to identify medical and demographic risk factors and to 
explore the relationship of FCR with information provision and health-related quality 
of life.
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MeTHoDs
setting and participants
Cross-sectional data from several Dutch population-based studies on cancer survivors 
were obtained through PROFILES (Patient Reported Outcomes Following Initial Treat-
ment and Long-Term Evaluation of Survivorship), a registry for the study of the physical 
and psychosocial impact of cancer and its treatment using a growing population-based 
cohort cancer survivors [12]. The registry data are available free of charge for non-
commercial scientific research (www.profilesregistry.nl). PROFILES is linked directly to 
medical data of the Netherlands Cancer Registry (NCR) [12].
Data collection by PRofIles
Details of data collection are reported elsewhere [12]. Data were gathered between 2008 
and 2010. By linking the NCR with the Central Bureau of Genealogy patients deceased 
prior to data collection were excluded. Those with cognitive impairment or unverifiable 
addresses were also excluded. Cancer survivors identified by the NCR as eligible for par-
ticipation were sent a study information letter by their specialist. This letter explained 
that by completing the questionnaire survivors agreed to participate and consented 
with linkage of the questionnaire data to the medical and demographic information in 
the NCR.
Current study
We selected datasets within the PROFILES registry that contained the Impact Of Cancer 
Health Worries subscale, resulting in six eligible datasets, with seven cancer types, 
providing information on 3839 cancer survivors.. Survivors were diagnosed with 1) 
melanoma, 2) colon or 3) rectal cancer between 1998-2007, 4) endometrial cancer be-
tween 1999–2007, 5) thyroid cancer between 1990–2008, 6) Hodgkin or 7) non-Hodgkin 
lymphoma between 1999-2008. We were interested in survivors who were disease free 
at time of survey completion. PROFILES did not register recurrence status or disease ac-
tivity parameters. Therefore, only survivors with early stage or locally advanced disease 
(stage I/II) at diagnosis were included (n=2780, 72%).
Instruments
Demographics and medical characteristics
Demographic information was collected using self-report questionnaires. Medical char-
acteristics were retrieved from the NCR and by self-report.
FCR in different cancer types
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Fear of cancer recurrence
The ‘Health Worries subscale’ of the Impact Of Cancer scale (IOC-HWS) was used to assess 
FCR [13] with 3 items 1) “I worry about my health”, 2) “I worry about the cancer coming 
back or about getting another cancer”, 3) “New symptoms (aches, pains, getting sick or the 
flu) make me worry about the cancer coming back”. Items were scored on a five-point 
intensity scale ranging from 1 (strongly disagree) to 5 (strongly agree). A IOC-HWS mean 
score was computed (range 1-5). Higher scores reflected more severe FCR. Psychometric 
properties of the IOC have proven to be sufficient in oncology settings [13]. In the cur-
rent study Chronbach’s alpha was 0.83.
Health-related quality of life
Two questionnaires were used to measure health-related quality of life (HR-QoL). The 
Short Form 36-item health survey (SF-36) was completed by colon cancer, rectal cancer, 
endometrial cancer and melanoma survivors. This questionnaire has six subscales. 
Scores were converted to a 0-100 linear scale [14]. A higher value indicated a more 
favourable health state.
Survivors of Hodgkin lymphoma, non-Hodgkin lymphoma and thyroid cancer 
completed the 30-item European Organization for Research and Treatment of Cancer, 
Quality of Life Questionnaire (EORTC-QLQ C30). This validated questionnaire assesses 
health-related quality of life dimensions in cancer survivors [15]. Scores of five functional 
scales and one global quality of life scale were transformed to a 0-100 scale [16]. A higher 
score reflected a better level of functioning and better quality of life.
Satisfaction with information provision
Three items from the EORTC QLQ-INFO25 questionnaire were selected to evaluate 
satisfaction with information as received during disease or treatment [17], 1) “Were you 
satisfied with the amount of information you received?” on a scale from 1 (not at all) to 4 
(very much), 2) “Do you wish that you had received more information.” and 3) “Do you wish 
that you had received less information?” (yes/no).
Comorbidity
Comorbidity was assessed by self-report (yes/no): heart condition, stroke, high blood 
pressure, asthma, diabetes, kidney disease, liver disease, thyroid disease and arthritis.
Positive responses were summed to obtain a total score (range 0–9) [18].
statistical analysis
Six datasets were merged into one dataset and compared with their source datasets by 
an independent data monitor. Analyses were performed using SPSS 20. If one or more 
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items on the IOC-HWS, measuring the primary outcome FCR, were missing, the case was 
excluded.
Descriptive statistics are presented as means (with standard deviation) or as numbers 
(proportions). Differences between completers and non-completers were examined 
with t-tests (continuous variables) and chi-square tests (categorical variables). Inde-
pendent sample t-tests, ANOVAs and Pearson correlations were conducted to evaluate 
the relation between demographics, medical characteristics, HR-QoL and FCR. Because 
of unequal sample sizes Hochberg’s GT2 tests were chosen for all post-hoc pair wise 
comparisons if ≥2 categories were compared in ANOVA. Subsequently, a multiple linear 
regression analysis of demographic/medical characteristics on FCR was conducted. 
Variables were entered in the regression model if in the univariate analysis a significant 
relation between the variable and FCR was found (p≤.01). An exploratory sensitiv-
ity analysis was run to see how much variance in FCR could be attributed to HR-QoL 
domains. HR-QoL domains and information provision were only entered if at least a 
clinically meaningful correlation (defined as r>.30, p≤.01) with the IOC-HWS was found. 
Assumptions were checked for violations.
ResUlTs
Participant characteristics
The IOC-HWS was completed by 2615 cancer survivors (Table 1). Non-completers 
(n=165, 6%) were older at time of survey (M=70.6 vs. M=63.6 p<.001), closer to diagnosis 
than completers (M=4.5 vs. M=5.1, p<.05), more often female (75 vs. 64%, p<.001) and 
without a partner (44 vs. 25%, p<.001). Completers consisted of colon cancer (n=558), 
rectal cancer (n=303), Hodgkin lymphoma (n=103), non-Hodgkin lymphoma (n=276), 
endometrial cancer (n=688), thyroid cancer (n=218) and melanoma (n=469) survivors. 
Most were female (64%) with a mean age of 64 years (SD 12.9), diagnosed with early-
stage disease (stage 1; 66%), treated with surgery only (64%), and most survivors were 
still within 5 years of cancer diagnosis (58%) (Table 1 and Table 2).
fCR by cancer type
No statistically significant differences were found between cancer types in FCR (p=.063; 
Table 2).
FCR in different cancer types
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Table 2. Fear of cancer recurrence by demographics and medical characteristics.
IoC-HWs (range 1-5)
Mean (±sD)
Test 
statistic
effect
size
P-value
DeMoGRAPHICs
Age at diagnosis (Mean (SD)) 2.77 (1.00) r=-0.027 na p=0.172
Age at survey (Mean (SD)) 2.77 (1.00) r=-0.058 na p=0.003 **
Gender
  Male
  Female
 
2.64 (1.01)
2.84 (1.00)
 
t=-4.898
 
 
d=0.19
 
 
p<0.001
 
 
**
 
Marital status
  Partner
  No partner
 
2.76 (1.01)
2.78 (1.00)
 
t=0.466
 
 
d=0.02
 
 
p=0.641
 
educational level
  Low
  Medium
  High
 
2.78 (1.04)
2.77 (1.00)
2.76 (1.01)
 
F=0.093
 
 
 
η2=0.01
 
 
 
p=0.911
 
 
ses
  Low
  Medium
  High
 
2.79 (1.05)
2.82 (0.99)
2.71 (1.00)
 
F=3.007
 
 
 
η2=0.01
 
 
 
p=0.050
 
 
 
*
 
 
Current occupation
  Employed
  Unemployed
 
2.73 (0.96)
2.78 (1.03)
 
t=-1.204
 
 
d=0.05
 
 
p=0.216
 
MeDICAl CHARACTeRIsTICs
Cancer type
  Colon cancer
  Rectal cancer
  Hodgkin Lymphoma
  Non-Hodgkin
  Endometrial cancer
  Thyroid cancer
  Melanoma
 
2.77 (1.02)
2.83 (0.99)
2.96 (1.09)
2.83 (1.06)
2.77 (0.99)
2.65 (0.98)
2.69 (0.96)
 
F=1.996
 
 
 
 
 
 
 
η2=0.01
 
 
 
 
 
 
 
p=0.063
 
 
 
 
 
 
stage at diagnosis
  I
  II
 
2.73 (1.01)
2.85 (1.01)
 
t=-3.081
 
 
d=0.12
 
 
p=0.002
 
 
**
 
Years since diagnosis
  < 2 years
  2 – 5 years
  5 - 10 years
  >10 years
 
2.96 (0.98)
2.82 (1.02)
2.66 (0.99)
2.54 (0.98)
 
F=11.694
 
 
 
 
η2=0.01
 
 
 
 
p<0.001
 
 
 
 
**
 
 
 
Primary treatment
  Surgery only
  Surgery + RT and/or CT
  RT and/or CT only
  Otherc
 
2.74 (1.00)
2.79 (0.97)
2.86 (1.07)
3.08 (1.14)
 
F=2.095
 
 
 
 
η2=0.01
 
 
 
 
p=0.079
 
 
 
Comorbidity
  None
  1-2
  ≥ 3
 
2.64 (0.98)
2.80 (0.99)
3.01 (1.04)
 
F=12.409
 
 
 
η2=0.02
 
 
 
P<0.001
 
 
 
**
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fCR by demographics and medical characteristics
In univariate analysis a younger age at survey, female gender, stage II disease, active 
medical follow-up, presence of comorbidity and shorter time since diagnosis were sig-
nificantly associated with FCR (Table 2). Survivors between 0 to 5 years post-diagnosis 
(0-2 and 2-5 years post-diagnosis) experienced higher FCR than survivors >5 years post-
diagnosis (5-10 years and >10 years post-diagnosis). Years since diagnosis was therefore 
dichotomized into 0-5 years post-diagnosis and >5 years post-diagnosis for the multiple 
regression.
fCR and health-related quality of life
Statistically significant small to moderate negative correlations between FCR and the 
functional scales of the EORTC (range r=-0.19 to -0.35) and SF-36 (range r=-0.23 to -0.47) 
were found (Table 3). Scale scores ranged between 76-88 (EORTC-QLQ C30) and 64–84 
(SF-36) indicating a relatively good level of functioning [19].
Table 3. Correlations between health-related quality of life, information provision and FCR.
scale Correlation with 
IoC-HWs
scale Correlation with 
IoC-HWs
eoRTC QlQ-C30 sf-36
  Physical functioning -0.19**   General health -0.47**
  Role functioning -0.21**   Physical functioning -0.23**
  Emotional functioning -0.35**   Role – physical functioning -0.25**
  Cognitive functioning -0.21**   Social functioning -0.31**
  Social functioning -0.22**   Role – emotional functioning -0.26**
  Global quality of life -0.25**   Mental health -0.42**
Information provision -0.16**
**p<.001
Table 2. Fear of cancer recurrence by demographics and medical characteristics. (continued)
IoC-HWs (range 1-5)
Mean (±sD)
Test 
statistic
effect
size
P-value
follow-up scheduled
  Yes
  No
 
2.84 (1.00)
2.48 (1.00)
 
t=7.257
 
 
d=0.28
 
 
P<0.001
 
 
**
 
FCR: Fear of Cancer Recurrence; SD: Standard Deviation; SES: socioeconomic status; CT: chemotherapy; RT: 
radiotherapy cOther = stem cell transplantation; na: not applicable
Effect sizes: Cohen’s d: 0-0.2 small; 0.2-0.5 medium. Eta-Squared (h2):0 – 0.02 small; 0.02 – 0.13 medium. 
*p<.05 **p< .001
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Table 4. Multiple linear regression analysis: medical/demographic characteristics on FCR (n=2053).
All cancer types (N=2053) β
   Variables
   Gender 0.12**
   Age -0.07*
   Years since diagnosis -0.07*
   Disease stage 0.08**
   Comorbidity 0.14**
   Active follow-up -0.10**
   
   Adj R2 0.06
   F 22.004
   Sig. p <.001
Nb. Dichotomized variables (Gender 0=male; Years since diagnosis 0=0-5 years 1=>5 years; disease stage 
I=0) *p<.05 **p<.001
fCR and information provision
The more satisfied survivors were with the information received, the less FCR they 
reported (r=-0.16, p<.01). Survivors who would have liked to have received more infor-
mation during the treatment period scored significantly higher on FCR than those who 
were satisfied with the amount of information received (M=3.09, SD=1.00 vs. M=2.68, 
SD=0.99; t=8.849, p<.001). Those reporting to have preferred less information during 
their treatment period did not differ in FCR from those who were satisfied with the 
amount of information. (M=2.95, SD=1.13 vs. no M=2.76, SD=1.00; t =-1.676, p=.09).
Multiple regression predicting fCR
The strongest demographic predictor of FCR was gender (β =.12): females reported 
higher FCR than males. Younger age at survey was also associated with higher FCR. Re-
garding medical characteristics, the number of comorbid conditions (β =.14) and stage 
II disease were both independent predictors of FCR. Cancer survivors with scheduled 
medical follow-up appointments reported higher FCR than those not in follow-up. This 
combination of demographic and medical characteristics accounted for a small amount 
of explained variance (6%).
Separate regression analyses for both HR-QoL measures were conducted. The addition 
of emotional functioning (EORTC-QLQ C30) (β=.31, p <.001) to the model resulted in a 
significant increase of explained variance (R2) from 6% to 15% (F(7,422)=11.791, p <.001). 
Mental health, general health and social functioning were entered into the second step 
for survivors completing the SF-36. Only mental health (β=-0.22) and general health 
(β=-0.39) significantly contributed to FCR (both p<.001). Social functioning was not a 
significant predictor of FCR (β=0.03, ns). The explained variance (R2) increased from 6 to 
29% (data not shown).
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ConClUsIon
The first aim of this study was to investigate and describe differences in FCR between 
(understudied) cancer types. We found that severity of self-reported FCR did not differ 
between survivors of stage I/II colon cancer, rectal cancer, (non-)Hodkgin lymphoma, 
thyroid cancer, endometrial cancer or melanoma. FCR appears to be a rather universal 
concern amongst cancer survivors that is not necessarily linked to cancer diagnosis. If 
differences in prognosis by cancer type were reflected in FCR severity, FCR would have 
been highest in cancer survivors with the worst 3-year relative survival rate (endometrial 
cancer, 89%) and lowest in survivors of thyroid cancer and (non-)Hodgkin lymphoma 
(95%) [20]. A caveat is that only stage I and stage II cancer survivors were included in 
the analysis and the prognosis of the studied cancer types was rather comparable and 
relatively favourable. For instance, one study demonstrated that head and neck cancer 
survivors – for which relative survival rates vary between 40-75%, depending on tumour 
location – reported more FCR than cancer types with a more favourable prognosis (> 
80%) [5,20]. Hence, differences in overall prognosis might have been too small to detect 
an effect on FCR.
The second aim was to identify demographic and medical associates of FCR. Medi-
cal characteristics significantly associated with higher FCR were: greater comorbidity, 
having routine medical follow-up appointments scheduled, stage II disease and shorter 
time since diagnosis. Comorbidity, the strongest associate of FCR, has been associated 
with higher FCR in earlier studies [21,22]. Comorbid conditions are accompanied by 
internal physiological cues that can be understood as signalling a possible cancer recur-
rence. Illness or disease symptoms therefore remind one of their vulnerability and may 
successively trigger FCR [23;24;10].
Previously mentioned triggers of FCR are medical examinations and annual check-
ups [6]. This may explain our observation that cancer survivors who still have routine 
medical follow-up appointments report higher FCR. However, it could also be the other 
way around; survivors with high FCR more frequently schedule appointments with their 
health care provider in order to feel reassured [4]. Furthermore, survivors with worse 
disease or more severe side-effects (who generally have higher FCR) might be in need of 
more medical help and remain in follow-up longer [25]
Most studies on FCR did not find an association between time since diagnosis and 
FCR [2,3,10]. A possible explanation why we did find a significant association is that 
our sample covered a wider range of years since diagnosis (0-11 years) than most other 
studies [10,2]. Stage II disease was also associated with higher FCR. Patients have certain 
illness representations and implicit beliefs about the nature and severity of their disease 
[23]. Irrespective of cancer type, overall, stage II disease may be perceived as more 
threatening than stage I disease and thus result in higher FCR.
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Concerning demographics, both female gender and a younger age at survey were 
significant predictors of FCR. Female gender has almost consistently been identified as 
one of the strongest associates of FCR [2-4, 10]. Studies have found that especially young 
women report high FCR [4,6]. Life stage related challenges such as caregiver responsi-
bilities (childbearing, raising children) and financial responsibilities are threatened by 
the unexpected nature of cancer at an early age. These challenges pose a substantial 
burden on young women [4].
Finally, the relationship between FCR, information provision and HR-QoL has been 
explored. There was only a small negative correlation between satisfaction with informa-
tion provision and FCR. Nevertheless, group comparison showed that cancer survivors 
who would have liked to have received more information, reported higher FCR than 
those satisfied with the amount of information received. This finding is in good agree-
ment with studies that found a shortage of information, or information of low quality, 
to be associated with more anxiety. Still, anxiety has also been associated with inhibi-
tion of information processing leading to difficulty understanding medical information 
and less satisfaction [26]. Poorer emotional functioning, poorer mental health and, to 
a lesser extent, worse physical functioning were associated with higher FCR. Due to 
the cross-sectional design of this study causality cannot be inferred, but a bidirectional 
relationship is plausible. That is, FCR may be a precipitating factor of a reduced HR-QoL 
but FCR can also be precipitated by problems in these domains of functioning [27;28]. 
Only 6% of the variance in survivors’ FCR was explained by demographic and medical 
characteristics in our regression model, suggesting that these factors do not exert a 
strong influence of FCR. After the addition of HR-QoL domains the explained variance 
in FCR increased to 15% and 29%. This indicates that other factors, such as HR-QoL and 
emotional wellbeing, may play a greater role in FCR than demographics and medical 
factors.
Completers vs. non-completers analysis of the IOC-HWS revealed significant differ-
ences between these two groups. Non-completers of this scale were older, a longer 
time since diagnosis, more often female and without a partner. Nevertheless, we do not 
believe that these differences have a profound effect on the representativeness of our 
sample as the number of non-completers (6%) was relatively small.
The data used in this study were extracted from the PROFILES registry. Data sharing 
promotes new research and fosters efficient use of research investments. The PROFILES 
registry provided us with data from seven studies and enabled us to investigate FCR in a 
large cohort of understudied cancer types.
Working with readily available data comes with many benefits but also has certain 
limitations. The measures used in PROFILES did not fit the research questions perfectly. 
We selected the IOC-HWS to measure FCR, but this scale has not yet been validated for 
this purpose. However, the items are fairly comparable to items from more commonly 
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used FCR measures, such as the Cancer Worry Scale and the Fear of Cancer Recurrence 
Inventory [29;6] and have good face validity as well.
No validated cut-off score is available and no differentiation could be made between 
survivors with high FCR and those with ‘normal’ FCR. The prevalence of high FCR in our 
sample is therefore unknown. The observational nature of the study does not allow us 
to assess causality between FCR, demographics, medical characteristics, information 
provision and (health-related) quality of life. Longitudinal research is needed to identify 
the direction of these relationships.
Finally, because information was unavailable, we were not able to identify and differ-
entiate between disease-free survivors, those with a recurrence, or an advanced disease 
at time of questionnaire completion. In order to reduce the probability of including 
survivors who were not disease-free we only selected those diagnosed with stage I or 
stage II disease.
To conclude, the present study provides an important contribution to the available lit-
erature on FCR in cancer survivors and the association between FCR severity and cancer 
types. Our findings indicate that cancer type does not exert a strong influence on FCR. 
Reported FCR severity does not differ between survivors of colon cancer, rectal cancer, 
thyroid cancer, Hodgkin lymphoma, non-Hodgkin lymphoma, endometrial cancer and 
melanoma. Demographics and medical characteristics were found to play a minor role 
in FCR while domains of physical and psychological functioning were more important 
contributors to FCR.
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AbsTRACT
background: High fear of cancer recurrence (FCR) is an understudied topic in prostate 
cancer (PCa) survivors. This study aimed to detect the prevalence, consequences and 
characteristics associated with high FCR in PCa survivors.
Materials and Methods: This cross-sectional study included patients diagnosed with 
localized PCa and treated with curative radical prostatectomy between 1992 – 2012. We 
administered the Cancer Worry Scale (CWS) to assess FCR severity (primary outcome 
measure). Secondary outcomes included distress, quality of life (QOL) , post-traumatic 
symptoms, and multidimensional aspects of FCR. Chi-square tests, t-tests and Pearson 
correlations examined the relationship between FCR and medical/demographic char-
acteristics. MANOVA analyses and chi-square tests identified differences between PCa 
survivors with high and low FCR.
Results: Two hundred eighty-three PCa survivors (median age of 70.0 years) completed 
the questionnaires a median of 7.1 years after surgery. About a third (36%) of all PCa 
survivors experienced high FCR. High FCR was associated with lower quality of life, more 
physical problems, higher distress and more post-traumatic stress symptoms. PCa survi-
vors with high FCR reported disease-related triggers (especially medical examinations), 
felt helpless and experienced problems in social relationships. High FCR was associated 
with a younger age and having received adjuvant radiotherapy.
Conclusions: Results illustrate that FCR is a significant problem in PCa survivors. Younger 
men and those treated with adjuvant radiotherapy are especially at risk. Those with high 
FCR experience worse QOL and higher symptom burden. Health care providers should 
pay specific attention to this problem and provide appropriate psychosocial care when 
needed.
FCR in prostate cancer survivors
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bACkGRoUnD
Fear of cancer recurrence (FCR) is the fear or worry that the disease will return or prog-
ress in the same organ or in another part of the body [1-2]. It is hypothesized that normal 
levels of FCR promote adequate threat monitoring behaviour [3] whereas studies found 
that high FCR is associated with functional impairment [4], lower quality of life, distress 
and reassurance-seeking behaviour (e.g. extra medical examinations) [5-7]. Due to the 
use of different assessment instruments, reported prevalence of FCR amongst cancer 
survivors ranges between 39–97% [6].
FCR in PCa survivors has been described in some studies [6,8-12] but only one study 
has reported the prevalence of high FCR using a validated cut-off score [12]. While mean 
levels of FCR were found to be lower in PCa survivors compared to those with breast, 
colorectal or lung cancer[2,6]; the prevalence of high FCR was higher in PCa survivors 
(32%, n = 23) than colorectal cancer survivors (24%, n = 10) but lower than in breast 
cancer survivors (40%, n = 23) (significance testing was not conducted). Larger scale 
studies are needed to provide more insight in the prevalence and factors associated 
with high FCR in PCa survivors.
One might expect a lower prevalence of high FCR in PCa survivors than in other cancer 
types as PCa is considered as one of the most curable forms of cancer: most PCa patients 
present with early stage disease (I-II), the 5-year relative survival rate in this group is 
nearly 100% and the prognosis following a recurrence is still relatively good [13]. In 
contrast to the PCa population, high FCR is associated with female gender and younger 
age [6,14].
Clinical practice suggests that PCa specific factors might contribute to FCR. For 
example, the regular monitoring of prostate-specific antigen (PSA) levels in the blood. 
From the patient perspective rising levels signals increasing PCa activity. PSA testing is 
therefore both clinically and psychologically meaningful for survivors and the uncer-
tainty that comes with rising PSA might trigger FCR.
Greater knowledge of factors associated with FCR in PCa survivors can be used to 
inform intervention development and improve care. Currently there is little data on the 
antecedents, triggers and consequences of FCR, or factors associated with high FCR 
in the PCa population. The aims of this study were to identify: 1) the prevalence (and 
characteristics) of FCR 2) the consequences of clinical FCR 3) medical characteristics and 
demographics associated with FCR, and 4) to explore the relationship between PSA test-
ing and FCR amongst PCa survivors who underwent curative treatment.
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MATeRIAls AnD MeTHoDs
Patient selection
Eligible patients were 1) diagnosed with localized prostate adenocarcinoma and 2) 
treated with curative radical prostatectomy (RP) (optional: radiotherapy (RT)) between 
1992-2012. Patients were excluded if they received hormone therapy. Eligible patients 
were identified by a urologist (IvO) between June–August 2013 from a patient database 
managed by the Department of Urology, Radboudumc. Deceased patients were identi-
fied and removed by Dutch Cancer Registry data linkage. Eligible patients received a 
mailed study information and invitation to participate from the Department of Urology. 
Consenting patients returned a written informed consent form and completed either 
an online or paper-and pencil questionnaire. Ethical approval was given by the Medical 
Ethics Committee, Radboudumc.
Instruments
Demographic and medical characteristics
Demographics, number of comorbid conditions and months until next medical follow-
up were gathered by self-report. Treatment modality, PSA level, time since last PSA test 
were obtained from medical records. We were not able to specify patients with a disease 
recurrence. Due to length of time since diagnosis (up to 20 years), data on recurrence 
status was unavailable in the hospital database used to identify participants.
Fear of Cancer Recurrence: Severity
Cancer Worry Scale: FCR severity was measured with the Cancer Worry Scale (CWS). 
The CWS consists of eight items ranging from 1 (“never”) to 4 (“almost always”). Scores 
range from 8 – 32, a higher score indicating more FCR. A score of ≥ 14 is optimal for 
differentiating between high and low FCR in breast cancer survivors [15]. To determine 
the optimal cut-off point, and to evaluate the accuracy of the CWS in identifying PCa 
survivors with low versus high FCR, a receiver operating characteristic (ROC) analysis 
with the 8 item CWS and the Fear of Cancer Recurrence Inventory – Severity subscale 
(FCRI-Severity) was performed (using the clinical cut-off score of ≥ 16 to indicate high 
FCR)[12]. The area under the curve was 0.93 (p < 0.001; 95% CI= 0.89 - 0.96) (Appendice 
1), which represents a good level of discrimination. In order to correctly differentiate PCa 
survivors with high FCR, from those with low FCR, a cut-off which optimizes sensitivity 
and specificity was selected. To differentiate between high FCR and low FCR a cut-off 
point of 12 versus 13 (low: ≤ 12, high ≥ 13) had the best performance with a sensitivity 
of 86%, a specificity of 84%, a positive predictive value of 71% and a negative predictive 
value of 93% (Appendice 2). The internal consistency of the CWS was high (Cronbach’s 
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α = 0.88). The correlation between the CWS and the FCRI-Severity subscale was r = 
0.83 and in 87% of the cases both the CWS and FCRI-Severity subscale agreed on the 
presence or absence of FCR. Cohen’s kappa was 0.67 (SE 0.05). which corresponds to a 
substantial degree of agreement between measures.
Fear of Cancer Recurrence: Multidimensional aspects
The 42-item Fear of Cancer Recurrence Inventory (FCRI) is a psychometrically sound ques-
tionnaire used to assess multidimensional aspects of FCR [2,12]. Seven subscales were 
used: Triggers (8-items), Severity (9-items), Psychological Distress (4-items), Functioning 
Impairments (6-items), Insight (3-items), Reassurance seeking (3-items) and Coping 
(9-items). All items were scored on a scale from 0 (‘not at all’ or ‘never’) to 4 (‘a great deal’ 
or ‘all the time’) [2,12].
PSA-related anxiety
The 3-item PSA Anxiety Scale of the Memorial Anxiety Scale for Prostate Cancer (MAX-PC) 
was selected to measure anxiety related to PSA [16]. All Items were answerable on a 0 
(‘not at all’) to 3 (‘often’) scale (α = 0.56).
Distress
The Hospital Anxiety and Depression Scale (HADS) is a 14-item self-report questionnaire 
frequently used to screen for distress. The HADS has a 7-item anxiety and a 7-item de-
pression subscale, all items are scored on a 0 (“never”) to 3 (“almost always”) scale; with a 
HADS total score ranging from 0 (no distress) – 42 (maximal distress) [17].
The Impact of Events Scale (IES) measures cancer-related distress and the extent to 
which patients experience intrusive thoughts about cancer (7 - items) and avoid think-
ing about cancer (8-items). Total scores range from 0 - 75 (severe distress)[18].
Quality of Life
Quality of life (QoL) was assessed with the 30-item European Organization for Research 
and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) and prostate 
cancer specific module (EORTC QLQ-PR25) [19,20]. The EORTC QLQ-C30 provides one 
global health status/QoL scale score and five functional scale scores. The QLQ-PR25 as-
sesses sexual functioning and disease and treatment related symptoms [19]. All scale 
scores were transformed to a 0-100 scale. A higher functional scale score reflects a better 
level of functioning , a higher symptom score indicates more severe symptoms [21].
Data-analyses
SPSS20 was used for analyses. Relevant data were screened for normality and outliers. 
Descriptive statistics were used to describe the medical and demographic characteris-
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tics of the sample. Incomplete data for the CWS were recorded as missing and excluded 
from analysis. Unless otherwise specified, all analyses were done at an alpha ≤ 0.05 level 
of significance. Chi-square tests, t-tests and Pearson correlations were performed to test 
the relationship between FCR (continuous score) and demographic (age at diagnosis, 
age at survey, partner status, children, education) and medical characteristics (years 
since diagnosis, years since surgery, treatment received, number of comorbidity, famil-
iar PCa, PSA level, days since PSA-test and days until next medical appointment). For 
subsequent analyses the CWS cut-off score was used to group patients according to low 
or high FCR (low: ≤ 12; high ≥ 13; see measurements CWS). Multidimensional aspects 
of FCR (measured with the FCRI) and psychological variables (Distress, QoL) were com-
pared between the high vs. low FCR group with MANOVAs. For a descriptive analysis of 
the FCRI and MAC-PC PSA anxiety scores, percentages of responses to the individual 
questions were calculated and compared between the two groups.
ResUlTs
Response
In total, 740 men met eligibility criteria and were asked to participate (see figure 1). 
504 responded (68%) of whom 391 agreed to participate (53%). Reasons for non-
participation are displayed in figure 1. Questionnaires were completed and returned by 
318 survivors (43%). Twenty-eight falsely included PCa survivors were excluded because 
they received hormone therapy (n = 24) or were diagnosed prior to 1992 (n = 4). Five 
PCa survivors did not complete the CWS and, two questionnaires were completed by 
someone other than the patient. Eventually, data of 283 patients were analyzed (38%). 
Data on non-responders, decliners or non-completers were unavailable.
Patient characteristics
Information about demographic, disease and treatment characteristics of the par-
ticipants are listed in Table 1. All PCa survivors received curative radical prostatectomy 
treatment with a median time since diagnosis of 7.9 years (range 0.9 - 20). Twenty-seven 
percent received additional radiotherapy (with curative intent). Median age at survey 
was 70.0 years (range 54 - 89).
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(with curative intent). Median age at survey was 70.0 years (range 54 - 89).  
Figure 1. Patient recruitment flowchart. 
 
 
Prevalence of high FCR 
1.4) for low fearful survivors (t (281) = -21.44 p < 0.001). 
 
 
figure 1. Patient recruitment flowchart.
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Table 1. Demographic, medical characteristics and their association with FCR (n=283).
n (%) Mean CWs
(range 8 – 32)
Test statistic; p-value
Age at diagnosis (years) Median 62.5
(range 39-76)
- r = -0.09; p = 0.146
Age at survey (years) Median 70.0
(range 54-89)
- r = -0.13; p = 0.025
Partner
    Yes
    No
255 (91%)
25 (9%)
11.9 (3.6)
13.0 (4.8)
t = 1.374; p = 0.171
 
Children
    Yes
    No
259 (92%)
23 (8%)
12.0 (3.7)
12.4 (3.8)
t = 0.465; p = 0.642
 
education
    Low
    Middle
    High
 
69 (27%)
75 (28%)
121 (45%)
 
12.1 (3.4)
11.8 (4.0)
12.2 (3.8)
 
F = 0.233; p = 0.793
 
 
Years since diagnosis Median 7.9
(range 0.9-20)
- r = -0.10; p = 0.102
 
Years since surgery Median 7.1
(range 0.7-20)
- r = -0.11; p = 0.086
Treatment
    Surgery only
    Surgery + RT
 
206 (73%)
75 (27%)
 
11.8 (3.7)
12.8 (3.7)
 
t = -2.033; p = 0.043
 
Comorbidity
    none
    1-2
    3 -4
    > 4
 
65 (23%)
160 (56%)
49 (18%)
8 (3%)
 
11.6 (3.2)
12.1 (3.4)
12.5 (4.8)
11.9 (4.6)
 
F = 0.591; p = 0.621
 
 
 
familiar PCa
    No relatives with PCa
    Father, brother or
    both with PCa
 
205 (73%)
77 (27%)
 
 
12.0 (3.9)
11.7 (3.0)
 
 
t = 0.729; p = 0.467
 
 
PsA level
    0 or ≤ 0.1
    > 0.1 -≤0.2
    > 0.2
 
247 (90%)
11 (4%)
17 (6%)
 
11.8 (3.7)
13.5 (3.4)
12.2 (3.4)
 
F = 1.061; p = 0.348
 
 
Days since PsA test Median 118.0
(range 4-3249)
r = -0.05; p = 0.475
Days until next medical appointmenta Median 79.0 (range 0-365) r = -0.04; p = 0.579
NB. PSA test: Prostate specific antigen test; FU: follow-up; RT: radiotherapy; PCa: Prostate cancer
a n = 174: not all PCa survivors had already scheduled their next appointment.
Prevalence of high fCR
Mean CWS score of the total sample was 12.0 (SD = 3.7) and 104 PCa survivors (36%) met 
cut-off criterion for high FCR. Mean CWS score for high fearful survivors was 15.8 (SD = 
3.3), and 9.8 (SD = 1.4) for low fearful survivors (t (281) = -21.44 p < 0.001).
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Multidimensional aspects of fCR
PCa survivors with high FCR reported significantly more triggers, distress and functional 
impairments, insight and reassurance seeking behaviour than those with low FCR (Table 
2). Item analysis of the FCRI subscales between low and high fearful survivors is shown 
in table 3.
Table 2. Differences in psychosocial functioning by low vs. high FCR.
low fCR (n=179) High fCR (n=104) p-value
EORTC QLQ – C30 Mean (SD) Mean (SD)
 Global Health / Qol 83.5 (15.1) 75.6 (17.4) <.001**
 Physical Functioning 89.3 (14.9) 88.1 (15.0) 0.528 
 Role Functioning 89.2 (19.3) 84.0 (24.0) 0.050 
 emotional functioning 92.7 (12.3) 85.5 (16.2) <.001**
 Cognitive Functioning 88.7 (17.0) 84.7 (19.1) 0.069 
 social functioning 92.8 (15.4) 86.8 (21.9) 0.009**
 
EORTC QLQ-PR25
 Sexual activity 55.5 (17.4) 59.3 (17.6) 0.248 
 Sexual functioning 49.6 (24.7) 53.5 (24.7) 0.407 
 Urinary symptoms 12.6 (11.1) 19.4 (15.2) 0.007**
 bowel symptoms 1.9 (4.7) 7.5 (10.5) <.001**
 Hormonal/treatment 7.3 (6.3) 11.5 (8.8) 0.003**
 Incontinence aid 19.1 (16.6) 23.7 (15.2) 0.31 
 
HADS
 Total 3.9 (4.2) 8.6 (6.2) <.001**
 Anxiety 1.8 (2.2) 4.4 (3.3) <.001**
 Depression 2.1 (2.6) 4.3 (3.6) <.001**
 
FCRI
 severity 7.2 (4.8) 19.9 (7.8) <.001**
 Triggers 6.1 (5.1) 14.2 (6.3) <.001**
 Distress 1.8 (2.3) 5.4 (3.5) <.001**
 Impairments 0.7 (1.7) 4.9 (5.4) <.001**
 Insight 0.1 (0.3) 1.4 (2.0) <.001**
 Reassurance 1.0 (2.3) 1.9 (2.3) 0.002**
 
IES
 Total 2.0 (5.3) 11.5 (13.9) <.001**
 Avoidance 1.1 (3.1) 6.1 (8.3) <.001**
 Intrusion 0.9 (3.0) 5.2 (6.3) <.001**
 
MAX-PC
 PsA-Anxiety scale 0.2 (0.8) 0.7 (1.7) <.001**
Nb. Differences in QLQ-C30 and QLQ-PR25 scores of 5-10, >10–20 and >20 were defined as ‘minimally’, 
‘moderately’ and ‘largely’ clinically significant. ** p<.001
Nb2. MANOVA was used to test for significant differences.
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Table 3. Multidimensional aspects of FCR in high and low fearful PCa survivors (items).
subscale
  Items (summed percentage “most of the time” and “all of the time”) High FCR
(n=104)
Low FCR
(n=179)
Triggers
  Medical examinations
Seeing or hearing about cancer
Appointments with the general practitioner or health professional
41%
28%
27%
10% *
5% *
5% *
Psychological distress
  Feelings of helplessness or resignation
Feelings of worry, fear and anxiety
17%
13%
2% *
2% *
Functioning Impairments
  Social relationships
Quality of life
Future planning
12%
11%
11%
1% *
2%
0% *
Reassurance
  Calling a doctor/other health professional
Going to the hospital/clinical for examination
Self-examination for physical signs of a recurrence
7%
7%
4%
6%
6%
3%
Coping
  Trying to think positively
Trying to understand what is happening and how to deal with it
Trying to replace the thought with a more pleasant one
33%
30%
28%
30%
23%
17%
Severity α
  Unpleasant thoughts or images (e.g. death, suffering) when thinking about a 
recurrence
The belief that it is normal to be anxious or worried about potential cancer recurrence
33%
28%
5%*
10%*
Insight b
  The extent to which you feel that you worry excessively about a potential recurrence
The extent to which other people think you worry excessively about a potential 
recurrence
87%
91%
100%*
100%*
nb. * p <.05
α Severity: answer categories “Often/Very often”.   b Insight: answer categories “Not at all/a little”
Psychosocial characteristics associated with high and low fCR
Distress: PCa survivors with high FCR reported significantly higher distress, depression, 
anxiety, intrusive thoughts and signs of avoidance (p < 0.001).
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QoL: PCa survivors with high FCR reported significantly worse emotional functioning, 
global health and social functioning (all p < 0.05). Furthermore, those with high FCR re-
ported more urinary symptoms (p = 0.007), more bowel symptoms (p < 0.001) and more 
treatment-related problems (p = 0.003) (table 2). All differences were small in magnitude 
(< 10 points) and thereby of minimal clinical significance.
Medical and demographic characteristics associated with high and low fCR
A younger age was significantly associated with higher FCR (p = 0.03) (Table 1). In addi-
tion, PCa survivors with high FCR had more often received adjuvant radiotherapy than 
those reporting low FCR (37% versus 21%, x ² = 8.18; p = 0.004). No significant associa-
tions were observed concerning the other demographics/medical characteristics.
PsA testing and fCR
Last measured PSA level, number of days since last PSA test and number of days to next 
medical follow-up, were not significantly associated with FCR (Table 1). PCa survivors 
with high FCR reported significantly more PSA-related anxiety (p < 0.001). Individual 
items of the 3-item PSA-Anxiety Scale indicated that 6% of the high fearful compared 
with 1% of the low fearful survivors had considered delaying their PSA test due to FCR 
(x² = 7.255 ; p = 0.007). Four percent of high FCR survivors considered having the test 
repeated at another lab compared with 2% of the low fearful survivors (x² = 1.230; p = 
0.267). Finally, 6% thought about having their own doctor repeat the test, compared 
with 2% of survivors with low FCR (x² = 3.47; p = .06).
DIsCUssIon
The first aim of this study was to investigate the prevalence of FCR in a large sample 
of PCa survivors. Approximately one third (36%) of the sample displayed high FCR as 
defined by a score of 13 or higher on the Cancer Worry Scale (CWS). This prevalence is 
similar to that reported in studies of breast (31%) and colorectal cancer survivors (38%) 
also using the CWS [15,22], and supports the findings of Simard et al. (2015) (32% of PCa 
survivors) who used the FCRI [12]. Despite the relatively favourable prognosis, high FCR 
remains a significant problem in a substantial minority of PCa survivors even years after 
diagnosis.
QoL differed significantly between participants who experienced high and low FCR, 
those with high FCR having a lower global health, poorer emotional functioning and 
social functioning. Furthermore, they experienced more problems with urinary, bowel 
and treatment-related symptoms. Findings were similar for psychological measures; 
those with high FCR experienced more depression, anxiety, post-traumatic symptoms 
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(intrusive thoughts, avoidance) and were significantly more distressed than those with 
low fear. Although directionality of the relationship cannot be determined, health-care 
professionals should be aware of high FCR in clinical practice, as it is associated with 
adverse outcomes in terms of both physical and emotional wellbeing.
Interestingly, of those with high FCR only a small proportion reported disturbances 
in functioning (11-12%) and most survivors did not feel that they worried excessively 
about a possible recurrence (87%). So, despite the association of high FCR with negative 
health outcomes (QoL, treatment related symptoms), item analysis seems to indicate 
that FCR is considered a manageable concern for most fearful PCa survivors. However, 
compared with low fearful survivors those with high FCR reported significantly higher 
percentages of disturbances in functioning or distress due to FCR.
In line with earlier studies, involving other cancer types, medical examinations were 
identified as an important trigger of FCR by high fearful PCa survivors (41%) [4,22-23]. 
Despite that high FCR has also often been associated with bodily-checking and self-
monitoring of symptoms [3;14], this was not the case in our study. Bodily-checking did 
not occur frequently in high fearful PCa survivors. A possible explanation for this finding 
is that rising PSA levels are typically the first sign of a recurrence, well before any clini-
cal signs are present. Bodily checking is therefore less relevant for PCa survivors than 
for other cancer types (e.g breast cancer). Time since diagnosis, last PSA test, and time 
until next medical follow-up were not associated with FCR. Nor was last measured PSA 
level associated with FCR. Our results imply that high FCR is stable over time and is not 
necessarily influenced by disease-specific events such as PSA testing. However, due to 
the cross-sectional study design, longitudinal, prospective studies are needed in order 
to establish trajectories of FCR before and after PSA testing.
Demographics and medical variables significantly associated with higher FCR were a 
younger age and adjuvant radiotherapy. A younger age has more often been associated 
with high FCR in other cancer types [6-7;14]. For PCa survivors, it could be that those who 
are younger experience more life disruption caused by cancer (e.g. concerning employ-
ment problems, financial responsibility), which may increase their vulnerability to FCR. 
However, reasons for the association with age are still speculative and lend themselves 
to further exploration in qualitative studies.
PCa survivors who received adjuvant RT following surgery reported higher FCR than 
those treated with surgery only. This is consistent with two other studies where RT or 
brachytherapy was associated with higher FCR in a sample of mixed cancer types [2] 
and prostate cancer survivors [10]. A possible explanation for the association between 
FCR and treatment modality is that the relationship between RT and FCR is mediated by 
recurrence status. In the academic centre where our sample was recruited RT is only con-
sidered for treatment when PCa shows a recurrence and medical intervention is needed. 
Thus, those patients who were treated with RT have all experienced a (biochemical) 
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disease recurrence prior to completion of questionnaire. It has previously been shown 
that having had a disease recurrence is in itself an independent risk factor for develop-
ing high FCR [2;24]. Unfortunately, due to absence of data it was not possible to specify 
recurrence status as an explicit variable in current study.
Some limitations of this study should be noted. First, due to the cross-sectional nature 
of this study our results do not imply causation. Longitudinal studies are needed to 
ascertain causality. Secondly, 6% of the PSA levels were >0.2: which is indicative of a 
current biochemical disease recurrence. At time of inclusion these individuals did not 
receive any medical intervention and were included. However, due to the relatively 
low number of those with heightened PSA levels we believe this had only a negligible 
impact on our findings. Third, all PCa survivors were selected from a database in an 
academic centre and the response rate was low (38%). Literature shows that patients in 
non-academic medical centers differ from those who visit academic medical centers (the 
latter are often younger and have a better socioeconomic status) [25] and results might 
not be representative off all PCa survivors. Additionally, even though the study informa-
tion made it clear the study was for everyone regardless of level of FCR, the main reason 
for non-participation in this study was the self-reported absence of FCR (n = 23). Our aim 
was to include all eligible survivors and not only those bothered by high FCR. Therefore, 
the percentage of PCa survivors experiencing high FCR could be overestimated due to 
self-selection bias. Fourth, as in most other self-report questionnaire studies, there is no 
guarantee that all returned questionnaires were completed by the addressed patient 
and not someone else. An introductory letter was attached to the questionnaire booklet 
asking the patient to fill-out the questionnaire themselves and it was assumed that the 
patient completed the questionnaire unless otherwise specified. Finally, the CWS was 
used to differentiate between high and low fearful PCa survivors. Only estimates of reli-
ability and criterion-validity were established in this study and other aspects of validity 
were beyond the scope of this study.
This study showed that high FCR is a significant problem in more than a third of all 
PCa survivors. Younger patients and those treated with adjuvant RT are most vulnerable 
to high FCR. While medical examinations are triggers of FCR in themselves, FCR was not 
found to be influenced by PSA level, time since last PSA test, or time until next medical 
follow-up. PCa survivors with high FCR reported worse emotional wellbeing and expe-
rienced more disease- and treatment-related symptoms even years after completion of 
treatment.
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Appendice 1. Receiving operating characteristics curve of Cancer Worry Scale (CWS) scores against the 
FCRI- severity subscale. Labeled points correspond to the CWS scores as follows: 1) 8 versus 9; 2) 9 versus 10; 
3) 10 versus 11; 4) 11 versus 12; 5) 12 versus 13; 6) 13 versus 14; 7) 14 versus 15; 8) 15 versus 16; 9) 16 versus 
17; 10) 17 versus 18; 11) 18 versus 19; 12) 19 versus 20; 13) 20 versus 21; 14): 21 versus 22.
Appendice 2. Sensitivity, specificity, positive predictive value (PPV) and negative predicted value (NPV) 
by CWS score.
sensitivity specificity PPv nPv
score (%) (%) (%) (%)
8 vs 9 100 20 36 100
9 vs 10 98 44 43 98
10 vs 11 98 58 52 98
11 vs 12 93 76 64 96
12 vs 13 86 84 71 93
13 vs 14 74 92 80 88
14 vs 15 62 97 90 85
15 vs 16 44 98 92 79
16 vs 17 38 98 92 78
17 vs 18 31 99 93 76
18 vs 19 25 100 100 75
19 vs 20 15 100 100 72
20 vs 21 10 100 100 71
21 vs 22 6 100 100 70
22 vs 23 3 100 100 69
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AbsTRACT
objectives: The aims of the study were to 1) describe the prevalence of fear of cancer 
recurrence (FCR) in partners of prostate cancer (PCa) survivors; 2) to compare the pro-
portions of high FCR in partners with high FCR in PCa survivors; 3) to explore partners’ 
demographic and survivors’ clinical characteristics associated with high FCR in partners 
and 4) to identify the relationship between high FCR and health-related quality of life 
(HRQoL) in partners.
Methods: Questionnaires were sent to partners of disease-free PCa survivors. Outcomes 
included FCR severity (Cancer Worry Scale, CWS) and HRQoL (RAND-36). T-tests and chi-
square tests were used to compare partner FCR with survivor FCR. Regression analyses 
were performed to determine if demographic and clinical characteristics were signifi-
cantly associated with partner FCR. MANOVAs identified differences in HRQoL between 
partners with high and low FCR.
Results: Questionnaires were completed by 168 partners. Mean levels of FCR were 
comparable between partners and survivors (p=0.144). Thirty-five percent of partners 
reported high FCR (CWS ≥14) compared to 38% percent of PCa survivors (CWS ≥13) 
(p=0.542). Higher survivor FCR and younger partner age were significantly associated 
with higher partner FCR. Partners with high FCR scored significantly lower on social 
functioning, emotional role functioning, mental health, general health and vitality than 
those with low FCR (all p<0.05).
Conclusions: Findings from this study illustrate that FCR is a significant concern for 
partners of PCa survivors. Clinicians should be aware of partner FCR when delivering 
care to men with PCa.
FCR in partners
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InTRoDUCTIon
Cancer survivorship comes with emotional and physical challenges for the cancer sur-
vivor and may also affect their carers and family, especially partners [1]. Most partners 
adjust well to the stress of cancer after treatment has been completed but a minority 
faces difficulties [2-3]. For instance, there is some evidence that female partners of can-
cer survivors perceive more psychological distress and a lower quality of life than male 
partners [4,5]. Partners may experience a significant physical and emotional care burden 
such as heightened distress, fatigue or the worry that the cancer may come back [6-7].
Fear of cancer recurrence (FCR) is the fear, worry, or concern about cancer returning 
or progressing [8]. The current literature suggests that FCR is a common concern for 
those who have survived cancer, with moderate to high FCR affecting on average 49% of 
cancer survivors [9]. For PCa survivors, it was found that a third (36%) of them reported 
high FCR [10]. While FCR has primarily been regarded as a patient concern, partners may 
also worry about the risk of cancer recurrence or the possibility of losing their loved 
one to a potential disease recurrence [11]. As no partner specific FCR models have been 
proposed more general FCR models may be suitable for partners as well. For instance, 
the conceptual FCR-model by Lee-Jones et al., (1997) explains FCR as a multidimensional 
construct that includes cognitive and emotional processing systems that influence the 
perception of FCR and lead to behavioral and emotional FCR responses. Also, certain 
structural characteristics (personality, history) may predispose persons to higher levels 
of worry or FCR. Partners’ psychological reactions to disease and treatment are supposed 
to follow the same underlying processes and Lee-Jones’s model may be applicable to 
them as well [12].
In cancer survivors, high levels of FCR do not improve spontaneously with time [13] 
and are associated with adverse outcomes in terms of emotional functioning, experi-
enced distress [9], greater utilization of healthcare [14] and poorer health behaviors 
(smoking, lower activity levels) [15]. For partners, potential consequences of FCR are less 
well understood but given its association with negative outcomes in cancer survivors it 
is reasonable to expect a comparable impact on partner wellbeing.
Currently there is a paucity of research on what FCR entails in partners of cancer survi-
vors and only one study has assessed high levels of fear of progression (FoP) in partners 
of PCa patients [16]. This study reported that half (51%, n=24) of all partners experienced 
high FoP at an average of 8.9 months post-diagnosis; especially partners of PCa patients 
whom had a relapse. This study’s sample size was relatively small and an unreported 
number of patients had experienced a recurrence which limits generalizability. The few 
studies that have addressed FCR in partners of non-PCa survivors often found similar or 
even greater FCR in partners (or carers) than in survivors themselves [17-21]. Also, help 
in managing concerns about cancer returning was one of the top three cited unmet 
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needs by partners and caregivers of both short- and long-term cancer survivors [22,23] 
with respectively 18% and 10% reporting FCR to be an unmet need at 6 and 24 months 
post-survivor diagnosis [23]. FCR appeared to be a consistent and core unmet need for 
many. Furthermore, greater knowledge of factors associated with FCR in partners can be 
used to guide improvement of care for partners.
The aims of this cross-sectional study were to: 1) describe the prevalence of high FCR 
in partners of PCa survivors; 2) to compare the proportions of partners with high FCR 
with the proportion of survivors with high FCR; 3) to explore partners’ demographic and 
survivors’ clinical characteristics associated with high FCR in partners, and finally 4) to 
identify the relationship between high FCR in partners and their health-related quality 
of life (HRQoL). It was hypothesized that a) partners experience similar mean levels of 
FCR as PCa survivors and that b) an equal proportion of partners and cancer survivors 
report high FCR. Based on the available literature [8,24] we expect c) a younger age to be 
significantly associated with FCR in partners and that d) partners with high FCR report 
a poorer HRQoL.
MeTHoDs
sample size justification
Sample size calculation is based on identifying high FCR in partners. A database with 
740 PCa survivors was available for partner invitation (exact number of partners un-
known). Assuming an equal proportion of high FCR in cancer survivors and partners, the 
estimated proportion of partners with high FCR is set to 37% (range 34-40%) [10,25]. In 
order to measure this proportion in current exploratory study with a 7% margin of error, 
we estimate that we will need approximately 173 partners to complete the question-
naires.
Respondents and procedure
The only eligibility criterion was that the partner was identified as being in committed 
relationship with a disease-free PCa survivor. Partners were invited to participate via 
a letter from the treating urologist that was sent between June-August 2013 to PCa 
survivors listed in an existing database. This database included all 740 PCa survivors 
who were curatively treated between 1992 and 2012 at the sites’ department of Urology. 
As it was unknown how many PCa survivors were in a committed relationship all were 
asked if they and (if applicable) their current partner would be willing to participate in a 
questionnaire study. Therefore, it was not possible to ascertain exact response rates for 
partners as they were not contacted directly for confidentiality reasons. Results from the 
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PCa survivor study have already been reported elsewhere (their response rate was 43%, 
for more details see Van de Wal et al., 2016 [10]).
By having the partner return a participation form, 311 indicated willingness to partici-
pate and 75 refused participation. Reasons for non-participation are displayed in figure 
1. Questionnaires were completed and returned by 219 partners. Due to incompleteness 
(<50% competed, n=8), false inclusion (PCa survivor not disease free, n=12) or survivor 
disease status unknown (n=31), 51 questionnaires were excluded from analysis result-
ing in n=168. Ethical approval was given by the Medical Ethics Committee, Radboud 
University Medical Center.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
figure 1. Flow diagram.
Measures
Demographics and clinical characteristics of partners
Variable selection was guided by Lee-Jones’s theoretical model of FCR (1997) plus past 
literature [12]. Partner demographics (age, education, children (yes/no), and years as a 
couple) and the variable cancer history were gathered by self-report. Gender was not 
asked. Educational level was operationalized as lower (elementary school and/or lower 
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secondary education), secondary (general secondary education and intermediate voca-
tional schooling) or tertiary (higher vocational schooling and/or university).
PCa survivor information
PCa survivors’ information was retrieved from an existing dataset and linked to partner 
information in the current study. Survivor information included clinical characteristics 
(treatment modality, time since diagnosis and time since surgery) and demographics 
(age, education and children (yes/no). Furthermore, survivors’ Cancer Worry Scale (CWS) 
scores were also available.
Fear of cancer recurrence
FCR scores (measured by the CWS) were available for both PCa survivors and partners. 
PCa survivors had completed the original Cancer Worry Scale (CWS) [26] in a previous 
study [10] whereas partners completed a modified version in the current study. For 
partners the wording of the original 8-item CWS was adjusted to make the question-
naire more suitable for their situation. For instance, the original item “How often have 
you thought about your chances of getting cancer (again)?” was changed to ““How often 
have you thought about the chances of your partner getting cancer (again)?” Responses to 
all items were provided on a 4-point Likert scale ranging from “never” to “almost always”. 
Scores range from 8-32, a higher score indicating more worries about a recurrence. A 
CWS score of ≥14 was found to differentiate between low and high FCR in breast and 
colorectal cancer survivors (sensitivity 77%/86%, specificity 81%/87%), however a cutoff 
point of ≥13 was found optimal for making this differentiation in PCa survivors (sensitiv-
ity 86%, specificity 84%) [10,25,27]. The modified CWS has not been validated in partners 
of cancer survivors yet. To detect high FCR in (female) partners, two options to define 
high FCR in this group were possible. The first using the validated CWS cut-off point of 
≥13 that was found for PCa survivors. However, research in couples coping with chronic 
diseases has shown that women report more burden regardless of whether they are the 
patient or caregiver [28,29]. This suggests there is a gender rather than role effect (i.e. 
patient versus partner) whereby women experience more burden or distress than men. 
Therefore, it seemed more logical to use the validated female breast cancer survivor 
cut-off score of CWS ≥14, rather than the cut-off for male prostate cancer patients. In the 
current study reliability of the CWS was sufficient for both PCa survivors and partners 
(α=.88 and .87). Incomplete items for the CWS (5%, n = 9) were imputed using mean 
substitutions.
Health-related quality of life (HRQoL) in partners
HRQoL in partners was assessed using the RAND-36 [30]. RAND-36 data was not avail-
able for survivors. The RAND-36 measures four physical health concepts and four mental 
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health concepts: physical functioning, role limitations caused by physical health prob-
lems, pain, general health perceptions, emotional wellbeing, role limitations caused by 
emotional problems, social functioning, and energy/vitality. The internal consistency of 
subscales ranged from α=.80-.90 in the present sample. All scale scores were transformed 
linearly to a 0 (worst health) to 100 (best health) range. Missing data were handled ac-
cording to the scoring manual that recommends use of mean substitution for handling 
of missing data [31]. If more than >50% of the items were missing on a subscale the sub-
scale score was not computed and was regarded as missing. The RAND-36 has sufficient 
psychometric properties whereby the alpha values for the subscales vary between .71 
to .92 and for the test-retest reliability between .58 to .82 over a 2 month period [30,31].
statistics
SPSSv20 was used to analyze the data. Descriptive statistics are provided as a frequency 
breakdown of categorical variables and medians (or means) with dispersion statistics 
for continuous variables. Unless otherwise specified, all analyses were tested at ≤ 0.05 
level of significance. Mean levels of FCR were computed for partners and survivors and 
compared with T-tests. Associations between survivors’ and partners’ mean CWS scores 
were explored using Pearson’s correlation. For all subsequent analyses the CWS cut-off 
score was used to group partners according to low or high FCR (low: ≤ 13; high ≥ 14). 
Chi-square tests were used to assess differences in proportions of high FCR between 
partners and survivors. A multiple linear regression analysis (enter method) of age at 
survey, partner (yes/no), cancer history (yes/no), education (dummy-coded with lower 
education as the referent), children (yes/no), time since diagnosis, treatment modality 
and survivors’ CWS score on partner FCR was conducted. Differences in HRQoL between 
partners with low vs. high FCR were compared with MANOVA.
ResUlTs
Participant characteristics
Demographics and clinical characteristics of partners and PCa survivors are shown in 
table 1. A total of 168 partners of PCa survivors participated. Partners had a median 
age at survey of 67.4 years (range 40 - 86) and PCa survivors 70.1 years (range 54 - 89). 
Survivors were on average 7.5 years post-diagnosis (range 0.9 - 20 years). Couples had 
been together an average of 43 years (range 8-57). Twenty-two partners (13%) reported 
being diagnosed with cancer in the past (mostly breast cancer 41%).
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Table 1. Demographics (n=168 partner-patient dyads).
Partners (n=168)
n (%)
PCa survivors (n=168)
n (%)
Age at survey
  Median (range)
 
67.4 (40–86)
 
70.1 (54-89)
education
  Lower
  Secondary
  Tertiary
 
94 (56%)
46 (27%)
28 (17%)
 
35 (24%)
40 (27%)
70 (48%)
Children
  Yes
  No
 
155 (92%)
14 (8%)
 
151 (94%)
9 (6%)
Years a couple
  Median (range)
 
43.0 (8-57)
 
n.a.
History of cancer
  Yes
  No
 
22 (13%)
147 (87%)
 
174 (100%)
n.a.
Time since diagnosis (years)
  Median (range)
 
n.a.
 
7.5 (0.9-20.0)
Time since surgery (Years)
  Median (range)
 
n.a.
 
5.9 (0.8 -19.2)
Treatment modality
  Surgery only
  Surgery + RT
 
n.a.
n.a.
 
126 (75%)
41 (25%)
Nb. RT = radiotherapy ; n.a. = not applicable.
The prevalence of high fCR in partners and PCa survivors
Partners’ mean rating of FCR was 12.6 (SD = 3.5), which is similar to mean levels of FCR 
reported by PCa survivors (M = 12.0 (SD = 3.8), t = -1.465, p = 0.144, 95% CI [-1.366 to 
0.200]). A significant moderate positive correlation was found between partners’ and 
survivors’ mean levels of FCR (r = .44, p <.001).
When using a CWS cutoff score of ≥13 for PCa survivors and the more conservative 
female breast cancer survivor cutoff score of ≥14 for partners, no significant difference 
in the percentage of high fearful survivors (38%) or partners (35%) was found (χ2(1, n 
= 326) = 0.372, p = 0.542). Fifty-seven of the high fearful partners, compared to 28% of 
the low fearful partners, were in a relationship with a high fearful PCa survivor (χ2(1, n = 
168) = 13.084, p <.001). Twenty-one percent of the couples consisted of both a survivor 
and partner with high FCR. Further exploratory analysis using the same cut-off for both 
(CWS ≥13) found significantly more partners reported high FCR (49% partners vs. 38% 
survivors, p = 0.03).
FCR in partners
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Demographic and clinical associates of high fCR (CWs≥14) in partners
The overall model for regression was significant (p <.001), and explained 21% (R2) of 
partner FCR. Only higher survivor FCR (β 0.310; p <.001) and younger age of the partner 
(β -0.304; p =.008) were significantly associated with higher FCR in partners (Table 2).
Table 2. Regression analysis of factors associated with partner FCR (n=159)
variable b se(b) β t sig (p)
Partner variables:
 Age at survey -0.129 0.048 -0.295 -2.706 0.008* 
 Years a couple 0.045 0.033 0.140 1.368 0.173 
 Cancer history (yes/no) 0.220 0.729 0.022 0.302 0.763 
 Education secondary vs. lower -0.749 0.600 -0.096 -1.249 0.214 
 Education tertiary vs. lower -1.212 0.714 -0.134 -1.698 0.092 
 Children (yes/no) -0.465 1.032 -0.037 -0.450 0.653 
Survivor variables:
 Time since diagnosis 0.043 0.060 0.064 0.719 0.477 
 Treatment modality 0.827 0.594 0.106 1.392 0.166 
 CWS score survivor 0.301 0.075 0.304 3.986 <0.001**
R2 0.21
f 4.324 p < 0.001
Δ R2 0.159
nb. CWS = Cancer Worry Scale
* p < 0.05
** p < 0.001
HRQol correlates of fCR in partners
Compared to partners with low FCR, partners with high FCR (CWS ≥14) scored signifi-
cantly worse on social functioning, emotional role functioning, mental health, vitality 
and general health (Table 3). Compared to scores of a normative female population 
partners with high FCR reported significantly worse social functioning and general 
health (both p < 0.05).
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Table 3. Health-related quality of life in partners with high FCR vs. partners with low FCR and a normative 
population.
low fCR
(n = 103)
High fCR
(n = 53)
normative 
sampleα
sf-36 domains Mean (sD) Mean (sD) p Mean (sD) p
Physical Functioning 81.8 (18.9) 76.7 (24.8) 0.151  80.7 (23.6) 0.260  
Social Functioning 88.5 (16.8) 77.6 (19.1) <0.001** 86.1 (20.9) 0.003**
Physical Role Functioning 75.7 (37.3) 71.7 (38.6) 0.529  78.3 (36.5) 0.207  
Emotional Role Functioning 88.4 (27.9) 76.1 (37.8) 0.023* 82.5 (33.5) 0.185  
Mental Health 82.0 (12.0) 74.0 (13.5) <0.001** 75.5 (18.9) 0.571  
Vitality 71.8 (14.5) 66.4 (16.8) 0.038* 66.3 (19.6) 0.971  
Pain 84.2 (19.7) 81.4 (21.8) 0.428  80.0 (25.4) 0.696  
General Health 70.0 (17.0) 63.9 (20.1) 0.042* 71.5 (21.8) 0.014* 
* p < 0.05 ** p < 0.001
α Normative sample, Dutch female general population (n=691); RAND-36 manual (Van der Zee, 1992).
DIsCUssIon
This study demonstrated that FCR is not restricted to cancer survivors but affects part-
ners as well. Amongst partners, who were on average 7.5 years post-survivor diagnosis, 
approximately one third (35%) scored above the non-validated cut-off for high FCR.
Using the conservative CWS cut-off score to define high FCR, the proportion of high 
fearful partners in current study is lower than reported by Zimmermann et al., (2011) 
where 51% of partners of PCa survivors (n=24) scored above the cut-off for clinical fear 
of progression [16]. Reasons for differences in percentages of high FCR could be that 
the studies differed in respect certain partner characteristics, for instance, our sample 
did not include partners of survivors who had experienced a recurrence. Also, different 
questionnaires were used and the sample by Zimmermann et al., (2011) was relatively 
small which makes it hard to generalize their findings. Our finding that even 7.5 years 
after diagnosis a number of partners continue to experience high FCR is concerning 
and indicates that FCR is not restricted to the period around disease and treatment. The 
Dutch prostate cancer guideline advises semi-annual or annual hospital follow-ups up 
to 5 years post diagnosis [32]. This, together with the fact that partners do not always 
join the patient during medical consultations, makes high FCR in partners a problem 
that can remain undetected, especially in the period beyond 5 years post-diagnosis.
Partners reported a mean CWS score of 12.6. As there is no comparison data available 
of healthy persons or partners of cancer survivors we compared it with the mean CWS 
score (12.4) found amongst family members of patients with Lynch Syndrome (HNPCC) 
and found no significant difference [26]. In accordance with previous studies and our hy-
FCR in partners
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pothesis we found that equal mean levels of FCR were reported between PCa survivors 
and their partners. For instance, Cohee et al. (2015) reported equivalent mean FCR scores 
between young breast cancer survivors and male partners [19]. Three studies that have 
addressed FCR in caregivers (partners and relatives combined) showed equal mean lev-
els of FCR between patients and caregivers [20] or reported that caregivers experienced 
higher levels of FCR [17,18]. Furthermore, in our study partners with high FCR were more 
often partnered with a high fearful survivor than partners with low FCR. Also, there was 
a significant moderate correlation between PCa survivors’ and partners’ FCR. Overall, this 
study provides early evidence that high FCR is not only a common problem amongst 
partners but that it is related to survivors’ FCR as well. Future studies could therefore 
employ dyadic approaches for a more in-depth analysis of patient-partner FCR.
We identified demographic and clinical factors associated with higher FCR in partners. 
Survivor FCR was the strongest significant contributor to partner FCR, further contribut-
ing to the evidence that FCR is a dyadic concern. The only other significant predictor 
was partners’ younger age which is in line with our hypothesis. Mellon et al. (2007) also 
found that younger age in caregivers was related to elevated FCR levels in caregivers 
[17]. Reasons why a younger age has been linked to higher FCR are still speculative. 
It could be that those who are younger experience a greater life disruption caused by 
cancer. Those who are older may have had more exposure to stressful life events leaving 
them more resilient to FCR [33]. However, Cohee et al. (2015) did not find an association 
between age and FCR in male partners of young breast cancer survivors [19]. In the latter 
study the only demographic characteristic significantly related to higher FCR was lower 
education. Regarding survivors’ time since diagnosis and treatment modality, we did not 
find a significant association with partner FCR. Our results indicate that partners experi-
ence FCR at different stages of the cancer continuum, directly after cancer treatment 
but also in the long-term cancer survivorship phase (> 10 years post-survivor diagnosis). 
Due to an insufficient number of published studies there is no clear consensus on which 
demographic or patient factors, except for a younger age, strongly contribute to partner 
FCR. This remains an important topic for future studies to address.
Finally, the relationship between high FCR in partners and their HRQoL was explored. 
Compared to HRQoL scores found in the Dutch healthy female population, those with 
high FCR scored significantly lower on social functioning and general health whereas all 
domain scores for those with low FCR were equal to those by the healthy norm popu-
lation [31]. This is in line with our expectations and corroborates the results of many 
previous studies amongst cancer survivors that reported an association between high 
FCR and poorer emotional wellbeing [9,10,27]. One study reported higher caregiver FCR 
to be related to poorer mental health [20]. We did not find any differences in physical 
(role) functioning or pain between partners with low or high FCR.
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Our results have important implications for clinical practice as they demonstrate that 
FCR is a significant concern for many partners of PCa survivors. A subgroup of partners 
might benefit from interventions designed to help them manage FCR. Most interven-
tions or supportive care for partners of PCa survivors have focused on emotional distress 
(in which FCR is sporadically addressed) and sexual intimacy [34-36]. To date, none have 
focused exclusively on FCR in partners (or couples). In a review by Wooten et al., (2014) 
the efficacy of psychosocial interventions for the wellbeing of PCa survivors’ partners 
remained inconclusive, although psycho-educational interventions and cognitive 
behavioral interventions showed some promising results [34]. As partners often have 
unmet needs in multiple areas, tailored generic interventions with multiple targets (e.g. 
sexual intimacy, FCR) might be more suitable than a symptom-specific intervention.
Also, there is limited but growing evidence that FCR interventions for cancer survivors 
are a promising approach in managing high FCR [37,38] and it would be interesting to 
see if these might be adapted for treatment of partners with high FCR. Future studies 
should delineate the most appropriate methods to offer high fearful partners help with 
FCR.
Several limitations of this study warrant attention. Firstly, due to the cross-sectional 
design causality and directionality cannot be implied. Prospective research is needed to 
identify the longitudinal trajectory of FCR in partners over time. Secondly, in the study 
information we asked all partners to participate regardless of level of FCR. Unfortunately 
one of the most common reasons for partner non-participation (21%) was no interest to 
participate due to absence of FCR. The percentage of partners experiencing high FCR 
could therefore be overestimated due to self-selection bias. On the other hand, there 
were also some partners who declined study participation because they perceived it 
as too confronting. Thirdly, it was also unknown a) how many survivors invited their 
partners to participate and b) how many survivors had a partner. Therefore the par-
ticipation rate of partners could not be precisely calculated. Non-participation bias has 
been found to be a problem in other couple-based and partner studies [39,40]. Finally, 
while we assume the majority of partners to be female, gender was not explicitly asked.
The aforementioned factors limit the generalizability of our findings. As there are cur-
rently no validated questionnaires available to assess FCR in partners of cancer survivors, 
we chose to use an adapted version of the Dutch CWS to measure FCR, and decided (on 
theoretical grounds) to define high FCR with the more conservative score (≥14) on this 
instrument. Nevertheless, we encourage the development and validation of strategies 
to identify partners (and caregivers) with high FCR who could potentially benefit from 
additional supportive care and/or intervention.
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Conclusion and implications
Findings from this study illustrate that FCR is a significant concern for partners of PCa 
survivors. Partners with high FCR reported a worse mental and general health when 
compared with those who experienced low FCR. Our findings support the need for in-
creased awareness of the presence of FCR in partners and better methods of screening 
for high FCR in partners (and caregivers). Furthermore, as partners with high FCR may 
benefit from help in managing their fears, more research on possible partner or couple 
interventions is encouraged. Clinical health professionals should be aware that FCR is 
not solely a patient affair but a problem that affects partners as well.
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AbsTRACT
background: Fear of cancer recurrence (FCR) is one of the most frequently cited 
problems by cancer survivors. More than one third reports high FCR, which is a clinical 
concern due to its association with negative health outcomes. The aim of the current 
study is to evaluate the efficacy of cognitive behaviour therapy (CBT) in reducing FCR in 
high fearful cancer survivors.
Methods/design: The SWORD-study has a randomised controlled design with two 
arms. A sample of 104 high fearful cancer survivors (breast, prostate or colorectal 
cancer) will be recruited from local hospitals. Cancer survivors will be randomised to 
receive CBT (intervention condition) or treatment as usual (control condition). For those 
in the intervention condition, the therapy will be individually delivered in a combina-
tion of 5 face-to-face therapy sessions and 3 online or telephone sessions by a trained 
therapist. Furthermore, these survivors will have access to a supportive website (or 
workbook) throughout the therapy. Survivors in the control condition will not receive 
the intervention and will not have access to the website. The primary outcome will be 
severity of fear of recurrence (Cancer Worry Scale). Quality of life (EORTC Quality of Life 
Questionnaire Core 30) and general psychological wellbeing will be assessed as second-
ary outcomes. Assessments will take place at baseline (before random assignment), at 
3, 9 and 15 months after the baseline assessment. The study has been approved by an 
ethical review board.
Discussion: If the intervention proves to be effective an evidence-based therapy to 
manage high FCR will become available for use in clinical practice.
Trial registration: This study is registered in the Netherlands National Trial Register 
(NTR4423).
SWORD: trial design
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bACkGRoUnD
The number of people diagnosed with cancer is steadily increasing while medical ad-
vancements have significantly decreased cancer mortality rates. In the period beyond 
diagnosis and active treatment cancer survivors are faced with several emotional chal-
lenges. Handling fear of cancer recurrence (FCR) is one of the most prominent ones [1].
FCR is defined as ‘the fear or worry that the disease will return or progress in the same 
organ or in another part of the body’ [2]. FCR is a universal concern that manifests itself 
on a continuum, with mild uncertainty and worry on one end to severe FCR on the other 
end. A certain level of FCR is therefore considered normal and may even be functional; 
it motivates appropriate self-protective responses (e.g. staying alert for signs of a po-
tential recurrence). However, high FCR can detrimentally affect a survivors’ emotional 
wellbeing [3] and may persist for years after completion of medical treatment [4-5].
Moderate to high FCR is present in about 30 to 70% of cancer survivors [4,6-8]. High 
FCR represents a form of distress related to the illness and aspects of treatment e.g. the 
cancer itself, follow-up care or periodic examinations. It is also related to psychosocial 
concerns such as worries about the future, disability or death [9]. FCR is in the top five 
of greatest concerns for cancer survivors and has consistently been identified as one of 
the most cited unmet needs [3, 10]. Even though the problem is frequently encountered 
in clinical practice, no clear consensus exists on the best management strategies due 
to the scarcity of evidence-based therapies. This makes FCR a challenging problem for 
many survivors and health care providers [11].
Interventions for fCR
A more detailed description of intervention studies that have specifically addressed FCR 
(or related constructs) can be found in appendice A (online only). Only one trial speci-
fied FCR as primary outcome of interest. Lebel et al., (2014) published a feasibility and 
preliminary outcome study of a single-arm 6-week cognitive existential group interven-
tion to address moderate to high FCR in breast- and gynaecological cancer survivors. A 
decrease in FCR was found immediately following completion of the therapy and this 
effect was sustained at the 3-month follow-up. In 71% of the cancer survivors FCR could 
be classified as reliably improved and none of the cancer survivors showed deterioration 
[12].
A construct that shares some defining features with FCR is fear of progression 
(FoP), the fear that the disease will further spread or progress in the body. A trial by 
Herschbach et al. (2010) compared the effect of two four-session group interventions 
(cognitive behaviour therapy vs. supportive-experiential group therapy) and usual care 
on reducing dysfunctional FoP [13]. Both interventions were carried out during cancer 
rehabilitation. FoP decreased significantly over time (up to 12-month follow-up) in both 
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intervention groups in contrast to the control group. Those with metastatic disease or 
a recurrence (21%) benefitted most from the interventions [12]. A secondary analysis 
of this data by Sabariego et al., (2011) showed superior cost-effectiveness of group CBT 
over supportive-experiential group therapy for patients with high FoP [14].
Four intervention studies to improve generic emotional outcomes in breast cancer 
survivors addressed FCR as secondary measure (see Appendice B (online only)). Two 
studies by Lengacher and colleagues (2009, 2011) investigated short-term effects of 
group mindfulness-based stress reduction (MBSR) on psychological status in breast 
cancer survivors. In the first study, a randomised controlled trial (RCT), breast cancer 
survivors participating in a 6-week MBSR programme reported a significant reduction 
in FCR over time compared to breast cancer survivors on a waitlist control group [15.] 
A second study by Lengacher et al., (2011) found significant improvement in FCR after 
completion of an 8-week MBSR programme [16]. Both studies have only assessed short-
term effects of the intervention and no information on long-term efficacy is available 
[15, 16]. The third study, a non-randomised trial, reported a significant decline in levels of 
FCR (cancer worry) following a 12-week emotion regulation group intervention targeted 
at anxiety and distress in breast cancer survivors. Yet, no long-term beneficial effects 
were found at 6-month or 12-month follow-up [17]. Finally, a brief self-guided nurse de-
livered uncertainty management intervention found no significant differences between 
the intervention and control group [18]. We are aware of two separate intervention trials 
for FCR currently in progress: Conquer Fear [19] and the AFTER-intervention [20]. Results 
of these studies have not yet been published.
To summarize, published intervention studies provide promising results in terms of 
beneficial effects of psychological interventions for FCR and related constructs. How-
ever, these studies had some limitations. While literature shows that moderate to high 
FCR is a universal problem in cancer survivors interventions have almost solely focused 
on survivors with breast- or gynaecological cancer [13, 15, 16, 18]. Furthermore, informa-
tion on treatment efficacy for long-term cancer survivors is limited because FCR was 
mainly addressed during the first year after diagnosis [13, 15, 16]. Therefore, it is hard to 
generalise findings of efficacy and feasibility beyond women’s cancers to other cancer 
types, to men and to long-term cancer survivors. Only two studies mention screening 
for high FCR as part of their standard eligibility procedure [12, 13]. By screening for 
high (dysfunctional) FCR, it is possible to identify those with the highest care need and 
to select those who might benefit most from the intervention. The SWORD-study was 
developed to address above mentioned limitations.
Current study
This paper describes the development of the intervention and study protocol for the 
SWORD-study (SWORD is the acronym for Survivors’ Worries of Recurrent Disease). In 
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this study an intervention known as “Beyond Fear” will be evaluated with regard to its 
efficacy in managing high FCR among breast, colorectal and prostate cancer survivors. 
In an RCT both the short-term and long-term effects of individual CBT for FCR will be 
investigated.
Our intervention expands on the theoretical formulation of FCR as a multidimensional 
construct proposed by Lee-Jones (1997)[21]. We updated this original formulation with 
recent research findings and clinical experience. According to our framework as shown 
in figure 1, FCR is a distressing emotion maintained by dysfunctional cognitive think-
ing patterns such as recurring unhelpful thoughts, negative (illness) beliefs, intrusive 
images or persistent rumination. These thinking patterns cause a person to interpret 
certain events or internal stimuli as potentially threatening or harmful to one’s physical 
health and wellbeing, thereby triggering FCR. Consequently, behavioural strategies that 
are intended to reduce the fear, such as avoidance, excessive self-monitoring or safety-
seeking behaviours, maintain FCR by preventing change in cognitive appraisal and/or 
by providing further exposure to triggers of FCR. While these behaviours may provide 
short-term alleviation of fear, they may actually maintain the fear on the long run [21, 
22]. CBT targets high FCR by changing dysfunctional thinking patterns and maladaptive 
behaviours as specified in this model.
Aims
The primary aim of the SWORD-study is to evaluate the efficacy of a combination of on-
line and face-to face cognitive behaviour therapy (blended CBT) in reducing the impact 
of FCR in breast, colorectal and prostate cancer survivors. The aim is not to remove all 
FCR, but rather to reduce its severity in order to improve quality of life.
MeTHoDs/DesIGn
The SWORD-study design and intervention are described conform the CONSORT guide-
lines for evaluation of randomised controlled trials [23] and conform the CONSORT 
extension for non-pharmacological treatment interventions [24].
Trial design
The SWORD-study is a longitudinal, multicentre, two-arm, randomised controlled trial 
with one intervention condition (CBT) and one control condition; treatment as usual 
(TAU). Four assessments will take place for both trial conditions: baseline (T0, before 
randomisation), 3 (T1), 9 (T2) and 15 months (T3) after the baseline assessment. For sur-
vivors in the intervention condition, the CBT will take place between the first and second 
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assessment. The longitudinal design allows for the assessment of both short-term and 
long-term effects of the intervention.
ethical consideration
The SWORD-study has been approved by the ethical review board of the Radboud Uni-
versity Medical Center (CMO Arnhem-Nijmegen). Approval of local ethics has been ob-
tained in centres where recruitment will take place. Only survivors who have completed 
written informed consent will be allowed to participate. The study will be conducted in 
compliance with the guidelines for Good Clinical Practice and the Declaration of Helsinki 
[25, 26]. This trial is registered in the Netherlands National Trial Register (trial number 
NTR4423).
figure 1. Theoretical model fear of cancer recurrence.
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Participants and procedure
A total of 104 (breast, prostate or colorectal) cancer survivors with high FCR are to be 
enrolled in this study. They will be randomly allocated to receive either CBT (n=52, inter-
vention condition) or TAU (n=52, control condition). Cancer survivors will be recruited 
from outpatient clinics at an academic centre and several general hospitals in the Neth-
erlands. Recruitment will take place at all sites simultaneously until the desired sample 
size is reached. Nurse practitioners are asked to provide an envelope containing study 
information (and an entry form) to all cancer survivors who are eligible for study par-
ticipation based on information from their medical record. If interested to participate, 
a person will complete the entry form at home and send it to the researcher (MW) who 
will then contact them by phone to provide further study information and to address 
questions. Those willing to participate are asked to provide written informed consent 
and to fill-out a screening questionnaire. After receipt of the completed questionnaire, 
the researcher will contact the patient once more to discuss the screening outcome and 
to second check all eligibility criteria.
eligibility
Cancer survivors will be eligible to participate if they: (1) have completed primary treat-
ment (with curative intent) for breast, colorectal or prostate cancer at least 6 months 
and not more than 5 years ago; (2) are disease-free at the moment of study inclusion, as 
defined by the absence of somatic disease activity parameters; (3) are at least 18 years 
of age; (4) score ≥ 14 on the Cancer Worry Scale, indicating high FCR; (5) have sufficient 
Dutch language skills to fill out questionnaires, to understand written text and to en-
gage in active conversation; (6) are able to travel to the Radboud University Medical 
Center (RUMC) for CBT; (7) have given written informed consent. Cancer survivors are 
not eligible to participate if they 1) already receive psychological/psychiatric treatment 
at moment of inclusion; or 2) have a second primary tumour at moment of inclusion.
sample size
The sample size is calculated for the primary outcome FCR as measured with the Cancer 
Worry Scale [6]. To detect a medium difference in FCR (Cohen’s d=0.50), with a two-sided 
type I error rate of 0.05 and a power of .80, a sample size of 128 patients is needed. To 
correct for the baseline measurement as covariate the sample size is multiplied with the 
factor (1-r2), where r denotes the correlation between the baseline and post-intervention 
FCR (0.6 based on preliminary research) [27]. Therefore, a total sample size of 82 patients 
is desired. Because of an anticipated attrition rate of 20%, 52 patients are required per 
condition (104 total) [12].
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Randomisation
After completion of baseline assessment survivors will be allocated to CBT or TAU ac-
cording to a computer generated randomisation list, with a 1:1 allocation ratio using a 
fixed block size of six participants. Stratification by cancer type (breast, colorectal and 
prostate cancer) will be applied Randomisation is computerised, using a randomisation 
website specifically designed for this study. An independent secretary will enter all 
necessary patient data into the programme and will communicate the randomisation 
outcome (CBT or TAU) to the researcher who further informs the study participant. 
Cancer survivors allocated to the CBT condition will be assigned to one of two therapists 
according to therapist availability.
InTeRvenTIon
Developmental process
The development of the intervention consisted of five stages:
1: Needs assessment: Breast cancer survivors (n=130) were approached with a ‘need 
for help’ question and the Cancer Worry Scale (CWS)[6]. All survivors were asked if they 
would accept CBT specifically focused on managing FCR when experiencing high FCR 
(response options: yes/possibly/no). They were also provided with a short explanation 
of the CBT-content and therapy outline. Eighty-seven survivors completed both the 
‘need for help’ question and the CWS. The majority (74%) of the responders considered 
or expressed a need for CBT (44% possibly; 30% yes). Almost the same response pattern 
was seen in those with high FCR (35% possibly; 30% yes) and those with low FCR (50% 
possibly; 30% yes) as based on the CWS. This procedure was replicated amongst 86 
colorectal cancer survivors. Fifty-six percent of these survivors considered or expressed 
a need for CBT (38% possibly; 18% yes). Colorectal cancer survivors with high FCR were 
more open to CBT compared to survivors with low FCR (Low FCR, 38% possibly; 10% 
yes: High FCR, 39% possibly, 32% yes). Thus, a substantial number of cancer survivors 
indicate a need for help with FCR.
2: Content and structure of the intervention. The intervention was developed by a col-
laboration of three clinical psychologists (JP/HK/PS), two researchers (MG/MW) and a 
psychiatrist (AS), all experienced in the field of psychosocial oncology and working at 
the RUMC. After literature consultation and multiple meetings, consensus was reached 
on core components and key techniques of the intervention (described in the section 
‘Intervention: Cognitive Behaviour Therapy for FCR’). CBT is one of the best established 
interventions for psychological problems in somatic conditions. In health care set-
tings, CBT is already frequently used for various somatic problems such as fatigue and 
insomnia [28, 29]. CBT is a structured, action-oriented form of psychological treatment 
SWORD: trial design
85
5
consisting of techniques directed at identifying and modifying negative (dysfunctional 
or unhelpful) thought patterns and dysfunctional behaviours [30]. Since cognitions, 
emotions and behaviours are interconnected, a change in cognitions and/or behaviour 
initiates changes in the other areas as well. The intervention will be offered as blended 
therapy. In blended therapy both online and offline therapy components are integrated. 
A website is available that supports the patient throughout the entire therapy as it 
runs parallel to the face-to-face therapy sessions. The website has been developed in 
collaboration with ICT specialists and contains over 70 pages of content including 
information (10 scripts), at-home assignments (27 tasks), assessments (6 tests), audio (2 
clips) and video (15 fragments). An incorporated library includes additional information 
on cancer-related topics. A feature to engage in an electronic consultation (‘e-consult’) 
with the assigned therapist is supplementary to the face-to-face sessions. Because not 
all survivors have access to the internet and some may lack the required computer skills, 
a paper workbook (with DVD/CD) will be available as well.
3: Advisory Committee. The third step was to involve health care workers and patient 
representatives as an advisory committee in reviewing the therapy content. The com-
mittee was composed of three cancer survivors (breast, colorectal and prostate cancer) 
and three health care workers (two nurse practitioners for breast cancer and colorectal 
cancer care and a urologist). They were asked to provide comments, ideas and sugges-
tions to further improve the intervention. In addition, a 13-item close-ended question-
naire, answerable on a 5-point Likert Scale (e.g. “Overall, what is your general impression 
of the website?”) was completed and members were asked to elaborate on their assigned 
score. The content and format of the intervention were rated with a mean of 4.3 out 
5 (a higher score indicating a more positive impression of the intervention). With the 
generated feedback the content was slightly revised.
4: Website usability testing. The user interface of the prototype website was tested by 
three patient representatives (breast, colorectal and prostate cancer) on feasibility and 
patient centeredness. A ‘think aloud procedure’ was employed, meaning that persons 
were asked to think aloud while using the website in order to provide us with more 
insight in 1) how the website is used without guidance of a professional and 2) how 
encountered problems are solved [31]. Afterwards the System Usability Scale (SUS) [32, 
33] and a feedback form were completed. The SUS is a short (10-item scale) which gives a 
global view of subjective perception of usability, the mean total SUS score (range 0 - 100) 
given by the three survivors was 87, which indicates a satisfactory level of perceived 
usability [33].
5: Pilot testing. Lastly, two therapists piloted the intervention with two high fearful 
breast cancer survivors who completed all therapy sessions. After some minor revisions, 
the final content of the therapy manual was established.
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Intervention: Cognitive behaviour Therapy for fCR
The intervention was developed as face-to-face CBT with access to a website that pro-
vides online materials and the option to engage in therapist-patient interaction. For the 
therapists, a structured manual with a detailed description of each therapy session has 
been developed. The CBT covers 3 months and comprises five individual one-hour face-
to-face sessions (session 1, 2, 3, 5 and 8) and three (15 minutes) e-consults or telephonic 
consultations (session 4, 6 and 7). In order to sustain behaviour change and monitor 
therapy progress, patients will be invited for a booster session at 3-month follow-up.
Intervention components were partially based on existing traditional CBT models for 
health anxiety and generalised anxiety. As with other forms of CBT, the primary emphasis 
of the therapy is on perpetuating factors of the problem in question. In this case, those 
factors maintaining high FCR. The principal therapeutic techniques are self-monitoring, 
cognitive restructuring (identification and re-attribution of unhelpful thoughts) and 
exposure- and response prevention. Other techniques are psychoeducation, relaxation, 
mindfulness, reframing, modelling (patient videos), at-home assignments, goal plan-
ning and attainment [34]. The first session is directed at case conceptualisation and 
formulation of a personal FCR model, taking into account personal characteristics, trig-
gers of fear, cognitions and consequences of FCR (see figure 1). The FCR model guides 
the course of therapy by identifying the most appropriate points or targets for inter-
vention (e.g. unhelpful cognitions). It is open to modification in the course of therapy 
because new insights might require adjustments in certain parts of the FCR model. The 
following four sessions (session 2 to 5) focus on acceptance, on identifying/modifying 
dysfunctional thinking patterns and on behaviour modification. If desired by patient 
or therapist, spouses will be invited to attend one or more therapy sessions. The final 
three sessions (session 6 to 8) are directed at consolidation of therapy progress and the 
establishment of a relapse prevention plan. Self-management skills are reinforced and 
active contribution to therapy progress and goal setting is encouraged. Completion 
of at-home assignments is of pivotal importance in order to practice the skills learned 
during therapy and to establish enduring change. A more detailed description of the 
intervention by session is described in table 1.
SWORD: trial design
87
5
Table 1. Content of the intervention by therapy session
session Delivery Week Time 
(minutes)
session components
1 face-to-face 1 90 –  Case formulation: a patient’s story.
–  Discuss therapy rationale.
–  Establish therapy goals.
–  Review FCR and complete a personal FCR model.
–  Introduce at-home assignments.
2 face-to-face 2 60 –  Explain the basic tenets of CBT.
–  Discuss and visualize the association between thoughts, 
feelings and actions.
–  Review the concept of helpful beliefs.
–  Practice in filling out thought records.
–  Introduce mindfulness and relaxation exercises.
3 face-to-face 3 60 –  Review the completed thought record(s) to identify 
unhelpful thoughts and behavioural consequences of FCR.
–  Differentiate realistic from unrealistic worries and establish 
more helpful thoughts.
–  Explore and identify dysfunctional behavioural patterns.
–  Create a ranked list of situations that induce FCR and 
propose a behavioural experiment.
–  Practice a mindfulness or relaxation exercise.
4 e-consult
(or telephone)
4 15 –  Review of progress (troubleshooting).
–  Encourage at-home skill practice.
5 face-to-face 6 60 –  Review therapy goals, discuss areas of concern and make 
future plans (beyond therapy).
–  Discuss completed thought records and/or behavioural 
experiments.
–  Identify personal strengths and resources of strength.
6 e-consult
(or telephone)
7 15 –  Review of progress (troubleshooting).
–  Encourage at-home practice of skills.
7 e-consult
(or telephone)
9 15 –  Review of progress (troubleshooting).
–  Introduce the relapse prevention plan.
8 face-to-face 11 60 –  Review therapy goals, progress made so far and discuss 
possible future pitfalls.
–  Define and finalize the relapse prevention plan.
–  Evaluate the therapy process.
–  Schedule an appointment for the booster session.
9 face-to-face
(booster 
session)
24 60 –  Review the FCR model and progress made during therapy.
–  Discuss difficult situations and how to overcome them.
–  Relapse prevention plan.
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Control condition: Treatment as Usual
Cancer survivors in the control condition have access to TAU and will not be offered 
additional psychological therapy for managing FCR. This condition reflects the natural 
course of FCR over time and gives insight in the standard care practices that are of-
fered to persons outside the study context (e.g. during routine medical follow-up). In 
the period after cancer treatment all patients are offered medical follow-up appoint-
ments conform the recommendations of the Dutch guidelines in oncology care [35]. For 
colorectal cancer, the Dutch guideline advises medical examinations every 6 months 
during the first 2 years of follow-up, continued by yearly examinations up to 5-years 
follow up. For breast cancer, the Dutch guideline advises medical follow-up examina-
tions every 3 months during the first year, every 6 months during the second year and 
examinations once a year during 2 to 5 years follow-up. For prostate cancer, during the 
first year after cancer treatment a follow-up schedule of 6 weeks, 3, 6, 9 and 12 months 
is recommended, and semi-annually or annually thereafter for 5 to 10 years. In the Neth-
erlands, psychosocial follow-up is not institutionalised and psychosocial care offered 
to cancer survivors with high FCR therefore differs between health care institutions. 
Information on additional medical or psychosocial care survivors have had during the 
study period will be collected for both the interventions and the control group. This 
includes utilization of psychosocial services (e.g. psychological therapy, mindfulness 
and social work), health care consultations (e.g. GP, medical specialists, and paramedical 
assistance) or medication use.
Participating therapists
All CBT sessions will take place at the RUMC, department of Medical Psychology in Nijme-
gen, the Netherlands. The CBT will be practiced by two qualified, registered healthcare 
psychologists with experience in delivering CBT for somatic conditions and experience 
in the field of psychosocial oncology. During the study, both therapists will have regular 
supervision by a registered clinical psychologist, also qualified as CBT supervisor (JP). 
Before the start of the study, both therapists had already performed one supervised 
treatment case conform the therapy manual.
Treatment integrity
To be able to draw valid conclusions on the therapy effects, treatment integrity (e.g. 
the implementation of the treatment as intended) is ensured conform the guidelines 
established by the Behaviour Change Consortium [36], i.e. with the use of a standardised 
therapy manual and ongoing therapist supervision. All sessions will be audio taped and 
5% will be randomly checked for adequate therapy implementation.
SWORD: trial design
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Detailed information on the study outcomes is available in table 2. Participants will be 
asked to complete questionnaires at four different time points, either online or on paper. 
Demographic and medical information will be gathered with self-report questionnaires 
and from medical records.
screening and primary outcome
Participants will be screened on high Fear of cancer recurrence with the Cancer Worry 
Scale (CWS). This questionnaire is validated as a screening instrument and is able to 
detect high FCR in Dutch cancer survivors [6]. A cut-off score of ≥ 14 appeared optimal 
for differentiating high fearful patients from non-fearful patients. The CWS has good 
psychometric properties (α=0.87).
secondary outcomes
Multidimensional aspects of FCR will be assessed with the Fear of Cancer Recurrence In-
ventory (FCRI). The FCRI gives a global idea of FCR in the preceding month and provides 
information about the principal characteristics of FCR (e.g. fear invoking stimuli/situa-
tions). The FCRI consists of 7 subscales; Triggers, Severity, Psychological distress, Coping 
strategies, Functioning Impairments, Insight, and Reassurance [37].
Quality of Life will be measured with the Dutch version of the European Organiza-
tion for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire Core 
30 (QLQ-C30). Complementary to the QLQ-C30, disease specific modules for breast 
cancer (QLQ-BR23), colorectal cancer (QLQ-CR38) and prostate cancer (QLQ-PR25) will 
be assessed [38]. Both the EORTC-QLQ-C30 and the disease specific modules have 
demonstrated moderate to good psychometric properties and clinical validity in cancer 
survivors [38-41].
Satisfaction with life will be evaluated with the Satisfaction With Life Scale (SWLS). The 
SWLS has sufficient psychometric properties (α=.87) and is able to detect changes in life 
satisfaction over time [42].
Distress will be measured with the Hospital Anxiety and Depression Scale (HADS) total 
score [43-44]. In addition, the Dutch version of the Distress Thermometer (DT) and the 
problem list will be completed as well [45].
Fatigue severity will be assessed with the fatigue severity subscale of the Checklist 
Individual Strength (CIS-8R)[46, 47].
Bodily vigilance refers to the tendency to focus on internal bodily sensations and will 
be assessed with the four-item Body Vigilance Scale [48].
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Coping with the experience of cancer will be measured with the Impact of Events Scale. 
This scale consists of 15 items that ask for the frequency of cancer-related avoidant and 
intrusive cognitions or behaviours [49] .
Perceived social support, or rather the perceived discrepancy between a patient’s de-
sired social support and the actual amount of social support received, will be assessed 
with the Social Support List – Dissatisfaction (SSL-D) scale [50].
Personality dimensions will be measured with the Big Five Inventory (BFI) [51]. This is 
a 44-item multidimensional personality inventory that covers the five main dimensions 
of personality trait (conscientiousness, agreeableness, emotional stability, extroversion 
and intellect or openness.)[52] The BFI will only be administered at baseline (T0).
Optimism, as a dispositional trait, will be assessed with the Life Orientation Test (LOT). 
This questionnaire contains twelve items on the optimistic and pessimistic trait of per-
sonality [53].
Health Care Use / cost-effectiveness: The EuroQol-5D (EQ-5D) will be used to calculate 
cost-utility. It has shown to be an appropriate measure for economic evaluations in 
health interventions with breast cancer patients after treatment [54]. The instrument 
is able to detect changes in patients’ self-reported health related quality of life and has 
good psychometric properties [54, 55]. Health care costs will be further monitored with 
cost diaries and the Trimbos/iMTA Costs associated with Psychiatric Illness (TiC-P) ques-
tionnaire [56]. Patients will be asked to report both direct health care costs (e.g. use of 
health care services, change of prescribed medication) and indirect costs (e.g. absence 
from work) during specified time periods (see table 2).
Technical usage statistics (intervention condition only).
Website use and completion of exercises can be seen as a form of treatment adherence. 
This includes data on number of exercises completed, frequency of logins, time online 
and webpages opened [57]. Technical data for those using the workbook will include the 
number of exercises completed.
Intended statistical analyses
SPSS will be used for all statistical analyses. All statistical tests will be two-sided (level 
of significance = 0.05). To ensure that the key variables are evenly distributed by ran-
domisation, baseline characteristics will be compared between the two conditions with 
Chi-square (categorical variables) and ANOVA (continuous variables) testing. Primary 
efficacy analysis will be conducted in agreement with the intention-to-treat principle. 
Additionally, a per-protocol analysis will be conducted using the data for those who 
successfully completed the intervention. Differences between the two conditions in the 
amount of change in FCR (T0 and T1) will be calculated with ANCOVA-analysis. Later, 
the follow-up effects (T3, T4) will be investigated with longitudinal data analysis. Next 
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to statistical significance the clinically significant improvement will be established ac-
cording to the method by Jacobson & Truax, calculating the reliable change index [58].
DIsCUssIon
While cancer survivors report FCR to be a key concern and unmet need no clear consen-
sus exists on the best management strategies for FCR in clinical practice. The SWORD-
study protocol describes a trial that will evaluate blended CBT as intervention for high 
FCR in cancer survivors. The primary aim is to reduce high FCR to more acceptable and 
less debilitating levels. Both post-intervention and follow-up effects of the therapy will 
be assessed. If efficacy can be demonstrated, an evidence-based therapy for high FCR 
will become available.
Strengths of this study include: an intervention specifically targeted at high FCR, the 
inclusion of breast, colorectal and prostate cancer survivors, screening for high FCR and 
the inclusion of survivors up to five years post medical treatment. Until now, only one 
published (feasibility) trial investigated an intervention specifically targeted at high FCR. 
Other studies have mentioned FCR as a secondary outcome or have investigated related 
constructs (e.g. FoP). Furthermore, because interventions were mostly targeted at sur-
vivors of breast or gynaecological cancer there was an overrepresentation of women in 
all samples (88-100% women). It is assumed that men and women experience and deal 
with emotional problems differently. Women are more comfortable in disclosing their 
feelings than men and might be more inclined to seek and accept expert help [59]. It is 
therefore debatable whether comparable intervention effects can be achieved in male 
cancer survivors. In order to overcome this problem, our trial includes survivors of male 
(prostate), female (breast) and mixed gender (colorectal) cancer.
FCR is a concern for many cancer survivors, ranging from mild to high levels. Hence, 
different forms of care, each with different intensity, should be available to cancer 
survivors based on their individual needs [60]. The first level of tailored care for milder 
FCR may only comprise of patient education or psycho-education while survivors with 
moderate FCR could benefit from a more intensive approach such as empowering self-
management through internet therapy. High specialised care can comprise individual 
CBT, of which our intervention would be a good example. In order to identify those who 
might benefit most from blended CBT screening for high FCR will take place and those 
scoring above the specified threshold (CWS ≥14) will be asked to participate.
To conclude, the current trial will answer the question whether blended CBT is an 
effective intervention to manage high FCR in breast, prostate and colorectal cancer 
survivors. If so, an evidence-based therapy to manage high FCR will become available 
for use in clinical practice.
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AbsTRACT
objective: This case study describes in detail the course and content of cognitive behav-
ior therapy (CBT) for clinical fear of cancer recurrence (FCR) in a breast cancer survivor.
Methods: CBT for clinical FCR consists of five face-to-face therapy sessions and three 
telephone (or electronic) consultations. The primary treatment goal was to reduce FCR 
severity by modifying cognitive processes and dysfunctional behavior. The therapy is 
described in detail and provides targets for intervention. FCR and quality of life assess-
ments were completed by the breast cancer survivor pre-therapy, post-therapy, and 6 
and 12 months post-therapy. Perceived control over FCR was assessed in each session. 
The clinical nurse specialist participated in evaluation interviews.
Results: Perceived control over FCR increased during the therapy. FCR severity declined 
to a non-clinical level. This clinically significant improvement was still evident at the 
6-month and 12-month follow-up assessments and was supported by secondary and 
exploratory outcomes, all of which improved to the non-clinical level. The patient, thera-
pist and clinical nurse specialist verbal evaluations confirmed the quantitative findings.
Conclusions: FCR offers a great challenge for health care professionals due to the lack 
of effective treatment options. This case study shows how clinical FCR can be addressed 
with CBT and may contribute to the improvement of care for cancer survivors.
SWORD: case study
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InTRoDUCTIon
Fear of cancer recurrence (FCR) is “the fear or worry that the disease will return or prog-
ress in the same organ or in another part of the body” [1]. Some degree of FCR is consid-
ered normal and functional in cancer survivors; it prompts appropriate self-protective 
responses, such as staying alert for signs of a potential recurrence and adherence to 
medical regimens. However, in 30–70% of individuals FCR becomes a chronic concern 
that detrimentally affects their emotional wellbeing, quality of life, and daily functioning 
[2-4]. This fear may persist long after completion of cancer treatment. Severe FCR, also 
referred to as clinical FCR, does not improve spontaneously with time [2,5].
Clinical FCR is characterized by the misinterpretation of physical symptoms, the belief 
that symptoms represent recurrence [6], excessive threat-monitoring behavior, frequent 
seeking of reassurance (e.g. extra medical examinations by request) [7], and/or avoid-
ance of situations that remind patients of their disease or treatment [2-3,8]. Clinical FCR 
not only negatively affects the patient but also medical care. It continues to be one of 
the unmet needs most frequently cited by cancer survivors [9]. Despite its high preva-
lence and unfavorable effect on wellbeing and health care use, adequate psychosocial 
management of clinical FCR is not routinely available. Furthermore, health professionals 
acknowledge that FCR is a common problem in clinical practice but are unsure about 
how to manage it. They often do not refer survivors for extra psychosocial care [10]. 
Evidence-based management strategies for FCR are needed.
We developed an individually delivered cognitive behavior therapy (CBT) program in 
order to reduce clinical FCR in cancer survivors. In contrast to two other interventions 
that are currently being investigated for the treatment of FCR [11,12] this intervention is 
developed as an individually delivered blended therapy: a combination of face-to-face 
contact with e-health or telephone consultations. Whereas the other two therapies rely 
on cognitive existential therapy (six group sessions)[12] or meta-cognitive therapy (five 
individual sessions) [11] the here described intervention is based on tenets of CBT, and 
consists of eight therapy sessions. CBT is already an established, effective treatment for 
anxiety-related disorders in the general population [13] and for cancer survivors, indi-
vidual CBT has proven effective for fatigue [14], insomnia [15], anxiety and depression 
[16]. One case study showed an effect of CBT on FCR in a cancer survivor with a general 
anxiety disorder [17]. We therefore expect CBT to be beneficial for FCR as a standalone 
problem as well.
In blended therapy part of the therapy is delivered in face-to-face sessions while other 
parts are given in a different form; in this case e-consultations (with access to a website) 
or by telephone (and using a workbook). While not much work has been published on 
blended care, this form of treatment is increasingly being applied by therapists [18]. 
Face-to-face interventions are relatively costly, resource intensive and there are also 
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known patient barriers to engage in face-to-face therapy such as time, reluctance to 
return to the hospital where cancer treatment took place, needing to take time off work 
and travel expenses [19]. Blended therapy may overcome some of these barriers as fewer 
face-to-face sessions are needed while continuous access to the website or workbook is 
available to facilitate further skill acquisition and learning. The patient hereby continues 
treatment between sessions and works on his own mental health which is beneficial for 
the development of self-management skills [18]. Due to scarcity of research it is not yet 
known whether similar treatment effects can be obtained with blended therapy as with 
face-to-face delivered interventions.
The aim of the current case study was to describe in detail the course and content 
of blended CBT for clinical FCR in a breast cancer survivor, including challenges of how 
successful treatment might be conducted and obstacles that might be encountered. 
The value of case studies in psychology is increasingly being recognized as this design 
lends itself for in depth description, exploration, and explanation of intervention fea-
sibility and potential effectiveness [20]. It provides insight into treatment content and 
the change of symptoms over time. The process of treatment was supported with both 
quantitative and qualitative outcomes that can be of clinical interest.
CAse PResenTATIon
Medical background
NG, a 60-year-old Caucasian woman from the Netherlands, was diagnosed with breast 
cancer (BCa) in the National Breast Cancer Screening Program (2012). Pathological 
examination revealed a 1.5-cm grade II infiltrating ductal carcinoma, estrogen recep-
tor positive, progesterone receptor and HER-2/neu negative with an extensive grade 
II intraducal component. The TNM Classification of Malignant Tumors was pT1cN0(i-)
M0, indicating no locoregional spread of the disease or metastasis. In accordance with 
Dutch oncology guidelines, NG was advised adjuvant radiotherapy, chemotherapy, and 
endocrine therapy after breast-conserving therapy. Four weeks postoperatively, she 
received 20 fractions of radiotherapy. After being referred to a medical oncologist and 
much consideration NG decided to forego chemotherapy because she feared its possible 
side effects (fatigue and hair loss). She was prescribed Tamoxifen 20mg daily and was 
referred for reconstructive surgery. After conserving therapy of the left breast, reduc-
tion surgery of her right breast was performed. NG had medical follow-up consultations 
every 6 months for the first 2 years and an annual mammography. She is married, has 
two children and three grandchildren. She completed primary education and works as 
a homemaker. NG has three sisters and two brothers. Her mother, aunt, and two sisters 
have had breast cancer.
SWORD: case study
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Clinical presentation of psychological problems
One year after diagnosis NG felt a new lump in her breast and suspected a recurrence. 
She contacted the nurse specialist and was invited for an ultrasonography which re-
vealed a cyst. The nurse specialist reassured NG that there were no reasons to suspect 
a malignancy and, conform guidelines, NG was advised to return for her annual clinical 
examination and mammography in a few months. One month later, NG felt the lump had 
changed and again contacted the nurse specialist. Pathological examination revealed 
no signs of malignancy. Shortly after, NG scored an 8 on the distress thermometer. She 
reported concerns regarding body image, FCR and relational problems. In the following 
two months, NG telephoned the nurse specialist twice, expressing her worries about a 
possible recurrence. During these calls she reported frequent self-examinations and lack 
of trust in her body. In order to better manage her FCR, NG was then referred to medical 
psychology.
MeTHoDs
The development of this intervention has been published elsewhere [21]. A call was sent 
out to nurse practitioners to refer high fearful cancer patients for pilot testing of the 
therapy protocol. NG was the first cancer survivor referred to medical psychology. The 
Cancer Worry Scale was administered to screen for clinical FCR [22]. Paper-and-pencil 
assessments took place prior to start of treatment (T0), after completion of treatment 
(T1), at 6 (T2) and 12-months’ (T3) follow-up. All assessments and evaluations were done 
by an independent researcher in order to prevent potential bias.
Measures
Primary outcome: Fear of cancer recurrence
Cancer Worry Scale (CWS): This 8-item questionnaire (range 8–32) was developed to 
identify dysfunctional FCR in cancer survivors [22]. The CWS has good psychometric 
properties and is validated in BCa survivors (α=0.87). A cut-off score of ≥14 is optimal for 
detecting high/clinical FCR [23].
Fear of Cancer Recurrence Inventory (FCRI): The FCRI provides information on principal 
characteristics of FCR. Six out of seven subscales were used: severity, triggers, psycho-
logical distress, functional impairment, insight, and reassurance seeking. A severity 
score of ≥13 is indicative of heightened FCR and a score ≥ 16 can be used to identify 
survivors who might benefit most from FCR interventions [24-25].
104
Chapter 6
Secondary outcome: Quality of Life
EORTC-QLQ-C30: The European Organization for Research and Treatment of Cancer 
(EORTC) Quality of Life Questionnaire Core 30 (QLQ-C30) and the BCa module (QLQ-
BR23) were completed. The QLQ-C30 consists of one global health status/quality of life 
scale, five functional scales, and symptom scales (range 0–100). A high score on a func-
tional scale represents a high level of functioning while it indicates greater impairment 
on a symptom scale [26-27].
Exploratory outcomes
Hospital Anxiety and Depression Scale (HADS): The HADS is a 14-item self-report scale 
that assesses symptoms of anxiety and depression [28]. A higher score indicating more 
distress (>15 clinical distress) [29].
Distress Thermometer (DT): The DT measures distress severity on a scale from 0 (no 
distress) to 10 (extreme distress) [30]. In the Netherlands, the DT is used for routine 
screening of distress in medical practice. A cut-off score of 5 is ideal to detect clinical 
distress [31].
Satisfaction With Life Scale (SWLS): The SWLS provides a global judgment of satisfac-
tion with one’s life (5-items, α=.87) [32].
Body Vigilance Scale (BVS). A 4-item questionnaire. Three items address attentional 
focus, perceived sensitivity to bodily changes, and the average duration of time spent 
attending to sensations. A fourth item rates attention paid to 15 bodily sensations (e.g. 
palpitations) [33].
The Impact of Events Scale (IES). The 15-item IES was used to assess cancer-specific dis-
tress. Subscales measure 1) the extent to which a cancer survivor experiences intrusive 
thoughts about cancer and 2) the tendency to avoid thinking about cancer [34].
Checklist Individual Strength (VVV). This 4-item short-form measures the experience of 
fatigue on a 7-point scale [35].
Life Orientation Test (LOT). This 12-item questionnaire measures optimistic and pes-
simistic personality traits. A higher score indicates a more positive attitude [36].
Perceived control over FCR scale. This purpose-designed scale monitors therapy prog-
ress, expressed as self-perceived control over FCR (scale 0-10). A higher score indicating 
more perceived control.
Data analysis
Post-treatment, 6 and 12 months’ follow-up scores were compared to baseline scores 
and scores of a normative BCa sample. Clinical significance of treatment effects was 
established using the procedure by Jacobson & Truax (1991) and normative BCa data 
for the CWS and FCRI [37,23-24]. Clinically significant improvement was defined as a 
score change within 2SDs of the normative sample mean and a greater likelihood of the 
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score being in the normative group than in the FCR group. For QoL, clinically significant 
change was a ≥10-point change between two time points [38].
CoURse & ConTenT of THe InTeRvenTIon
Theoretical model
The intervention follows the theoretical formulation of FCR by Lee-Jones (1997) [39]. In 
this model (figure1), FCR is a distressing emotion maintained by dysfunctional cognitive 
patterns, such as recurring unhelpful thoughts, negative beliefs, intrusive images, or 
persistent rumination. These cognitions cause a person to interpret events or internal 
stimuli as potentially threatening to their health and wellbeing, thereby triggering FCR. 
Behavioral strategies that may provide short-term alleviation of fear, such as avoidance, 
or safety-seeking behaviors, may actually sustain FCR in the long run by preventing 
changes in cognitive appraisal and/or by providing further exposure to triggers of FCR. 
CBT targets FCR by changing dysfunctional cognitive patterns and behavioral responses as 
specified in this model [21,39].
This conceptualization of FCR shares similarities with the Health Anxiety Model by 
Salkovskis (2001) [40]. For instance, both models share the elements of fear producing 
stimuli and behavioral consequences of anxiety/fear. However, the FCR model is cancer 
specific. Criteria of anxiety disorders do not easily apply to clinical FCR in cancer survi-
vors; only the minority of high fearful cancer survivors were found to fulfill the diagnos-
tic criteria for hypochondria, illness anxiety disorder (or generalized anxiety disorder) 
[25,41-42]. What defines FCR is that high fearful survivors report intrusive thoughts and 
symptoms that are mainly related to the specific cancer experience. Survivors do not 
necessarily worry about their general health but tend to worry specifically about the 
possibility of a recurrence [25,41].
Treatment manual
This intervention is a combination of face-to-face contact with e-health or telephone 
consultations. By default, patients are offered the online version of the therapy. In case 
of computer illiteracy – no access to a computer or lack of a skill set to adequately use the 
computer [43] - the paper-and-pencil workbook (with DVD) is offered as an alternative.
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Table 1. Content of the intervention by therapy session.
session Delivery Week Time (minutes) session components
1 Face-to-face 1 90 • Case formulation: a patient’s story.
• Discuss therapy rationale.
• Establish therapy goals.
• Review FCR and complete a personal FCR model.
• Introduce at-home assignments.
2 Face-to-face 2 60 • Explain the basic tenets of CBT.
• Discuss and visualize the association between thoughts, 
feelings and actions.
• Review the concept of helpful beliefs.
• Practice in filling out thought records.
• Introduce mindfulness and relaxation exercises.
3 Face-to-face 3 60 • Review the completed thought record(s) to identify 
unhelpful thoughts and behavioural consequences of FCR.
• Differentiate realistic from unrealistic worries and establish 
more helpful thoughts.
• Explore and identify dysfunctional behavioural patterns.
• Create a ranked list of situations that induce FCR and 
propose a behavioural experiment.
• Practice a mindfulness (bodyscan) or progressive muscle 
relaxation exercise.
4 telephone 4 15 • Review of progress (troubleshooting).
• Encourage at-home skill practice.
5 Face-to-face 6 60 • Review therapy goals, discuss areas of concern and make 
future plans (beyond therapy).
• Discuss completed thought records and/or behavioural 
experiments.
6 telephone 7 15 • Review of progress (troubleshooting).
• Encourage at-home practice of skills.
• Identify personal strengths and resources of strength to 
deal with FCR.
7 telephone 9 15 • Review of progress (troubleshooting).
• Introduce the relapse prevention plan.
8 Face-to-face 11 60 • Review therapy goals, progress made so far and discuss 
possible future pitfalls.
• Define and finalize the relapse prevention plan.
• Evaluate the therapy process.
• Schedule an appointment for the booster session.
9 Face-to-face
(booster 
session)
24 60 • Review the FCR model and progress made during therapy.
• Discuss difficult situations and how to overcome them.
• Relapse prevention plan.
Nb. This table was first published in the study protocol by Van de Wal et al., (2015) [21].
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blended therapy for fCR
Therapy is delivered by trained psychologists and consists of five individual face-to-face 
sessions (sessions 1,2,3,5 and 8), with three electronic or telephonic consultations (ses-
sions 4,6 and 7) within three months and one follow-up session three months later (ses-
sion 9). The first four sessions are scheduled weekly, other sessions fortnightly. Between 
sessions, home assignments are completed using a workbook (with DVD) or the website.
The face-to-face sessions are structured and are carried out according to protocol. 
With the exception of the first session – which takes 90 minutes – all other face-to-face 
sessions last around 45 minutes. In the first face-to-face session the therapist gathers a 
full social and medical history of the patient, identifies the presenting problem (FCR), and 
sets the stage for the next therapy sessions which requires more time than 45 minutes. 
E-health/telephone consultations take approximately 15-20 minutes and are structured 
in a similar way as the face-to-face sessions. During these sessions the emphasis is on 
providing motivational support and giving personalized feedback to ensure that the 
home assignments are understood.
The primary treatment goal is to reduce the severity of FCR by increasing the sense of 
control over fear, by modifying cognitive processes and dysfunctional behavior related 
to FCR. In this case, the patient (NG) was treated by a female therapist. An overview of 
the treatment content is given in table 1.
Content of the intervention
Session 1: face-to-face
NG told the therapist that BCa was first tentatively diagnosed 18 months ago; it took 
two months before she received a definite diagnosis. This diagnostic delay caused her 
a lot of uncertainty and anxiety. Although adjuvant chemotherapy was indicated and 
advised, NG decided not to have chemotherapy because she was worried about side 
effects, such as fatigue and hair loss. Even so, she now occasionally worried whether she 
had made the right choice: “Would chemotherapy have lowered my risk of recurrence?”. NG 
reported thinking daily about cancer recurrence and its consequences. She considered 
certain events as particularly stressful: the weeks before a medical examination, breast 
changes, aches or pains, and the diagnosis of cancer in relatives. These events would 
most certainly trigger FCR. For instance, NG examined her breasts several times a day 
and any change in the look or feel of her breasts frightened her. For reassurance, she 
had asked her nurse specialist for extra medical examinations twice past four months. 
On both occasions, ultrasound revealed a lymph-filled mass but there was no reason 
to suspect a recurrence. However, NG was only briefly reassured and further efforts to 
dismiss FCR were unsuccessful. She felt unequipped to manage FCR herself, but did find 
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some relief in visiting a lymphedema therapist twice a week for manual lymph drainage 
and remedial exercise therapy, to reduce breast swelling and lymphatic obstruction.
NG experienced mood disturbances, functional impairments and continuously wor-
ried about her future. As such, she would not plan any activities ahead. NG described 
herself as being insecure; she had received psychological therapy in the past. In the 
1980s NG suffered from a maladaptive response to psychological stress whereby she 
experienced symptoms of mental overload and overstrain (“surmenage”). For this, she 
had completed a 3-month rehabilitation program (rational emotive therapy). She also 
expressed concern that, given her family history, there could be a BRCA gene mutation 
in her family.
figure 1. Personalized model of FCR.
SWORD: case study
109
6
At the end of the first session the therapist helped NG visualize and complete a per-
sonal FCR model on a whiteboard (Figure1). This model served as a guide for the next 
therapy sessions by identifying the most appropriate cognitive and behavioral targets 
for intervention. NG received education about FCR (e.g. that it’s normal and functional 
to experience some FCR, but that it may become dysfunctional at some point) and 
the aim and rationale of CBT were explained (the aim is not to take away all FCR, but 
rather to reduce its severity to lower, more functional levels). Beside the main objec-
tive of reducing FCR severity, NG had formulated three realistic, but rather vague, ad-
ditional treatment goals for herself: fewer “down” days, fewer worries about the future, 
and greater optimism. The therapist and patient worked to operationalize these goals 
by answering the following questions: What would the patient like to happen? What 
does the patient mean by “down” days”? Worries about the future were directly linked to, 
and therefore combined with, the main therapy goal of reducing FCR. Greater optimism 
was operationalized as becoming more skilled in formulating helpful, positive, thoughts 
in response to dysfunctional beliefs. Fewer “down” days would be achieved when there 
were less daily symptoms of a low mood (e.g. increased activity, less withdrawing from 
social events and less irritability).
Session 2: face-to-face
Last week NG had studied automatic, unhelpful thoughts and had learned how to 
replace them with more helpful ones. In this session, the therapist proposed a three 
stage ABC model of FCR with activating events (A), beliefs (B), and consequences (C) 
to explain how the perception of events influences how one feels and acts [44]. It was 
explained how activating events were often triggers identified in the personal model of 
FCR (e.g. discovering a lump during breast self-exams), that automatically triggered cer-
tain beliefs (“This lump feels similar as when I discovered breast cancer…”) and thereby 
influences how one feels (panic) and acts (call the nurse to request an extra medical 
check-up). The therapist told NG that we cannot always change the situation that we 
are in, but that we are able to identify and modify the beliefs we hold and we can come 
up with alternative, more functional thoughts. In therapy, this is done by completing 
thought records where the ABC model is part of. Together the with the therapist NG 
completed a thought record describing a recent situation that had caused her fear. NG 
told she had met a pale, bald boy in a wheelchair after returning home from her first 
therapy session (A). This encounter left NG sad for the rest of the day and caused her to 
worry about cancer (C). By dissecting this situation together with her therapist, NG came 
to recognize that she had unhelpful catastrophizing thoughts (“Oh, this boy has cancer... 
How terrible!” and “This is not going to end well!.. Cancer means death’) that had caused her 
to feel this way and left her worrying about a possible recurrence. NG agreed to practice 
completing two thought records (containing steps A,B and C) in the next week.
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Session 3: face-to-face
After successfully identifying automatic unhelpful cancer-related thoughts during the 
previous weeks, the therapist introduced the next step in CBT: challenging unhelpful 
thoughts and replace them with more helpful ones. Because unhelpful recurrence 
related thoughts might technically be free of distortions, the focus of this step lies more 
on the modification of beliefs (coming up with alternative, more helpful thoughts) than 
trying to dispute the dysfunctional ones. At first, NG was inclined to interpret ambigu-
ous cancer-related information negatively and she felt over involved in cancer stories 
from others (“if that woman has a disease recurrence, it will probably happen to me as 
well”). During this session, NG learned to reframe FCR provoking beliefs into less disturb-
ing ones (“Every medical situation is different. It is not rational to compare hers to mine”). 
Her personal FCR model showed impulsive controlling behavior in attempt to manage 
FCR. Therefore, the therapist introduced a response prevention exercise. NG created 
a hierarchy of situations that induced feelings of FCR. Her highest rated situation was 
her daily breast examination – checking for lumps, swollen nodes, or disfigurement. NG 
believed that daily breast-exams would help to detect a recurrence early. The therapist 
suggested daily exposure and response prevention exercises: NG would refrain from 
breast self-exams in the next two weeks, thereby confronting her worst fear. Over time, 
anxiety would become more manageable and the frequency of breast examinations 
would decrease.
Mindfulness and relaxation exercises were introduced. Because NG was mainly experi-
encing physical stress a quick relaxation technique was preferred over mindfulness. The 
therapist explained what stress is and how relaxation can counteract the stress response 
to FCR. In session, NG practiced a progressive muscle relaxation technique that she 
could easily apply at home when she experienced physical symptoms of anxiety (e.g. 
muscle tension).
Session 4: telephone
As NG was not sufficiently computer literate for an e-health consultation, a telephone 
consultation was her preferred option. In this session it was evaluated how helpful the 
exercises were, and if there were any difficulties with at-home practice. NG had practiced 
the ten-minute relaxation exercise but experienced emotional discomfort doing this. 
The therapist explained to NG that it takes regular practice (also in peaceful circum-
stances) to achieve greater benefit from relaxation exercises. She was encouraged to try 
another relaxation exercise at home in the next week.
NG did continue practicing cognitive restructuring and response prevention tech-
niques in everyday situations. Furthermore, instead of actively seeking out cancer-
related stimuli she now tried to pay less attention to them. Prior to therapy, she would 
read the obituary notices in the newspaper daily, searching for information indicating 
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cancer as the cause of death. At this point in therapy, NG realized that her search-
behavior merely triggered FCR, upsetting her. NG experienced difficulties in carrying 
out her exposure and response prevention exercises. While she still felt a strong need 
to perform breast-exams in front of the bathroom mirror twice a day, NG successfully 
stopped herself from examining her breasts twice that week, being reassured by the fact 
that she would visit her lymphedema therapist that day who “would also examine her 
breasts during therapy”.
The therapist explained that exposure exercises could temporarily increase anxiety as 
NG worked on decreasing her controlling behavior. NG recognized that these moments 
of exposure also offered opportunities to practice cognitive reframing and to generate 
more helpful beliefs.
Session 5: face-to-face
NG felt more in control of her fears and was no longer stuck in a negative thought spiral. 
Although hearing or reading about cancer still triggered cancer-related thoughts, she 
felt better equipped to reframe them into more helpful ones. For instance, NG had 
attended her sister’s wedding anniversary where a relative told her about his medical 
problems (coughing up blood) and the medical examinations he had had. Although NG’s 
first thoughts were: “He has cancer…. and maybe even die of it.”, she successfully replaced 
this belief by a more helpful one: “There’s no point in assuming the worst, we’ll just have to 
wait for his medical results”. NG did not find the relaxation assignments helpful and the 
willingness to practice had further declined. The therapist decided it would be best not 
to pursue relaxation exercises any further.
Prior to therapy NG performed breast exams daily. Now, two months later, she felt 
confident enough to stop breast self-exams completely as long as she regularly visited 
the lymphedema therapist (a safety behavior). NG and the therapist decided to work 
towards completely ending lymphedema therapy and mutually agreed that, after the 
last lymphedema therapy session, NG could examine her breasts monthly (at most) as 
recommended by Dutch breast self-examination guidelines.
From therapy NG learned that sharing her concerns brings relief. While she had al-
ways considered herself talkative, fear of rejection or disapproval prevented her from 
expressing her feelings and sharing her thoughts with others, so that she kept her fears 
to herself. At this point, NG said she would like to involve her husband in her process of 
change, in order to strengthen their relationship.
Sessions 6 and 7: telephone
Session 6 and 7 were in face-to-face format. In the previous session NG expressed that she 
had the feeling that it would be good for her to share her concerns with others. However, 
she found FCR difficult to discuss with family members as she did not want to burden 
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them. Yet she also experienced feelings of guilt from not sharing her concerns with her 
partner (“It would be nice to hear what my partner thinks and good for him to hear what goes 
on in my head”). Therefore, the therapist suggested to NG that it could be beneficial to 
invite her partner to session 6 and 7 for a conjoint therapy meeting. This would create 
an opportunity to improve communication, mutual trust and openness between the 
partners and to give NG’s partner more insight into the depths of the problem NG was 
experiencing. Furthermore, her partner would be able to provide his views on FCR and 
on how NG is doing in daily life. For these reasons, her partner attended session 6 and 7.
NG was increasingly more able to look to a future beyond cancer. She felt confident 
enough to plan future activities and formulate future goals in terms of weeks, months and 
years. She planned two vacations abroad, something she had not dared to do past two years 
due to FCR. By the end of session 7, NG was more proficient in replacing negative thoughts 
with more helpful ones:“I do not know what the future will bring in terms of health, but worrying 
is not going to help and I do not want the rest of my days to be overshadowed by doubt.”
At the end of session 7 NG and her partner both agreed that it was not needed for her 
partner to join the final session. They felt that they had achieved their mutual goals and 
therefore initiated the ending of the conjoint treatment sessions. NG’s partner expressed 
that he had found it useful to join the two sessions as it provided him with more insight 
in the process of change NG was going through. NG felt supported by her partner: “It 
feels like therapy has brought us closer to each other. We have become more able to talk 
together”. For instance, NG’s partner had helped her to form more pragmatic future goals 
such as planning a holiday together.
Session 8: face-to-face
NG attended this session individually. The past two weeks she had been working on 
a relapse prevention plan and in session 8 the relapse prevention plan was reviewed 
and further refined. One of the first steps for NG was to learn to identify her “red flags”: 
situations that left her more vulnerable to a FCR relapse. Situations included periods of 
sickness and general stress. Secondly, the therapist helped NG to come up with a list of 
warning signs that may indicate a nearing relapse: more nervousness, more arguments 
with her husband, feelings of sadness, avoiding more social activities and not wanting 
to plan activities ahead. Next, NG identified strategies that could help her manage her 
fears: “I should not beat myself up, I should stop that train of thoughts from running wild. 
Just stop everything for a second… Distance myself from the situation… Analyze what is 
going on… And maybe discuss my fears with my husband as well”. One of her top priorities 
was to continue practicing her CBT skills.
NG felt she had enough tools to work on her fears after completion of therapy and 
that control over FCR had increased. She now examined her breasts monthly and felt 
confident enough to end lymphedema therapy.
SWORD: case study
113
6
Session 9: face-to-face 3-month follow-up
NG and her husband attended the 3-month follow-up session. NG reported that she was 
doing well and no longer struggled with FCR. She had come to accept that FCR is a nor-
mal emotion that presents itself in certain situations and was no longer overwhelmed 
by her fears. NG was satisfied with the process and outcomes of therapy and found 
that completing thought records was the most helpful part of therapy. She felt better 
equipped to deal with FCR in daily life and was able to use learned skills and techniques 
to cope with situations that trigger FCR. Lymphedema therapy had been completed and 
NG no longer felt the strong need to examine her breasts. Both therapist and patient 
decided that no further contact was needed. At the third assessment, six months after 
completion of therapy, three weeks before her annual mammography, NG reported not 
being overwhelmed by her fears, but instead, she felt in control.
ResUlTs
Quantitative therapy evaluation
Perceived control over FCR
During treatment, the patient’s sense of control over FCR increased to almost maximum 
(Figure 2).
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figure 2. Perceived control over FCR during therapy sessions.
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Severity and other dimensions of FCR
FCR severity decreased between pre- and post-treatment assessment (T0-T1) and con-
tinued to decrease during follow-up (T2-T3) to non-clinical levels (CWS<14). FCR was 
within the lower range of scores of a normative BCa sample at 6-12 months and showed 
clinically meaningful improvement (Table 2). FCRI scores for severity, triggers, functional 
impairment and insight showed meaningful improvement at all-time points.
(Breast cancer-specific) QoL
Physical functioning, emotional functioning, and QoL scores had increased post-
treatment (T1) (table 3). At 12-months post-treatment (T3) these functioning scales, 
and symptoms scales fatigue and insomnia, showed clinical significant change. All 
domain scores (T1–T3) were within the normal range of BCa controls. Future perspective 
increased between pre-treatment (T0) and 12 months follow-up (T3). Body image and 
sexual functioning/enjoyment varied over time and were highest at 6 months follow-up 
(T2). Breast symptoms reduced after therapy but increased at follow-up (T2–T3).
Table 2. Fear of cancer recurrence at four times and compared to mean scores of breast cancer survivors 
(BCS).
Screening T0 T1 T2 T3 BCS
range M(SD)
CWsa (8-32) 25 21 14 10 10 13.4 (3.9)
fCRIb -
  Severity (0-36) - 26 13 10 12 14.3 (7.6)
  Triggers (0-32) - 22 10 12 12 13.6 (6.9)
  Distress (0-16) - 10 12 2 4 5.4 (3.8)
  Func impairment (0-24) - 8 3 0 0 3.1 (4.1)
  Insight (0-12) - 7 4 4 0 1.7 (2.4)
  Reassurance (0-12) - 6 6 5 4 3.2 (2.9)
a Dutch breast cancer survivors b Canadian breast cancer survivors
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Table 3. Quality of life scores at four times compared to median scores of breast cancer survivors.
T0 T1 T2 T3 BCS
Median (IQR)
eoRTC-C30
  Physical Functioning 73 93 80 80 80 (66.7-89.3)
  Role Functioning 100 100 100 100 83.3 (50-100)
  Emotional Functioning 66 100 100 100 75 (50-91.7)
  Cognitive Functioning 100 83 66 83 83.3 (66.7 - 100)
  Social Functioning 100 100 100 100 100 (66.7 - 100)
  Global Health / QoL 75 100 83 100 66.7 (50 -83.3)
  Fatigue 22 0 0 11 33.3 (11.1 - 44)
  Nausea 0 0 0 0 0
  Pain 0 0 0 0 16.7 (0-50)
  Dyspnea 0 0 0 0 0
  Insomnia 100 66 66 66 33.3 (0-33.3)
  Appetite 0 0 0 0 0
  Constipation 0 0 0 0 0
  Diarrhea 0 0 0 0 0
  Financial 0 0 0 0 0
eoRTC-bR23
  Body Image 50 58 75 66 100 (75-100)
  Sexual Functioning na 33 33 na 0 (0-33)
  Sexual Enjoyment na 66 66 na 33.3 (33.3-66.7)
  Future Perspective 33 66 100 100 66.7 (33.3-66.7)
  Breast Symptoms 33 8 16 25 8.3 (0-25)
  Arm Symptoms 0 0 0 0 11.1 (0.033)
nb. range: 0-100 for all scales
na: not applicable; QoL: quality of life
Exploratory outcomes
NG was clinically distressed (DT,IES) before therapy, scores fell within the normal range 
at all times after therapy (Table 4). Changes were evident on both the IES avoidance and 
intrusion subscales. Distress and fatigue had decreased 12 months post-therapy (T3), 
while optimism and satisfaction with life increased compared to pre-therapy (T0). NG 
completed 32/33 assignments, indicating good adherence.
Qualitative nurse evaluation
Five months after NG had completed therapy, she was seen by the nurse specialist for 
her annual medical check-up. Two weeks before the consultation, NG did not show signs 
of distress, as measured with the distress thermometer. While NG told the nurse that 
their appointment did trigger FCR, she now felt better equipped to manage her fears.NG 
did not request any extra medical examinations, nor did she contact the nurse outside 
their regular appointments. She now examined her breasts monthly.
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Table 4. Secondary outcomes at T0-T3.
T0 T1 T2 T3
range
Distress Thermometer
  Thermometer (0-10) 4 0 0 0
vvv
  Fatigue (4-32) 13 5 7 7
HADs
  Total (0- 42) 9 2 5 1
  HADS-Anxiety (0-21) 8 0 4 1
  HADS-Depression (0-21) 1 2 1 0
Ies
  Total (0-75) 38 2 7 0
  Intrusion (0-35) 24 1 5 0
  Avoidance (0-40) 14 1 2 0
sWl
  Total (5-35) 30 31 33 32
loT
  Total (0-32) 16 22 19 22
bvs
  Attentional Focus (0-45) 14.3 6.13 18.01 4.26
DIsCUssIon
This case study provides an intensive overview of the course and content of CBT for a 
highly fearful breast cancer survivor. Comparison of the pretest, post-test and follow-up 
scores showed that FCR severity decreased to non-clinical levels after completion of 
CBT. This clinically significant improvement was still evident at the 6 and 12 months 
post-therapy. Secondary outcomes improved to the level of non-fearful BCa controls. 
Self-perceived control over FCR increased sharply after the third therapy session. While 
speculative, a possible reason for this is that NG reported benefit from the home) assign-
ments on cognitive therapy, which was a central aspect of therapy in the second and 
third session. Lymphedema therapy contributed to high FCR as it was both a trigger of 
FCR (being reminded of the disease and its treatment) as well as a safety behavior (“If 
anything feels off in my breast, the therapist will notice”). Working towards ending this 
therapy, and normalizing breast self-exams instead, may therefore have also played a 
role in NG’s improvement.
Even though CBT is manualized, this study illustrates the importance to tailor treat-
ment components to a patient’s needs. In the first therapy session, a personalized FCR 
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model was established that served as a guide for selecting treatment components. By 
visualizing the information from the intake assessment in a personal model, the thera-
pist identified intrusive cognitions and controlling behavior as two important processes 
maintaining FCR. Furthermore, NG wanted to involve her partner in her therapy. The 
therapist agreed that this could have a beneficial effect on NG’s process of change. The 
next two sessions, which should have been telephone consultations, were instead face-
to-face consultations so that both NG and her partner could be present. Inflexible adher-
ence to the manual would not have addressed the marital concerns that also played a 
role in maintaining NG’s FCR. Finally, NG experienced emotional discomfort practicing 
relaxation exercises at home, even in comfortable circumstances. After practicing for 
three weeks, NG indicated that she still experienced discomfort and thereby expressed 
a strong preference not to practice relaxation anymore. The therapist therefore decided 
it would be best for the remaining sessions to focus on treatment components more 
beneficial for therapy progress, such as cognitive restructuring.
NG was the first high fearful cancer survivor referred to medical psychology since this 
CBT program became available, she was therefore selected for this case study. Based 
on this pilot case, two changes have been made to the finalized treatment protocol: 1) 
partners are now allowed (and invited) to join the patient for all face-to-face sessions 
from session 5 onwards and 2) assignments on identifying personal strengths and re-
sources of strength to deal with FCR have been moved from session 6 to session 5. The 
main reason for both adjustments is that social support (and especially partner support) 
seems to play an important role in maintaining FCR and should therefore be addressed 
timely [3-4]. NG had an excellent response to CBT and there were no complicating fac-
tors: she was highly motivated, showed no treatment resistance, was not taking any 
psychotropic medications and had near excellent homework adherence. We assume 
that other patients, especially those with a more avoidant way of coping, might show 
more initial resistance and may find it harder to complete the home-assignments.
Since this was an uncontrolled case study, it is not known whether the amelioration 
of clinical FCR was due to treatment or spontaneous remission over time. Nevertheless, 
a review by Simard et al. found reported that 18 (out of 22) longitudinal studies did 
not find a spontaneous change of FCR over time in the post-treatment period (range 
3 months–6 years post-treatment) [2]. Indicating that, when no intervention is offered, 
FCR seems to be a relatively stable and persistent problem over time [2,5]. Our case was 
diagnosed with BCa more than 2 years ago and nurse reports made notion of persistent 
FCR since time of treatment. So, while we cannot rule out the factor “time”, literature 
favors the possibility that our found decline in FCR might be attributable to a treat-
ment effect. Given the complexity of most psychotherapeutic interventions, it is hardly 
possible to delineate the most effective treatment components of CBT for clinical FCR. 
118
Chapter 6
Treatment gains may also be attributable to non-specific factors, such as therapist atten-
tion and good therapeutic rapport.
To conclude, This study demonstrates one way of using CBT to managing high FCR 
in cancer survivors. As it is yet unknown whether CBT is effective and which patients 
benefit most, large scale studies need to address the feasibility and efficacy of this inter-
vention in a more heterogeneous sample.
AUTHoRs ResPonD To QUesTIons ConCeRnInG THe CAse of nG.
Judith Prins, clinical psychologist, treatment supervisor and researcher; 
Petra servaes, clinical psychologist and treatment provider; belinda Thewes, 
clinical Psychologist and researcher and Marieke van de Wal, psychologist and 
researcher.
Issue 1. In this case, CbT was used to reduce fCR severity in a cancer survivor. fCR 
can also be a concern for patients with a different chronic disease (e.g. fear of pro-
gression in diabetes). What are the authors’ thoughts about using this therapy for 
treating fears associated with other somatic conditions?
Judith Prins, Petra Servaes, Belinda Thewes, Marieke van de Wal: We know from both 
clinical experience and scientific work that patients suffering from various chronic 
conditions, such as multiple sclerosis, heart disease, rheumatoid arthritis, and diabetes 
mellitus also experience fear of disease progression [45]. However, the manifestation 
of fear in patients with chronic diseases is varied and depends largely on the natural 
course of the disease (e.g. progressive deterioration vs. intermittent relapses with de-
terioration over time vs. potentially curable relapses). For instance, for those diagnosed 
with diabetes mellitus type 1 it is known that their health will gradually decrease over 
a 20-30 year period and that serious health problems, such as kidney or eye complica-
tions and neuropathy, are almost inevitable. Whereas for cancer patients, the pattern of 
disease progression is more varied, with some experiencing relapse followed by a rapid 
deterioration, or intermittent relapse, or potentially curable relapse. Whilst the general 
elements of this therapy, such as self-monitoring, cognitive restructuring, behavioral 
modification and mindfulness could be generalized to treat fear of disease progres-
sion in other chronic somatic conditions, the specific content of the assignments and 
psycho-educational material should be tailored to make it disease specific.
Relating to the issue above, would this intervention also be applicable to cancer patients 
who are not disease-free but already have a recurrence and experience fear of progression?
Yes most of the techniques could be applied to fear of progression in cancer patients 
as well. Group CBT has been demonstrated to help cancer patients with a progressive 
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disease cope with fear of cancer progression [46]. Whilst it is likely that techniques con-
tained within the described intervention would be helpful for patients with progressive 
disease, the content of the intervention would require adaptation. For example, in a 
palliative setting there may also be the need to add additional themes, such as working 
towards acceptation of one’s inevitable death, dealing with existential concerns and 
planning for end-of-life care. These are topics not covered in our manualized CBT for 
FCR in disease-free cancer survivors.
Issue 2. You highlight an interesting “gray area” in which it might be difficult to 
differentiate adaptive health behaviors from safety behaviors (in this case, visiting 
a lymphedema therapist). Could you further elaborate on this?
Judith Prins, Petra Servaes, Belinda Thewes, Marieke van de Wal: There is a fine line be-
tween health behavior that is considered adaptive and behavior that can be classified as 
maladaptive. While there is nothing wrong with a patient being vigilant, the problem with 
FCR is that high fearful survivors tend to become hypervigilant. CBT for FCR promotes 
body awareness and vigilance by teaching patients appropriate self-management skills 
(e.g. carrying out breast self-exams according to the frequency advised by the oncology 
guidelines) and by providing them with mindfulness and relaxation exercises. However, 
we discourage excessive reassurance seeking behavior whereby patients repeatedly 
visit health care providers to ask about their symptoms. Most cancer patient will require 
medical attention during follow-up care and some will be instructed to perform regular 
self-checks (for example breast self-examination). The goal of treatment is to encourage 
patients to get the balance right.
In the case of NG, initially the focus of her lymphedema therapy was to receive manual 
lymph drainage to reduce swelling of the breast. However, once her lymphedema was 
managed, visiting the lymph edema became a safety behavior and a means for NG 
to seek medical reassurance that her cancer had not recurred. At this point it became 
maladaptive as it provided her only with temporary relief from FCR and did not alleviate 
her concerns in the long run. When differentiating unhelpful from helpful medical reas-
surance seeking, therapists should not only explore whether the frequency is in excess 
of what is recommended, but also the patients’ perception of why they are consulting 
a health professional and whether this is beyond their professional role. For example, 
patients should not visit a lymphedema therapist to be reassured about their concerns 
for a recurrence.
In this case study FCR was not only related to visits to the lymphedema therapist but 
initially also with increased contact moments with the nurse specialist. Could you comment 
further on FCR from the perspective of healthcare service utilization? How does this factor 
into the value of CBT and other therapies for FCR?
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Judith Prins, Belinda Thewes, Marieke van de Wal: We know that there are mixed findings 
on the relationship between FCR and healthcare service utilization There is evidence 
that cancer survivors with high FCR are more likely to refuse discharge from a cancer 
center [47] are less satisfied with their care [48] and are more likely to seek readmission 
to a cancer center [47], suggesting that untreated high FCR is possibly associated with 
increased healthcare costs. However some high fearful patients adopt an avoidant way 
of coping and may avoid healthcare services medical check-ups that may trigger FCR 
[49]. Documenting evidence of avoidance is difficult as avoidant patients may also avoid 
participating research about FCR. A recent review on the cost-effectiveness of psycho-
social interventions for cancer survivors concluded that CBT for psychosocial problems 
in cancer survivors has a good value for money [50]. Also, one study demonstrated 
the cost-effectiveness of CBT over a supportive-experiential group in targeting fear of 
progression [51]. We believe that it would therefore be interesting to look further into 
the cost-effectiveness of CBT for FCR.
Issue 3. Regarding the authors’ decision to invite partners to one or multiple 
therapy sessions: why was this done? Please elaborate.
Judith Prins, Petra Servaes, Belinda Thewes, Marieke van de Wal: Cancer has an impact on 
both patient and partner. In the treatment of cancer related psychological problems, like 
FCR, it can therefore be very useful to involve both.
Partners are often very dependent on the patient for information about their current 
health status and the related subjective risk of recurrence. They have little knowledge 
of what is going on in a patient’s mind or body. Therefore, partners cannot apply the 
same coping strategies to deal with FCR as the patient does, such as self-monitoring of 
symptoms. Partners often question the patient: “How do you feel? Are you sure every-
thing is okay?” and if this happens regularly it may further heighten the patient’s FCR. 
Many cancer patients report not disclosing fears either because they do not like to share 
their feelings or because they do not want to burden their loved ones. However a lack of 
discussion about FCR between couples may actually intensify FCR for both the patient 
and the partner. Thus, we believe it is important to always identify what the role of the 
partner is in maintaining FCR, and if needed, consider inviting the partner to join one or 
two sessions.
Issue 4. nG was referred to your department by R. berry the nurse specialist. Do 
you have any recommendations for healthcare providers when to refer patients to 
receive additional care for fCR?
Judith Prins, Belinda Thewes, Marieke van de Wal: We know from an earlier study that 
healthcare professionals find it very difficult to identify FCR and that they also struggle 
with knowing how to deal with it [10]. It is normal for patients to have concerns about a 
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possible recurrence during the survivorship trajectory and especially when confronted 
with medical examinations and follow-up consultations related to cancer. To differen-
tiate normal FCR from high FCR, it is therefore important for healthcare providers to 
use objective measures to screen for high FCR. Although there is no consensus which 
screening instrument is best, several brief measures are available as described in an ex-
tensive literature review of quantitative measures of FCR [52]. If no validated screening 
instrument is available basic questions may also be sufficient. Additionally, healthcare 
providers should be aware of reassurance seeking or avoidant behavior that might 
indicate high FCR, such as frequent unscheduled telephone contacts or cancelling ap-
pointments. Finally, professionals should inform themselves of local resources available 
to help patients that struggle with high FCR and how to refer patients to them.
Issue 5. In this therapy you have used a manualized intervention, which was very 
fixed in structure. Yet you have decided to change the protocol by inviting nG’s 
partner and leaving out the mindfulness exercise. What is your opinion on strictly 
following protocols vs a more tailored approach in which you are more flexible.
Judith Prins, Petra Servaes, Belinda Thewes, Marieke van de Wal: In clinical studies 
therapists should try to follow the protocol as closely as possible. The intervention 
was developed in a certain way and has been tested for efficacy; even minor protocol 
deviations may influence the therapy effects. However, some patients might not fit the 
protocol and require deviations. Deviations inevitably occur and then it’s important to 
document them and to discuss them within your team.
We believe that clinical practice should take advantage of evidence-based treatment 
procedures or manuals that are available. In clinical practice therapeutic protocols 
should be treated as guidelines that should be personalized if needed. Rigid adherence 
to a standardized and empirically validated treatment protocol may enhance treatment 
fidelity but it does not necessarily offer the best therapy. It may deny and discount 
emotional experiences that are important for the patient and may negatively affect the 
therapeutic alliance. For instance, NG did not wish to continue mindfulness practice and 
the therapist respected that decision.
Issue 6. Do you think it is realistic and feasible to implement this intervention in 
clinical practice if future research demonstrates the same positive results as found 
in this study? Are there any specific barriers or pitfalls?
Judith Prins, Petra Servaes, Belinda Thewes, Marieke van de Wal: If proven efficacious, we 
plan to conduct a formal implementation study of this intervention including an analysis 
of barriers and facilitators for implementation. We know from earlier studies and our own 
experience that the implementation of psychosocial interventions outside of academic 
centers is possible and needed, however certain barriers are experienced. For instance, 
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personnel involved may lack the required time to receive adequate protocol training or 
supervision, there is diffusion of responsibility and financial constraints can be an issue. 
The effect size is often lower when an intervention is tested outside a specialized centre 
where a small number of therapists are highly trained and closely supervised [53]. Fur-
thermore, outside of research settings patients are less selected. Patients in randomized 
controlled trials are often a selected group that does not necessarily reflect the diversity 
of patient characteristics seen in the broader population. In order for this intervention 
to be broadly implemented it is likely that as this therapy reaches more diverse patients 
some further tailoring of the intervention will be required. CBT has already been used to 
treat FCR in a number of breast, prostate and colorectal cancer survivors [21]. Therapist 
evaluations in using CBT to treat FCR were very positive. One of the things they have 
mentioned is that patients appreciate the cancer type specific content of the interven-
tion. Our treatment includes videos and examples on all three cancer types so patients 
can easily identify with the patient models. Prior to implementation it may be necessary 
to include a greater diversity of cancer types in the videos and exercises.
There may also be patient perceived barriers to successful implementation. FCR is a 
sensitive topic and patients may be reluctant to address the topic themselves as they 
still consider it to be taboo. They may feel like they should not burden their healthcare 
provider and try to self-manage their concerns about a recurrence. An important task 
for practitioners is to discuss FCR during clinical visits and in case of suspected high FCR 
consider referral for counseling.
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AbsTRACT
Purpose: Fear of cancer recurrence (FCR) is a common problem experienced by can-
cer survivors. Approximately one third of survivors report high FCR. This randomized 
controlled trial (RCT) aimed to evaluate whether blended cognitive behavior therapy 
(bCBT) can reduce FCR severity in cancer survivors curatively treated for breast, prostate 
or colorectal cancer.
Patients and Methods: This RCT included 88 cancer survivors with high FCR (Cancer 
Worry Scale (CWS) score ≥14) between 6 months and 5 years post cancer treatment. 
Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive 
bCBT, including five face-to face and three online sessions (n=45) or care as usual (CAU, 
n=43). Participants completed questionnaires at baseline (T0) and three months later 
(T1). The intervention group completed bCBT between T0 and T1. The primary outcome 
was FCR severity assessed with the CWS. Secondary outcomes included other distress 
related measures. Statistical (one-way between-group analyses of covariance) and clini-
cal effects (clinically significant improvement) were analyzed by intention-to-treat.
Results: Participants who received bCBT reported significantly less FCR than those in the 
CAU condition (mean difference=-3.48; 95% CI, -4.68 to -2.28; p<.001) with a moderate 
to large effect size (d=0.76). Clinically significant improvement in FCR was significantly 
higher in the bCBT than CAU group (13 of 45 [29%], compared to 0 of 43 [0%], p<.001), 
self-rated improvement was higher in bCBT as well (30 of 42 [71%], compared to 12 of 
38 [32%], p<.001).
Conclusion: bCBT has a statistically and clinically significant effect on FCR severity in 
cancer survivors and is a promising new treatment approach.
SWORD: effect study
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InTRoDUCTIon
Fear of cancer recurrence (FCR), defined as “fear, worry or concern about cancer return-
ing or progressing” [1], is one of the most commonly cited concerns of cancer survivors. 
Whereas normal levels of FCR may foster adequate self-monitoring or vigilance [2], high 
levels of FCR are associated with intrusive thoughts and re-experiencing the event, 
avoidance of reminders of cancer, hyper-vigilance, difficulty in making future plans and 
increased emotional distress [2-7]. High FCR affects 31%-38% of Dutch breast, prostate 
or colorectal cancer survivors and persists long beyond completion of medical treat-
ment [3,8-10].
Healthcare professionals are unsure how to best manage FCR as evidence based 
strategies are not yet routinely available [11]. As a result FCR is often poorly addressed 
in clinical settings. There are few controlled trials of interventions that address FCR. Her-
schbach et al. (2010) found that “fear of progression” decreased significantly following 
group cognitive behavioral therapy or supportive-experiential therapy when compared 
with a no intervention control group [12]. Humphris et al., (2012) reported a small effect 
of an individually nurse-delivered intervention for FCR in oropharyngeal patients [13]. 
Pilot studies in predominantly female cancer survivors have also demonstrated that 
both individual and group interventions may be effective in reducing FCR [14,15]. Most 
interventions evaluated to date use group therapy [12,14] or individual face-to-face 
therapy [13,15] whereas ehealth methods have not yet been used to treat FCR.
There are some limits to the use of face-to-face psychological therapy. Specialized 
face-to-face interventions are resource intensive and there are known patient-reported 
barriers to engage in face-to-face psychological treatment, such as time investment, 
stigma, reluctance to return to the hospital and indirect costs (e.g. time off work, travel 
costs)[16]. There is also a lack of suitably trained clinicians to deliver specialized inter-
ventions outside metropolitan cities.
Blended therapy may overcome some of these barriers. In blended therapy, only part 
of the therapy is delivered in face-to-face sessions while the remainder is offered in a 
different format, such as via e-consultation [17]. Fewer face-to-face sessions are needed 
while continuous access to a website facilitates skill acquisition and consolidation of 
in-session learning. While internet based therapy has been found to be equally effective 
and more cost-effective than face-to-face therapy for people with chronic somatic con-
ditions [18-20] evidence for its efficacy in cancer survivors is still limited [19,21]. Further-
more, no studies have examined the efficacy of blended therapy for cancer survivors.
In the current paper, we present the results of a randomized controlled trial (RCT) 
investigating the efficacy of blended cognitive behavior therapy (bCBT) for high FCR 
amongst breast (BC), colorectal (CRC) and prostate cancer (PC) survivors who are 6 
months up to 5-year post-medical treatment.
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PATIenTs AnD MeTHoDs
Design
A parallel group, prospective RCT [bCBT vs. care as usual (CAU)], with 1:1 allocation 
ratio was conducted. The study protocol has been published [22] and was approved 
by the ethical review board of the Radboud University Medical Center (CMO Arnhem-
Nijmegen). The trial is registered in the Netherlands National Trial Register (NTR4423). All 
participants provided written informed consent.
Participants
Eligible cancer survivors: 1) had completed primary medical treatment for BC, PC or CRC 
at least 6 months and no longer than 5 years ago (except hormone therapy for BC); 
2) were disease-free at moment of enrollment, as defined by the absence of somatic 
disease activity parameters, 3) were at least 18 years, 4) scored ≥14 on the Cancer Worry 
Scale, 5) were proficient in Dutch; 6) were able to travel to the hospital, and 7) provided 
written informed consent. Cancer survivors already receiving psychological or psychiat-
ric treatment were excluded.
Recruitment
Between January 2014 to December 2015 healthcare professionals at five participating 
hospitals (one academic, four regional) provided study information to cancer survivors 
during medical follow-up consultations or via mail (figure1). Interested survivors returned 
an opt-in card. They were then contacted by a researcher (MW) to address questions, 
provide further information and to conduct verbal screening. Subsequently, a screening 
questionnaire was sent and eligible survivors received the baseline questionnaire (T0).
Interventions
bCBT. The intervention was delivered as blended care during a 3-month period: five 
individual one-hour face-to-face sessions (session 1-3,5 and 8) combined with either 
three 15-minute e-consultations (chat-application, no video) with access to a website 
(session 4,6 and 7). If participants were unable to use the website (or had no access to 
the internet) the e-consultations were replaced by three 15-minute telephone consulta-
tions and a workbook was provided. Website and workbook were identical in content. 
The intervention is based on the theoretical formulation of FCR proposed by Lee-Jones 
(1997) which builds on Leventhal’s Self-Regulation Model of Illness to understand coping 
with illness/health threats [2,23]. Intervention techniques included psycho-education, 
cognitive restructuring and behavioral modification. Further details of the therapy have 
been published in the trial paper and a case study [22,24].
SWORD: effect study
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Allocated to CAU (n=43)
 
Baseline questionnaire not 
returned (n=2)
Study information supplied to potentially eligible survivor (total n=750)              
a) During clinical follow-up (n=448; BC (n=225), CRC (n=216), PC (n=7)).
b) Sent by mail  to PC survivors (n=302)
Screening sent (n=151)
BC (n=40), CRC (n=26), PC (n=85)
Non-participation after 
screening (n=61)*
   Excluded (n=42)
 Metastases (n=5)
 2nd tumor (n=5)
 Low FCR (CWS<14) (n=33)
 Poor Dutch language (n=1)
 Already psychological help 
(n=1)
  Declined to participate 
(n=12)
 High FCR (CWS≥14) but no
need for help with FCR
(n=11)
 High FCR (CWS≥14) already 
participating other 
intervention study (n=1)
   Unknown (n= 7)
 Screening not returned (n=7)
Responded (n=162)
BC (n=45), CRC (n=30), PC (n=87)
Non-participation after 
telephonic screening  (n=11)
   Excluded (n=5)
   Declined to participate (n=3)
   Contact not established (n=3)
Lost to follow-up  (n=2)
Intervention and study dropout (n=1)
Disease recurrence (n=1)
Intention-to-treat: Analysed  (n=45)
Excluded from analysis  (n=0)
Data imputed with LOCF (n=2)
Allocated to bCBT (n=45)
Declined bCBT (n=3)
Travel distance too far (n=1)
Health-related complication (n=1)
Not interested (n=1)
Received bCBT(n=42)
Completed all  sessions  (n=28; 66%)
       Reasons for discontinuing: 
           Therapist reasons 
Sick leave therapist (n=4)
Other need-for help question (n=2)
             Patient reasons
FCR reduction established (n=2)
Health-related problems (n=2)
bCBT not meeting expectations (n=2)
Unease caused by bCBT (n=1)
Not known / no-show (n=1)
Lost to follow-up (n=4)
Not interested in further participation (n=3)
New primary cancer diagnosed (n=1)
Intention-to-treat: Analysed  (n=43)
 Excluded from analysis  (n=0)
Data imputed with LOCF (n=4)
Analysis 
Eligible and interested (n=90)
BC (n=37), CRC (n=22), PC (n=31)
Consenting patients randomly assigned (n=88) 
Follow-up 
figure 1. CONSORT flow chart showing recruitment and enrollment of 88 participants.
* Does not add up to n=45 because three participants met two or more exclusion criteria.
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CAU. Participants in CAU did not receive bCBT. There were no restrictions regarding 
use of psychosocial support during the study period.
Treatment integrity
Therapist competence [25]. Two registered healthcare psychologists with at least five 
years of CBT experience in psychosocial oncology offered bCBT. Protocol training and 
biweekly group supervision with a clinical psychologist (JP) helped to ensure therapist 
competence and fidelity to the treatment manual. Forty-three (60-minute) group super-
visions took place.
Therapist treatment adherence. Three independent raters (trained master psychology 
students)[26] used a checklist to score a random selection of 43 audio taped face-to-
face sessions (5%) on amount of session time relevant for bCBT and the percentage of 
therapy components covered [27]. The analyses showed that 93% of the time spent in 
therapy was relevant for bCBT and that 75% of the sessions covered all required session 
components. There was moderate to good inter-rater agreement (k=.60, proportion of 
observed agreement 89%)[28].
Measures
All paper-and-pencil questionnaires were completed at T0 (pre-randomization) and at 
T1 (3-months post baseline assessment). Demographics and medical characteristics 
were self-reported at T0.
Cancer survivors were screened for high FCR with the Cancer Worry Scale (CWS) 
which measures concerns about developing cancer or developing cancer again [9,29]. 
The 8-items are rated on a 4-point scale ranging from 1 (“never”) to 4 (“almost always”)
(α=0.81). Scores range from 8 to 32, lower scores indicate less FCR. A diagnostic cut-off 
of 13 versus 14 has been validated for BC and CRC survivors and was used to differenti-
ate between low and high FCR [8-9]. In this study, those scoring ≥14 were classified with 
high FCR and were eligible to participate [9]. The CWS was also the primary outcome 
measure.
Secondary outcomes were: multidimensional aspects of FCR (Fear of Cancer Recur-
rence Inventory)[30], cancer- specific distress (Impact of Events Scale)[31], distress 
(Hospital Anxiety and Depression Scale, Distress Thermometer)[32-35], body vigilance 
(Body Vigilance Scale)[36], fatigue (CIS-8R)[37], quality of life (QoL, EORTC QLQ-C30)[38], 
health status (EQ-5D)[39], satisfaction with life (Satisfaction With Life scale)[40], optimism 
(Life Orientation Test)[41] and perceived social support (SSL-D)[42]. Healthcare diaries 
completed between T0 and T1 provided information on use of supportive care services. 
Further details of primary and secondary outcomes are in the trial protocol [22]. Thera-
pists reported number of sessions completed, therapy duration and rated improvement 
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for bCBT participants. Data retrieved from the website included: frequency of log-ins, 
total duration (minutes) and activity (number of assignments opened/submitted).
sample size
The sample size was calculated using a two-stage procedure. First, to detect a medium 
effect size (Cohen’s d=0.50)[43] in FCR (CWS) with a two-sided type I error rate of 0.05 
and 80% power in an independent samples t-test, n=128 were needed. However, since 
we planned to use the pre-measurement as covariate in an ANCOVA, this calculated 
sample size was reduced as the pre-measurement reduces the residual variance. For 
ANCOVA this factor is equal to (1-r2), where ‘r’ is the correlation between pre and 
post-measurement (0.6)[44]. Therefore, in the second step we multiplied the sample 
size derived from t-test power calculation by this factor (128*[1-0.62]) resulting in 82 
participants. With an anticipated attrition rate of 20%[14] our accrual target was 104 
participants. Eighty-eight patients had been enrolled when the planned recruitment 
period ended. Since actual study dropout rate was lower (6%) than anticipated the study 
remained sufficiently powered.
Random assignment and blinding
After completion of T0, participants were randomized to bCBT or CAU with a computer-
generated allocation sequence, fixed block size of six and stratified by cancer type. 
Research assistants carried out randomization. Participants in bCBT were assigned to 
therapists A (male) or B (female) based on therapist availability. One researcher was not 
blinded and informed participants about randomization outcome.
sTATIsTICAl MeTHoDs
statistical effects
Statistical analyses were performed with SPSS22[45]. Baseline differences in demo-
graphics or medical characteristics between groups were analyzed with independent 
t-tests or chi-square analysis. All analyses were intention-to-treat (ITT). Missing values 
on primary and secondary outcome measures at T1 were imputed using last observation 
carried forward (LOCF). LOCF is a conservative approach as FCR was expected to remain 
stable over time without intervention [3,46-47] while improvement could occur in bCBT. 
For sensitivity analyses, multiple imputation (20 iterations) and complete case analysis 
evaluated the sensitivity of the results to the missing data [48].
One-way between-groups analyses of covariance (ANCOVA) were used with group 
allocation (bCBT/CAU) as the fixed factor. For primary outcome analysis, baseline levels 
of FCR (CWS) and tumor type (stratification factor) were entered as covariates. For each 
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secondary outcome analysis, baseline scores on the corresponding questionnaires 
and tumor type were defined as covariates. Table 2 reports mean adjusted differences 
between T0 and T1 by group, with standard errors, alpha levels and the 95%CI. Cohen’s 
d was calculated using the pooled standard deviations and unadjusted means on T1.
Clinically significant change
The reliable change index (RCI) was calculated to determine if statistically significant 
change had occurred [49]. The RCI represents the change between an individual’sT0 and 
T1 scores divided by the standard error of difference between the scores. Three possible 
outcomes were: reliable improvement (RCI<-1.96), no reliable change (RCI -1.96 to 1.96) 
or reliable deterioration (RCI>1.96). The minimum difference between T0 and T1 CWS 
scores that constituted significant change was 4.48 points.
Secondly, clinically significant change (CSC) was defined as a decrease of the CWS 
score to the normal range (i.e. range of scores normal to those with low FCR, CWS <14)
[22]. A person was classified with clinically significant improvement (CSI) if both criteria 
were met (RCI<-1.96 and CSC). Self-rated improvement had occurred if the participant 
answered “yes” to the statement, “I no longer experience problems of FCR” or “I feel much 
better but still experience some FCR.”
ResUlTs
The CONSORT diagram (figure1) identifies the number of cancer survivors approached, 
screened, randomly assigned, and retained. Eighty-eight cancer survivors were ran-
domly assigned to bCBT (n=45) or CAU (n=43).
Demographics and medical characteristics by cancer type are described in Table1. 
Therapist A and B treated 19 and 26 participants respectively. CAU and bCBT participants 
did not differ on medical or demographic characteristics (table2) nor baseline study 
outcomes (table3). Missing data at T1 were equally distributed over the groups (4 CAU; 
2 bCBT). Baseline FCR was similar between those who completed T1 (n=82) and those 
who had missing data (n=6, mean diff. 0.61, p=0.702, 95%CI [-2.528 to 3.739]).
SWORD: effect study
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Table 1. Demographic and clinical characteristics by cancer diagnosis.
Characteristic breast cancer
(n=36)
n (%)
Prostate 
cancer
(n=30)
n (%)
Colorectal 
cancer (n=22)
n (%)
p-value
Age, years* Mean (sD) 51.0 (8.0)
Range 31- 65
65.8 (6.4)
Range 44 - 76
62.3 (10.8)
Range 32 - 77
p < 0.001
sex, Female 36 (100%) 0 (0%) 11 (50%) n.a.
education
  Low (ISCED 0-1-2)
  Medium (ISCED 3-4-5)
  High (ISCED 6-7-8)
 
9 (25%)
15 (42%)
12 (33%)
 
10 (33%)
10 (33%)
10 (33%)
 
10 (46%)
4 (18%)
8 (36%)
 
p = 0.397
Partner, Yes 29 (81%) 26 (87%) 18 (82%) p = 0.795
Treatment type
  Surgery only
  RTx only
  Surgery + RTx
  Surgery + CTx
  Surgery + RTx + CTx
 
5 (14%)
0
7 (19%)
10 (28%)
14 (39%)
 
17 (57%)
3 (10%)
10 (33%)
0
0
 
7 (32%)
0
1 (5%)
11 (50%)
3 (14%)
 
p < 0.001
Hormone therapy✝ 28 (78%) n.a. n.a. n.a.
Time since diagnosis, years 2.7 (1.5) 2.2 (1.1) 2.7 (1.5) p = 0.295
Time since last treatment, years ** 2.3 (1.5) 1.4 (1.0) 2.3 (1.4) p = 0.012
fCR at baseline, Mean (sD) 20.1 (2.7)
range 16 - 26
18.3 (4.0)
Range 14 - 32
20.6 (4.3)
Range 14 - 29
p = 0.051
Note: n.a.: not applicable. RTx, radiotherapy; CTx, chemotherapy; ISCED, International Standard Classifica-
tion of Education; SD, standard deviation; bCBT, blended cognitive behavior therapy; CAU, care as usual. 
*Age: Breast cancer survivors are significantly younger than prostate and colorectal cancer survivors.** 
Time since treatment: Prostate cancer survivors are significantly closer to end of treatment than those with 
breast or colorectal cancer. ✝Breast cancer survivors only, with the exception of one prostate cancer survivor 
received hormonal injections prior to radiotherapy.
Primary outcome: fCR severity
The decrease in FCR between T0 and T1 was significantly greater for those who received 
bCBT compared with CAU with a medium to large effect size (ES) (d=.76; table3). A weak 
to moderate correlation was found between number of completed therapy sessions 
(0-8) and FCR severity at T1 (r=-0.371,p=.012).
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Table 2. Demographic and Clinical Characteristics of Participants by Study Group.
Characteristic bCbT
(n=45)
n (%)
CAU
(n=43)
n (%)
 
p-value
Age, years
  Mean
  sD
 
58.0
11.3
 
59.7
10.0
 
p = 0.471
sex
  Male
  female
 
21 (47%)
24 (53%)
 
20 (47%)
23 (53%)
 
p = 0.988
education
  low (IsCeD 0-1-2)
  Medium (IsCeD 3-4-5)
  High (IsCeD 6-7-8)
 
11 (24%)
19 (42%)
15 (34%)
 
18 (42%)
10 (23%)
15 (35%)
 
p = 0.109
Partner status
  Partner
  no partner
 
36 (80%)
9 (20%)
 
37 (86%)
6 (14%)
 
p = 0.451
 
Primary cancer site
  breast
  Prostate
  Colorectal
 
18 (40%)
15 (33%)
12 (27%)
 
18 (42%)
15 (35%)
10 (23%)
 
p = 0.934
Treatment type
  surgery only
  RTx only
  surgery + RTx✝
  surgery + CTx
  surgery + RTx + CTx
 
18 (40%)
0 (0%)
9 (20%)
12 (27%)
6 (13%)
 
11 (26%)
3 (7%)
9 (21%)
9 (21%)
11 (26%)
 
p = 0.162
Hormone therapy* 15 (30%) 13 (33%) p = 0.755
Time since diagnosis, years
  Mean
  sD
 
2.4
1.5
 
2.8
1.3
 
p = 0.185
Time since last treatment, years
  Mean
  sD
 
1.9
1.5
 
2.1
1.4
 
p = 0.185
number of comorbid diseases**
  none
  one or two
  three or more
 
19 (42%)
19 (42%)
7 (16%)
 
14 (33%)
22 (51%)
7 (16%)
 
p = 0.627
Psychological help in the past
  Yes
  no
 
22 (50%)
22 (50%)
 
26 (60%)
17 (40%)
 
p = 0.381
fCR at baseline
Mean
sD
 
19.6
3.7
 
19.6
3.7
 
p = 0.914
RTx, radiotherapy; CTx, chemotherapy; ISCED, International Standard Classification of Education; SD, stan-
dard deviation; bCBT, blended cognitive behavior therapy; CAU, care as usual.
* breast cancer only; ✝One prostate cancer survivor received hormonal injections prior to radiotherapy.** 
Most frequent co morbidities: back pain (34%), osteoarthritis (30%), hypertension (23%), heart disease 
(12%) and depression (11%).
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secondary outcomes
bCBT participants experienced significantly greater improvement than those in CAU on 
the FCRI total score and four out of the seven FCRI subscales (severity, triggers, distress 
and functioning impairments) with moderate to large ESs (d=.45 to .72) and on global 
QoL, emotional and cognitive functioning (d=.64 to .73) (table3). Significant improve-
ment with small to large ESs (d =.47 to .74) was also found on nine out of eleven support-
ing psychosocial indices (anxiety, depression, general distress, cancer-specific distress 
(intrusions/avoidance), fatigue, bodily vigilance and health status) for bCBT compared 
to CAU.
sensitivity analyses
Multiple imputation and complete case analysis were performed to handle missing 
data. Overall findings were equivalent using both methods.
Clinical significant improvement
No participants reported an increase in FCR. The proportion of participants reporting 
reliable improvement, clinical significant change, clinical significant improvement 
and self-reported improvement at T1 was significantly higher in bCBT than in CAU 
(table4,figure2).
Table 4. Clinically significant improvement at 3 months in FCR severity, self-rated improvement and thera-
pist rated improvement by treatment group.
Criteria bCbT
(n=45)
CAU
(n=43)
fishers’exact 
Test
Reliable Change: improvement* 51% (n=23)
[95% CI, 37.0 to 62.0]
9% (n=4)
[95% CI, 3.7 to 21.6]
p < 0.001
Clinically significant change** 42% (n=19)
[95% CI, 29.0 to 56.7]]
10% (n=4)
[95% CI, 3.7 to 21.6]
p = 0.001
Clinically significant improvement*** 29% (n=13)
[95% CI,17.7 to 43.4]
0% (n=0)
[95% CI, 0 to 0.8]
p < 0.001
Self-rated improvement**** 71% (n=30)
[95% CI, 56.4 to 82.8]
32% (n=12)
[95% CI, 19.1 to 47.5]
p < 0.001
Therapist rated improvement † 100% (n=28) n.a. n.a.
Nb. n.a. not applicable; CAU, care as usual; bCBT; blended cognitive behavior therapy, CI; confidence inter-
val for proportions [53].
* Statistically reliable change, RCI <-1.96
** Decrease of the CWS score to the low fearful range (<14)
*** Criteria of reliable improvement and clinically significant change are both met.
**** Self-rated improvement had occurred if the patient answered “yes” to the statement, “I have completely 
recovered from FCR” or “I feel much better but still experience some symptoms of FCR.” CBT (n=42); CAU 
(n=38). † Completers only (n=28)
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Implementation of bCbT
After the first session, 17% (7/42) of the participants were unable to use the website due 
to lack of internet skills and requested the workbook. Mean duration of therapy was 
10.9 weeks (range 0-28) and 66% (n=28) completed all sessions (figure1). In adjusted 
analyses completers scored significantly lower on FCR at T1 than non-completers (14.2 
vs.17.0,p=.008,95%CI [-4.781 to -0.768]). Those treated by therapist A reported similar 
levels of FCR at T1 as those treated by therapist B (15.1 vs.15.3,p=.841,95%CI [-1.772 to 
2.166]).
Website usage. For bCBT website users (n=35), median frequency of logins between T0 
and T1 was 12.6 logins per user. Median login duration was 28.3 minutes. Participants 
opened approximately 52 and submitted a median of 47 assignments to therapists 
(range 0 (“none”) to 54 (“all”))(table5).
Table 5. Website statistics
All website users (n=35) Completers only (n=25)
Median (range) Median (range)
Number of logins during therapy 12.0 (1 – 29) 13.5 (5 – 29)
Inlog duration per session (minutes) 28.3 (3 – 64) 30.0 (8 – 64)
Number of assignments opened* 52.0 (0 – 54) 54.0 (33 – 54)
Number of assignments submitted* 47.0 (0 – 54) 51.0 (27 – 54)
* Total number of assignments: 54
supportive care
Significantly more participants receiving CAU (34%,n=11) had visited a psychologist 
or social worker at least once in the period between T0 and T1 compared with bCBT 
(6%,n=2)(χ2=8.461;p=0.004).
DIsCUssIon
The objective of this study was to test the efficacy of bBCT in reducing FCR severity in BC, 
PC and CRC survivors. The between-group effect size on FCR at post-intervention was 
moderate to large (d=0.76) in favor of bBCT. Around one-third of bCBT participants had 
clinically significant improvement whereas no clinically significant improvement was 
observed in the control condition. More bCBT than CAU participants had self-reported 
improvement. To the best of our knowledge, this is the first RCT to demonstrate effects 
of a psychological intervention on FCR reduction in a mixed-group of cancer survivors.
Secondary outcomes concerning QoL, multidimensional aspects of FCR, general and 
cancer specific distress, fatigue, body vigilance, health status and satisfaction with life 
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confirmed the positive effects of bCBT. No significant differences were found in perceived 
social support, social functioning, physical functioning, role functioning and optimism. 
There was no effect on FCRI subscales ‘coping strategies’ and ‘reassurance seeking‘. 
Higher scores on these subscales may reflect both versatility and dysfunctional coping. 
Therefore, the aggregated FCRI total score should be interpreted with caution [50].
In the intention-to-treat analyses strong effects were found, even though one third 
in bCBT were non-completers and one-third of the CAU participants had received ad-
ditional supportive care. Per-protocol analyses were considered redundant. Our findings 
are in line with a feasibility study, a pilot study and two trials that reported beneficial 
effects of individual and group face-to-face therapies on FCR [12-15]. The effect size 
(0.76) lies in the range of ESs for individual and group psychotherapy for anxiety (0.56), 
depression (0.53), distress (1.01) and QoL (0.89) in cancer survivors[43]. A meta-review 
found that ehealth interventions combined with professional guidance produced 
equivalent effects as classic face-to-face therapies [18]. Blended care therefore appears 
to be a promising approach. The intervention was delivered by highly motivated and 
experienced therapists, which may partially account for the large effects.
Therapist treatment adherence was satisfactory. Log data analysis showed that bCBT 
participants regularly logged into the website and completed nearly all homework 
assignments, indicating good therapy compliance. Intervention non-completion rate 
was 34%. This percentage is somewhat higher than the non-completion rate for group 
FCR interventions (20-24%)[14,12] but lower than that of an individual nurse-delivered 
intervention (42%)[13]. In current study, six patients discontinued therapy due to thera-
pist reasons. During sick leave of one therapist, four patients were offered to continue 
therapy with another therapist but all declined. While the protocol stated that the thera-
pist should aim to defer referral to other psychological services during the intervention 
trial two patients were referred which was a deviation from protocol.
This study has several limitations. Despite adequate power and a rigorous recruitment 
method, it is not certain to what extent the results of the present study generalize to 
other cancer survivors with high FCR. Firstly, the response rate to the initial study invita-
tion letter was low (21%). However, it is noteworthy that the invitation was provided to 
a group of patients who were not screened for FCR and that due to the opt-in recruit-
ment method reasons for non-response are not known. Based on Dutch FCR prevalence 
estimates of high FCR, it is likely that around one-third of patients who received the 
invitation had high FCR. Furthermore, research conducted in the Netherlands and the 
UK suggests that around 20% of cancer survivors require help dealing with FCR [51,52], 
so the response rate to the initial invitation in this study is consistent with the preva-
lence and unmet need for help with FCR reported in the literature. Secondly, healthcare 
professionals were sometimes reluctant to recruit participants for this trial due to the 
no treatment control group. Therefore, some survivors were referred to psychosocial 
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services outside the study context. Future studies on the implementation and effective-
ness of FCR interventions should explore uptake by cancer survivors in clinical settings 
and barriers and facilitators of participation in blended therapy for FCR.
Some design limitations warrant further comment. The study did not include an 
active control group and we cannot rule out that therapist attention resulted in the 
observed changes. Therefore, the reported findings may be an overestimation of the 
treatment effects. Secondly, while using an online component in therapy is innovative, 
16% required to use a workbook rather than the website. This suggests that web-based 
therapy may not suit everyone. Finally, the small sample sizes do not allow comparisons 
among patient subgroups to identify moderators of the treatment effect. Nevertheless, 
the present study offers novel insights on the efficacy of bCBT for cancer survivors.
Screening for high FCR and making referrals to psychological services is an impor-
tant role for healthcare professionals. Given that some FCR is normal, many health 
professionals find it difficult to identify patients with high FCR. Developing educational 
programs for health professionals concerning the prevalence of FCR, characteristics, 
consequences and treatments for FCR is therefore a priority.
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The studies presented in this thesis were performed to gain a better understanding of 
the nature of FCR and to test the efficacy of blended cognitive behavior therapy (bCBT) 
to reduce FCR in cancer survivors. The primary findings of all studies are described in 
chapter 9 (the summary) of this thesis. Strengths and weaknesses of individual studies 
have already been addressed in each study separately (chapter 2-7). In this general dis-
cussion overall implications and points of discussion will be addressed in major themes. 
Textboxes (1-6) are presented to summarize key points and to provide recommenda-
tions.
PART I: UnDeRsTAnDInG fCR In CAnCeR sURvIvoRs AnD PARTneRs.
1) Conceptualization & assessment of fCR
1.1 The definition of FCR.
For sake of consistency, in chapter 2 - 6 the definition of FCR as proposed by Vickberg 
(2003) [1], and adapted by Simard and Savard (2009) [2] was used: “The fear or worry that 
the cancer will return or progress in the same organ or in another part of the body”. While 
this is the most often used definition of FCR, there is no consensus among researchers 
that it adequately captures all aspects of FCR. For instance, it is questionable whether 
this definition meets the variety of ways in which patients conceptualize their FCR (eg. 
fear of a new primary cancer, fear of metastases).
A first step to address this definitional issue was made in 2015 in an international col-
loquium meeting on FCR. Here, a revised definition of FCR was developed through an 
expert consensus process by the international collaboration “FORWARDS” (Special Inter-
est Group on FCR, International Psycho-Oncology Society) in order to reflect the variety 
of ways in which patients conceptualize FCR and to be more inclusive of people with 
new primaries, recurrences, metastases and active disease (progression). The revised 
definition after a Delphi process was “Fear, worry, or concern about cancer returning or 
progressing” [3]. To practice what we preach, we decided to employ this new definition in 
chapter 7, taking a small first step in the direction of reaching consensus and providing 
uniformity in the growing field of FCR. It is expected that this new clinical definition will 
unify, focus and improve future research on FCR. For instance, existing FCR question-
naires will need to be critically evaluated to see how they map onto this new definition.
1.2 Assessment and prevalence of high FCR.
As addressed in the introductory section of this thesis there are over 30 assessment 
instruments available to researchers and clinicians to assess FCR in cancer survivors [4]. 
In chapter 2 the Impact of Cancer Scale - Health Worries Subscale (IOCS-HWS) was used 
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to assess FCR in cancer survivors [5] whereas in chapter 3, 6 and 7 the Cancer Worry 
Scale (CWS) measured FCR [6]. While the IOSC-HWS is not validated to assess FCR, this 
was the only available FCR measure in the dataset extracted from the PROFILES-registry 
[7]. Given its high face validity we deemed it to be an appropriate FCR instrument for 
that study despite in the subsequent studies selecting another measure, the CWS, as 
our primary outcome. The CWS was selected for all following studies – which were 
conducted at the Radboud University Medical Center - because it had already been 
validated to assess FCR in Dutch breast and colorectal cancer survivors and was found 
to have sufficient psychometric properties in both populations [8,9].
Using the CWS we found that 36% of prostate cancer survivors reported high FCR 
(defined as a CWS score ≥14); a percentage relatively similar to high FCR in Dutch breast 
(40%) and colorectal cancer survivors (38%) [8,9]. These numbers are slightly lower than 
percentages reported in an international literature review where on average 49% of 
cancer survivors were reported to have moderate-to-high FCR [10]. For breast cancer 
survivors, approximately 40% (range 24-55%) reported moderate-to-high FCR which 
corresponds to proportion found in Dutch breast cancer survivors. Percentages for 
colorectal and prostate cancer survivors cannot be extracted from the review as FCR 
was not specifically addressed in these groups. Factors such as choice of questionnaire, 
differences in definition of high FCR, time of assessment, heterogeneity of samples and 
cultural differences have most likely influenced these differences in findings [10].
In the study in chapter 4 another challenge in FCR assessment emerged. In recent 
years, FCR was mainly studied in cancer survivors and there has been a lack of research 
on FCR in partners or informal caregivers [10,11]. No validated questionnaire was avail-
able to assess FCR in partners or caregivers and we therefore adapted the wording of the 
CWS to make the instrument more suitable to assess FCR in partners. By administering 
this modified version of the CWS it was found that 35% of the partners reported high 
levels of FCR (CWS cut-off score ≥14). Furthermore, partner FCR was strongly related to 
patient FCR indicating that FCR may be a shared concern between partners and patients. 
Given our findings, future development and validation of assessment instruments to 
detect high FCR in partners and informal caregivers is strongly encouraged.
1.3 Critical evaluation of the Cancer Worry Scale.
In chapter 3 – 7 the CWS was the primary instrument of choice, several limitations of 
this scale were identified in these studies and merit further discussion.
1. In chapter 3 we reported the results of the first study that used the CWS in prostate 
cancer survivors. Some patients reported difficulties with item #8 “How concerned are 
you about the possibility that you will ever need surgery (again)?” For prostate cancer 
survivors, another surgery is simply not an option; a recurrence will be treated with 
radiotherapy or hormones. For those cancer survivors having had breast cancer the 
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majority fears additional chemotherapy rather than surgery. Could the content of 
item 8 have impacted the CWS total score, and have resulted in a lower cut-off score 
for prostate cancer survivors? In our opinion, individual items of the CWS need criti-
cal evaluation.
2. In light of the new definition of FCR, assessment instruments should be equally suit-
able for both patients with progressive disease and those who fear a new cancer or 
cancer recurrence/metastases. It is questionable if the CWS fulfills this criterion, for 
instance, the wording of item #4: “How concerned are you about the possibility of get-
ting cancer (again) one day?” and item #5: “How often do you worry about developing 
cancer (again)?” seem to imply that one is disease free at time of answering.
3. The CWS has primarily been used in the Netherlands. The use of non-uniform, 
language-specific, measures of FCR has led to difficulties in interpreting and compar-
ing research data. In order to overcome this problem, in chapters (3, 6 and 7) we 
have also reported on findings from the Fear of Cancer Recurrence Inventory (FCRI) 
[2]. Ideally, in the future, one gold standard assessment instrument for FCR should 
be developed, translated into multiple languages and be used by all FCR researchers 
and clinicians.
4. The CWS was initially validated so it could be used in Dutch breast cancer patients 
and a cut-off score was established to differentiate high from low FCR [8]. The CWS 
was validated by comparing it’s discriminative and predictive power against the 
two items of the Cancer Acceptance Scale (CAS). When the initial validation of the 
CWS took place, there was no other Dutch FCR questionnaire available but the CAS. 
With current new insights, it is questionable whether the CAS is an appropriate gold 
standard and ideally the CWS should have been validated against a clinical interview. 
For instance, in the SWORD-study (chapter 7) we used the validated cut-off point of 
Custers et al., (2014) to screen patients for high FCR and those with a score of 14 or 
higher on the CWS were seen as eligible for participation [8]. However, on several 
occasions therapists reported that enrolled patients were not overly fearful accord-
ing to their clinical judgment which raises questions about the suitability of the CWS 
to adequately differentiate between high and low FCR, and the use of the CWS as a 
screenings measure.
5. Although FCR is highly prevalent the majority of cancer survivors copes well and do 
not require help with FCR. The CWS does not include a question on need for help. 
As is reflected in the flowchart of the intervention study (chapter 7), a proportion of 
patients identified as having high FCR (thereby scoring above cut-off ) indicated no 
need for help when approached to participate in an intervention study for FCR.
Taken together the CWS has flaws and limitations that need to be kept in mind when 
generalizing findings from this dissertation. For future research it is important that 1) 
consensus will be reached on the definition of FCR, 2) a clinical interview for FCR needs 
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to be developed (or refined), translated into Dutch, validated and psychometrically 
tested, and 3) self-report questionnaires for FCR can then be validated as screening tools 
using the clinical interview as a gold standard.
1.4 When does FCR become clinical?
To date, there is no consensus clinical definition to help health professionals determine 
the point at which FCR becomes pathological [12]. Accordingly, there is also no specific 
guidance available to researchers and clinicians as to which measures are best to use to 
screen for high FCR. In order to achieve further progress in identifying clinical FCR, it is 
important to reach consensus on its core features. Recently, an international meeting 
of experts in FCR was held and priority was given to the identification of the essential 
characteristics of clinical FCR that are necessary to accurately and consistently measure 
FCR severity [3,12]. During this consensus meeting the following five hallmarks of clini-
cal FCR were identified by a panel of experts:
1. high levels of preoccupation, worry, rumination, or intrusive thoughts;
2. maladaptive coping;
3. functional impairments;
4. excessive distress; and
5. difficulties making plans for the future.
In 2015, the first semi-structured interview for FCR, the SI-FCR, introduced clinical 
judgment in classifying high versus low FCR [13]. This clinical interview, with 18 open-
ended questions, addresses all above mentioned features and classifies patients as clini-
cally fearful when the frequency, duration and emotional impact of FCR are sufficient 
to cause impairment in at least one domain of functioning, despite coping efforts. The 
SI-FCR has sufficient psychometric properties with a very good inter-rater reliability on 
the presence/absence of current FCR (kappa=0.86). Which makes it a psychometrically 
sound instrument. A benefit of using face-to-face interviews to assess clinical FCR is that 
a patient may place FCR in a broader context and clinicians can ask to elaborate on this 
information. However, the interview takes approximately 90-120 minutes to administer, 
requires strong clinical assessment skills and the interpretation requires more expert 
knowledge and subjective judgment as compared with use of a self-report question-
naire. Therefore, the SI-FCR is more suitable to be used by psychologists and psychiatrist 
rather than researchers, nurses or clinicians. A possible next step could be to translate 
the SI-FCR into Dutch and to carry out a validation study to see how the instrument 
performs in the Dutch population.
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box 1. Recommendations for conceptualization and development
– An expert panel has proposed a revised definition of FCR and it is encouraged 
to use this definition of FCR in future studies. The field of FCR research could 
further benefit from consensus on the selection of appropriate FCR assess-
ment measures for screening, research and diagnostic purposes in order 
to make established recommendations to researchers and clinicians about 
which measures to use and when.
– The absence of a gold standard makes it hard to define high/clinical levels of 
FCR in cancer survivors, to compare the prevalence of high FCR across studies 
(and cancer types) and to compare significant change in FCR outcomes be-
tween intervention studies. The SI-FCR is the first semi-structured diagnostic 
interview for FCR. Given its good psychometric properties it may be a suitable 
instrument to use in the Dutch population as well. Translation into Dutch and 
validation is advised.
– Partners also experience FCR. Future development and validation of assess-
ment instruments to detect high FCR in partners and informal caregivers is 
strongly encouraged.
2) Demographic, medical and psychosocial correlates of fCR
In chapter 1 we introduced the four-component model of Lee-Jones (1997), describing 
how FCR can be precipitated and perpetuated by factors such as antecedents, cogni-
tions, triggers and (behavioral) consequences [14]. This model was also central to the 
chapters in this thesis and its framework lies at the heart of the SWORD intervention. 
Components of this model were investigated in chapter 2-4 of this thesis. It should be 
noted that all studies in this thesis were cross-sectional and causality can therefore not 
be implied.
2.1 Personal factors (demographics).
Evidence from recent reviews presents inconclusive evidence for an association between 
medical factors (e.g. time since diagnosis, tumor type), demographics (e.g. gender and 
education) and FCR. Only a younger age has consistently been found to predict FCR 
[10,11,15]. Consistent with previous literature, younger age was found to be associated 
with higher FCR in both studies on FCR in cancer survivors (chapter 2 and 3), and the 
study on FCR in partners (chapter 4). Furthermore, in the PROFILES-study (chapter 2) 
women reported higher levels of FCR than men. In the other two studies (chapters 3 
and 4) it was impossible to investigate the effect of gender on FCR because the sample 
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consisted of men or women only. Concerning education it has been suggested that 
higher educated patients have a better understanding of their disease and its treatment, 
and are better informed; thereby they experience less FCR [10]. However, in none of the 
performed studies did we find a significant association between FCR and education. 
Amongst partners, patient FCR was the strongest associate of high FCR (chapter 4). 
An earlier study suggested that FCR may be equally present in partners as in cancer 
survivors themselves [16] and present findings supports this hypothesis. Partners and 
informal caregivers are currently an underserved and under-researched group. If it is in-
deed the case that partners influence each other’s fears, couple-based interventions for 
FCR may be required. Although the SWORD intervention encouraged patients to bring 
their partner to one or more conjoint bCBT sessions if needed, no specific exercises or 
activities designed for the partner were included (also see chapter 5). One out of five 
patients (21%) brought their partner to one or more sessions. Given the high prevalence 
of FCR amongst partners and caregivers further research is needed to identify the needs 
of partner and caregivers with respect to FCR and to design interventions to address 
those needs.
2.2 Medical factors (treatment and medical characteristics).
There is currently inconsistent evidence on the relationship between medical character-
istics, such as indices of disease severity or cancer type, and FCR. Given that there is a 
difference in objective risk for recurrence between cancer types, it is possible that there 
is a difference in the subjective experience of FCR between these groups as well. To date, 
most studies on the prevalence of FCR have included patients with one cancer type only 
and comparisons between cancer types had seldom been made [10]. In chapter 2 we 
compared FCR severity between seven understudied cancer types and found FCR to be 
a relatively universal concern that does not necessarily seemed to be linked to a specific 
cancer diagnosis. No significant differences in mean levels of FCR were found between 
any of the included groups (colorectal cancer, melanoma, thyroid cancer, (non-)Hodgkin 
lymphoma and endometrial cancer). Furthermore, in chapter 7, mean levels of FCR did 
not significantly differ between those with breast, prostate or colorectal cancer prior to 
therapy. Regarding other treatment- and disease-related variables (e.g. disease stage, 
time since diagnosis or treatment modality), we did not find any consistent association 
between medical characteristics and FCR in chapter 2 – 4. This might be attributable to 
the heterogeneity of the studied populations in terms of time since diagnosis, treatment 
modalities, and age (e.g. younger patients often have different treatments and clinical 
features). However, this may also suggest that that rather than the objective clinical as-
sessment of the risk of recurrence psychological factors and demographics play a more 
important role in the FCR experience. Cancer survivors often do not have a medical 
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background and FCR may therefore be based more on the subjective experience of the 
cancer treatment rather than on medical facts.
2.3 Triggers of FCR.
Both internal and external stimuli (“triggers”) are believed to play a role in activating 
cognitive responses to FCR. Internal stimuli, such as somatic cues, can be interpreted 
as signs of early recurrence thereby triggering FCR. External stimuli, such as medical 
follow-up visits, may remind survivors about their disease and may increase worry and 
FCR [14]. In chapter 3 the most common triggers of FCR in prostate cancer survivors 
with low and high FCR were investigated. Medical examinations, seeing or hearing 
about cancer and medical appointments were the most frequently cited triggers of 
FCR. Those with high FCR reported more exposure to triggers than those with low FCR. 
In chapter 6 the case of a highly fearful breast cancer survivor was presented. During 
therapy this patient completed ‘thought records’ whereby she analyzed situations in 
which she experienced FCR with therapist support. Seeing or hearing about cancer, and 
performing breast-self exams were her core triggers. In the intervention study, chapter 
7, those who had received the intervention reported significantly less triggers of FCR 
post-treatment than those who did not. It is unlikely that exposure to triggers of FCR 
spontaneously decreased over 3-months’ time for the bCBT group only.
Possible explanations could be that bCBT reduces the emotional reactivity or selective 
attention to triggers of FCR, but also that bCBT changes the way intrusions by triggers 
are interpreted and teaches patients to pay more attention to triggers that support an 
alternative interpretation. Thereby, triggers become less disturbing and recall of situa-
tions or events that trigger FCR may decrease. Identifying triggers of FCR lends itself to 
further exploration in both quantitative and qualitative studies. A better understanding 
of triggers will improve knowledge of the nature of FCR, and may be used to guide fu-
ture intervention development (e.g. decide on which treatment components to include, 
such as exposure and response prevention exercises).
2.4 Psychosocial and behavioral correlates of FCR (“consequences”).
Because all studies (chapter 2–4) were cross-sectional in design, causality cannot be 
implied and future longitudinal studies are needed to address the directionality of 
the relationship between psychological and behavioral characteristics of FCR. Strictly 
speaking, the term “consequences” should therefore be avoided. In recent reviews it is 
acknowledged that FCR is associated with poorer emotional functioning, distress and 
a worse functional status [10,11]. The findings presented in the current thesis are in 
line with this work. Overall, we found that both survivors and partners with high FCR 
had a lower general health, a worse quality of life, more distress, and scored lower on 
domains of emotional functioning and physical functioning than those with low FCR. 
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More research is needed to tease out the direction of the relationship between FCR and 
the psychological variables included in the theoretical model [14]. Behavioral factors 
associated with FCR were assessed with the FCRI and the MAX-PC in the chapter on FCR 
in prostate cancer survivors [2,17] (chapter 3). High fearful survivors were more inclined 
to delay their PSA-test, to have their test repeated at another lab and/or to have their 
general practitioner repeat the test than those with low FCR. As reported in the intro-
duction, avoidance behavior related to high FCR can manifest itself in both active (e.g. 
reassurance seeking) and passive behavior (passive avoidance). In the study on prostate 
cancer survivors we therefore found that those with high FCR employ both types of 
avoidance behavior more frequently than those with low FCR. It would be interesting to 
further investigate what patient characteristics are consistently associated with either 
type of avoidance behavior. In the case study (chapter 6) reassurance seeking behaviors 
were also highly prevalent; this breast cancer survivor was inclined to contact the nurse 
specialist by phone, request extra medical examinations and perform multiple breast 
self-exams a day. Recently, next to emotional and behavioral responses to FCR, there has 
been a growing interest in studying the physiological factors associated with anxiety 
(e.g. muscle tension, trembling) [18]. For instance, an accelerated heart rate can be 
misinterpreted as threatening and thereby induce or maintain FCR. To date, no studies 
have addressed the association between FCR and objective measurable physiological 
consequences but this would be another interesting area to explore. For instance, from 
personal correspondence we know that a research group is planning to investigate the 
relationship between emotional utterance and FCR using voice quality from recorded 
patient-physician conversations (prof. G. Humphris, personal correspondence). While 
detailed information is not yet available, it would be interesting to know more about the 
potential clinical relevance of this method.
2.5 Cognitions.
The role of cognitive processing strategies, information processing styles, metacogni-
tions (‘thinking about thinking’) and attentional processing (e.g. attentional bias towards 
the threat of cancer) on FCR were beyond the scope of this thesis and have therefore not 
been addressed. To date, only two studies have addressed the role of implicit cognitive 
processes (attentional bias) in FCR, and, due to methodological limitations, their results 
remain inconclusive and more research is needed [19,20].
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box 2. key findings on correlates of fCR
– Consistent with previous literature, younger age was consistently associated 
with FCR in all of our conducted studies. Inconsistent findings emerged for 
gender, disease stage, treatment modality and time since diagnosis. No 
evidence was found for a relation between FCR and tumor type, number of 
children or education.
– Those with high FCR reported experiencing more triggers than those with 
low FCR.
– Survivors and partners with high FCR reported a lower general health, a 
worse quality of life, more distress, and scored lower on domains of emotional 
functioning, and physical functioning, than those with low FCR.
– High FCR was associated with reassurance seeking and avoidance behavior in 
prostate cancer survivors.
PART II: MAnAGInG fCR In CAnCeR sURvIvoRs
Increasing awareness of the psychosocial burden that FCR places on patients and partners 
has led to the recent development of several psychological interventions to tackle FCR. 
In chapter 6 and chapter 7 we have discussed the findings of the SWORD-intervention, 
an individually delivered blended care intervention to manage FCR in cancer survivors. 
Both the effect study and case study demonstrated a significant beneficial effect of the 
intervention. Participants in the intervention group reported significantly lower FCR sever-
ity compared with those in the care as usual (CAU) control group. In this section, some 
methodological considerations are addressed and future research directions discussed.
3. Methodological considerations from sWoRD
3.1 SWORD-study design.
RCTs, such as the SWORD-study (chapter 5 - 7), are considered the gold standard for judg-
ing benefits of treatment because it is conceptually easier to attribute found effects to 
the intervention under interest. The study has been reported in correspondence to the 
CONSORT guidelines [21] and was registered in a trial register (NTR) prior to start of patient 
recruitment. In this superiority trial, we compared the effect of an active psychological 
intervention with a care as usual group. Due to the absence of an active attention control 
group, we cannot be certain that the effects are attributable to the intervention rather 
than to therapist attention (or other generic aspects of therapy) in itself. Interestingly, 34% 
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of the participants in the control condition also decided to seek and accept psychological 
help during the study period. While we are unsure of the exact reason, we know from 
personal correspondence that some sought help for anxiety-related complaints.
The incidence of patient availability sharply decreases when a clinical trial begins 
and returns to its original level as soon as the trial is completed” - Lasagna’s law [22]
3.2 Recruitment challenges & Participants.
Despite our efforts to gain realistic estimates of patient availability and participation 
interest (chapter 5), recruitment for the trial proved to be challenging. Two recruit-
ment strategies were used: 1) The nurse or clinician invited patients to the study during 
routine follow-up visits and 2) Study information was sent to patients by mail (prostate 
cancer survivors only). Despite using a multi-center recruitment strategy and providing 
recruiters with education and support, recruitment was threatened by several factors. 
As described in chapter 7, due to the care as usual control group patients were also 
referred to receive psychosocial support outside study context. Nurses indicated that 
they did not always want to refer a patient to the study because of the potential risk 
for the patient to be randomized to the control condition. Secondly, nurse specialists 
reported that patients with a more avoidant coping style were reluctant to accept any 
kind of extra support when offered help. Thirdly, not all health care professionals were 
willing to consecutively ask patients for study participation but only approached those 
whom left the impression to have high FCR. It is therefore possible that a number of 
eligible patients were missed. This resulted in a smaller sample than initially planned, 
which may have compromised the validity of our findings. Systematic screening for high 
FCR is recommended to ensure that those who are burdened by FCR are timely identi-
fied and can be referred to receive extra psychosocial support.
In chapter 7 we saw that a number of patients with a CWS score ≥14 declined study 
participation because they felt their FCR was not severe enough to accept help. This 
phenomenon has been reported before. While many cancer survivors cope with prob-
lems such as distress or pain despite being aware that health care service are available 
to support them, less than a quarter report actually using them [23-25]. Furthermore, a 
meta-analysis by Brebach et al., (2016) reported that the uptake rate for psychological 
interventions was actually lower for those who actually had a significant clinical problem 
(in this case high distress) than those with a non-clinical concern. To tackle this problem 
it could be considered to provide health care professionals with more education about 
how to offer people psychological interventions so that patients are more willing to 
take it up. Also, in chapter 7, we found that some patients classified as having low FCR 
- based on the CWS cut-off – were willing to accept psychological help but could not 
participate because they did not meet the eligibility criterion for high FCR.
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3.3 Screening for high FCR.
Methodological problems of the CWS have already been addressed in the first part of 
the general discussion. A few patients who were classified as high fearful with the CWS 
were regarded as low fearful by the treating therapist. In order to prevent patients with 
low FCR entering trials for high FCR, a semi-structured interview such as the SI-FCR 
can be used, or if only self-report questionnaires are available, a questionnaire with a 
more solid validation procedure (using an interview as gold standard) has preference. 
However, timing of screening may have influenced the discrepancy between screening 
scores and therapist ratings on initial assessment. Some patients were asked to com-
plete the CWS within two days after medical follow-up, and it is known that those with 
normal FCR may show a temporary increase in FCR around time of follow-up [26]. Start 
of bCBT was approximately four weeks after screening. Again, if we look to the DSM-V for 
our understanding of mental disorders, we see that in the current definition of FCR there 
is no fixed set of criteria (e.g. time of onset, duration of complaints) that is to be met in 
order to classify someone as having high or clinical FCR [27]. With the currently available 
tools, someone can be classified as having high if their complaints have been present for 
two weeks, two months or two years. While we know that high FCR appears to be stable 
over time [2], situational circumstances may still lead to a short-term FCR increase (or 
decrease) and should always be taken into account as well.
box 3. Methodological considerations
– Future FCR intervention studies may benefit from the inclusion of an active 
control condition to determine if there is an additional benefit of the inter-
vention over therapist attention and other generic therapy variables.
– As for many clinical trials, patient recruitment proved challenging due to 
barriers at both the organization and patient level. Selection bias may have 
influenced the generalizability of the findings.
– Training health care professionals in how and when to offer patients a psy-
chological intervention may improve patient identification and intervention 
uptake rates. Systematic screening for high FCR is thereby encouraged.
– When screening for high FCR in an intervention trial, a need-of-help question 
could be added to identify those survivors who have need for support in deal-
ing with FCR.
– It should be considered to use (semi-)structured interviews to detect high 
FCR rather than self-report questionnaires.
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4. ClInICAl ConsIDeRATIon fRoM sWoRD.
4.1 Blended care in clinical practice.
Working with a website is new to many patients and therapists and demands commit-
ment, skills and willingness from both. If used correctly, therapists can continuously 
monitor a patients’ online progress and may provide intermittent feedback on assign-
ments. Face-to-face meetings can be replaced with e-consults and, given the fixed 
format of the website and assignments, face-to-face sessions may be less susceptible 
to therapist drift [28]. For instance, in chapter 7 we found good protocol adherence for 
both therapists. Other benefits of blended care include less patient visits to the hospital 
and continuous access to online materials [29]. Studies that have addressed the clinical 
and cost-effectiveness of bCBT are still limited but in chapter 7 we found that the effect 
size was in the upper range of effect sizes found for individual face-to-face therapy for 
anxiety [30]. There is still not much known about the optimal way to ‘blend’ online and 
face-to-face sessions; it could be that those with severe FCR need more intensive treat-
ment including face-to-face sessions than those with moderate FCR. Also, the risk of 
cancer increases with age, with a sharp rise in incidence for those 65 years or older [31]. 
In the 65+ age group, around 80% of the Dutch elderly are connected to the internet 
and 55% uses the internet on a daily base [32]. This means that at least 20% cannot 
benefit from blended care delivered online and alternatives should be available to them. 
In line with this, despite having an internet connection we found that some elderly 
male patients participating in the SWORD-study (chapter 7) requested to work with 
the workbook due to computer illiteracy. Finally, when using blended care (or ehealth) 
interventions, technical difficulties, including but not limited to, non-working chat 
application, poor sound quality, and unsupported web browsers are to be expected. 
For future clinicians and researchers it is recommended that technical support by an IT 
company should be available for both therapist and patient to access.
4.2 Uptake and adherence of bCBT.
For bCBT to be effective for high FCR in clinical practice, it is important that cancer 
survivors are willing to accept the intervention (“uptake”) and do not drop-out before 
the intervention has been completed (“adherence”) [33]. In the SWORD-study it was 
not possible to calculate the actual uptake rate (that is, cancer survivors with high FCR 
actually willing to participate in the trial) because we did not screen a consecutive 
sample, Future studies should aim to gather further data on the uptake of the SWORD 
intervention as this will be important for its implementation in routine care. Informa-
tion on adherence was available. Of the participants who started bCBT, 66% completed 
all eight sessions (chapter 7). For four patients willing to complete the intervention, 
therapy ended prematurely because of therapist sick leave. The majority of the other 
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intervention drop-outs occurred in the first three sessions for a variety of reasons; either 
treatment did not meet patient expectations, other presenting problems were more 
prominent requiring a different type of intervention or unforeseen life events prema-
turely interrupted therapy.
Therapist adherence to the treatment manual was satisfactory and so was patient 
compliance. Patients logged in to the website approximately once a week, with mean 
online login duration of nearly half an hour and completed near all homework assign-
ments (+/- 90%). Frequency and duration of login were substantially higher than the 
results of recently published unguided web-based self-management interventions for 
cancer distress would suggest [34,35]. In the SWORD-study, patients were aware that 
their online progress was being monitored and they were told that completed assign-
ments would be discussed with their therapist during the next face-to-face session (or 
e-consult). This guided approach may have been very encouraging for patients. Beatty 
et al., (2016) found in their review on predictors of adherence in online psychosocial 
interventions that lack of feedback or personal contact was associated with low adher-
ence and that guided interventions seemed to result in better adherence [36].
4.3 Generalizability of the SWORD findings to clinical practice.
It is not known to what extent the results of RCTs on FCR interventions in cancer survi-
vors (‘efficacy’) can be generalized to real life clinical practice (‘effectiveness’). External 
validity is often threatened by selection bias due to selective recruitment. In the SWORD-
study (chapter 5 & 7) we intended to recruit a consecutive sample, but we ended up 
with a convenience sample. The sample consisted of breast, colorectal and prostate 
cancer survivors six months up to five years post-cancer treatment. The intervention was 
developed and tailored to these three tumor types and it is not known what effect bCBT 
has for cancer survivors with a different cancer diagnosis. Therapists who delivered the 
intervention were both enlisted as health-care psychologists in the health professional-
register (BIG), had each more than 10 years of work experience with cancer survivors, 
worked in an academic setting, received bCBT training and attended biweekly group 
supervisions. The expertise level may have contributed to the high intervention effect. It 
remains to be seen if this effect can be replicated in regional health-care centers where 
less resources are available. Furthermore, although relevant to the Dutch population, 
the generalizability of these results to other countries is not known. Factors that may 
have bolstered the generalizability of our findings included patient recruitment from 
both academic and regional hospitals, lack of stringent inclusion and exclusion criteria 
for participation, a primary intention-to-treat analysis with a conservative method to 
deal with missing data (last observation carried forwards) and little (missing at random) 
study drop-out.
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box 4. blended care
– Blended therapy is a novel therapeutic approach. It requires commitment, 
skills and willingness from both patient and therapist.
– The “optimal blend” between online and offline therapy components is still 
unknown.
– bCBT showed good adherence by both therapist and patient. The website 
was visited weekly and almost all assignments were completed.
– Not all patients were skilled enough to use the website so alternatives should 
be available to them.
– Several patient and environmental factors may have influenced the external 
validity of our findings on the efficacy of bCBT for FCR.
5. fUTURe ReseARCH DIReCTIons In fCR MAnAGeMenT
5.1 Long-term effects research.
Only one intervention trial, comparing group CBT with group supportive-experiential 
therapy (SET) and a no treatment control group has to date reported on the long-term 
effects [37]. Herschbach et al., (2011), found a reduction in fear of progression (a concept 
related to FCR) for both interventions. We should be informed on whether a blended 
care intervention also has lasting beneficial effects. In the SWORD-study, chapter 7, FCR 
severity has also been assessed at 6 and 12 months’ post-intervention (and at similar 
time points for the control group). It is planned to analyze and document these findings 
once follow-up data collection is completed. An advantage of blended therapy for long-
term efficacy is that the website can remain available after ending face-to-face sessions 
with the therapist.
5.2 Economic evaluation of FCR interventions.
Psychological interventions for cancer survivors, especially intensive, multi-session, 
face-to-face therapies, can be rather costly. Previous literature suggests that high FCR 
is associated with increased health care use and societal costs [38-40]. Today, interven-
tions not only need to be effective on both the short- and long-term in order to qualify 
for coverage by insurance companies; but cost-effectiveness needs to be demonstrated 
as well. Economic evaluations of interventions are therefore an important next step in 
FCR research [41].
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5.3 What works for whom and why?
In chapter 7 we saw that not everyone benefitted from the intervention. While no par-
ticipants showed worsening of FCR, there were a few patients who had no benefit from 
therapy at all. The case study (chapter 6) was in detail analyzed and provided us with 
possible reasons why the therapy worked for this specific patient, such as good under-
standing of the therapist formulation and positive expectation of the therapy following 
initial assessment and problem formulation. Unfortunately, we were not able to gather 
similar detailed information for those treated with bCBT (chapter 7). Demographics 
have often been investigated in relation to therapy effect, with mixed results. For in-
stance, Chilcot et al., (2014) investigated moderators of CBT for menopausal symptoms 
following breast cancer and found that symptom level (of distress) and beliefs about 
coping at baseline but not demographics were the main predictors of therapy effect 
[42]. Studies in chronic pain confirmed the importance of perceived control and coping 
[43]. Variables with a strong conceptual link to the intervention have been investigated 
as well, for instance, Renaud et al., (2014) found that those who were better at iden-
tifying and articulating thoughts and feelings, gained most from CBT for anxiety and 
depression [44]. Furthermore, self-reported cognitive functioning was related to success 
of CBT in fatigued cancer survivors [45].
What may have also played a role is that in chapter 7, some people were screened as 
having high FCR but were not rated as having high FCR by skilled therapists. Perhaps 
those people didn’t improve because they didn’t need it in the first place. Knowing who 
benefits most from the intervention has important consequences for the allocation 
of limited health care resources and the ability of professionals to tailor therapy. It is 
therefore an area of concern for future FCR studies.
5.4 FCR-specific or generic interventions.
Evidence is accumulating that FCR-specific interventions are effective in reducing FCR 
severity. However, the benefits of FCR-specific over generic interventions for cancer sur-
vivors are unclear. There is some evidence that generic interventions (i.e. those targeting 
a broad range of psychological problems) may also be effective in managing FCR. Two 
studies by Lengacher at al., (2009; 2011) that investigated the effects of Mindfulness 
Based Stress Reduction (MBSR) in emotionally distressed breast cancer survivors also 
reported a significant decline in FCR [46-47]. The generic approach is often considered 
cheaper to deliver (as it applies to many more patients and not only those high on FCR), 
but patients with severe FCR may need and wish more intensive treatment and do less 
well with these generic interventions than those with only moderate complaints. There 
have been no direct comparisons in treatment outcomes between FCR-specific and 
generic interventions. Future studies should address this gap. A further limitation in ge-
neric interventions is that they often do not take into consideration the characteristics of 
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those to whom the intervention will be offered. The intervention is open to all; not only 
those who probably benefit most.
5.5 Internet-based FCR interventions.
Current face-to-face and blended care treatments for FCR can only target a minor-
ity of patients who struggle with FCR and who can access specialist psychosocial care 
through an academic center. In the future it will be important to roll out effective and 
cost-effective FCR interventions to the much larger number of cancer survivors in the 
community that struggle with FCR. As mentioned before, while around 30% experiences 
moderate-to-high FCR, low-to-moderate FCR is experienced by up to 70% of the cancer 
population. For the latter group, there is currently no extra psychosocial support avail-
able while we know that many patients would welcome extra help [48-49]. Given the 
high prevalence of FCR and poor outcomes in terms of emotional wellbeing, it might 
be worthwhile to investigate the effectiveness of an internet-based self-management 
intervention for FCR. Self-management interventions can target cancer survivors who 
experience FCR but who may not require intensive psychological therapy. Ehealth has 
already proven effective for breast cancer survivors [34] and patients with other chronic 
somatic conditions [50-51] especially when targeting disease-specific outcomes.
box 5. Research priorities in fCR management
– Investigate the long-term effects of FCR interventions.
– Investigate whether interventions for FCR are cost-effective.
– Conduct mediation and moderation analysis of therapy effects.
– Identify whether generic interventions are just as effective as FCR-specific 
interventions.
6. IMPlICATIons foR ClInICAl PRACTICe
Findings from both parts of this thesis have implications for clinical practice.
6.1 Medical healthcare professionals.
Professionals have identified high FCR as a common problem in clinical practice [52]. 
First, given the high prevalence of FCR in cancer survivors and partners (chapter 2 - 
4), many people would benefit from some extra psychosocial care for FCR. For those 
with low-to-moderate FCR, timely information provision about FCR (normalization) by 
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healthcare providers could be sufficient while for those with moderate-to-high FCR 
referral to an experienced psychosocial care professional should be considered.
Secondly, identifying high FCR in clinical practice remains a challenge. There is no 
consensus on the best self-report screening measure available to support the health-
care professional in identifying patients with high FCR. Due to its length and complexity 
the SI-FCRI, a semi-structured interview [13], may be particularly useful for psychosocial 
professionals whereas a FCR self-report questionnaire, such as the CWS or FCRI, could 
be considered by medical healthcare professionals [2,6,8]. However, informally assessing 
the frequency, duration and intensity of FCR via questioning during clinical assessment 
is also valid approach and is recommended as a supplement to the use of screening 
questionnaires. Third, healthcare professionals have an important role to play in recog-
nizing behavioral factors associated with FCR, such as increased contact with healthcare 
services or avoidance. Sometimes behaviors are hard to miss as it directly affects the 
professional himself, for instance, the frequent request for an extra medical exam or 
telephone consultation in order for a patient to feel reassured. However, behavior 
may also be less overt; a breast cancer survivor answering “yes” to the question if she 
performs breast self-exams, without mentioning that she does this up to fifteen times 
a day; or the prostate cancer survivor who cancels all his meetings with the general 
practitioner and urologist because he is too afraid for a bad result on his PSA-test. When 
in doubt, a case should be discussed in a multidisciplinary meeting, or in consultation 
with a psychosocial professional. When FCR is detected medical professionals can also 
play an important role in educating patients about FCR normalizing mild to moderate 
or transient FCR and referring those with moderate-to-high FCR for more specialized 
psychological intervention. Finally, it is important that medical professionals pay atten-
tion to FCR in partners or caregiver as well.
6.2 Psycho-oncology health professionals.
In chapter 7 we tentatively conclude that bCBT is an effective, feasible and acceptable 
psychological intervention to reduce FCR severity in breast, prostate and colorectal can-
cer survivors. If future research shows that the intervention effects are sustained at the 
long run, a logical next step would be the implementation into standard care. However 
further research is needed to explore the feasibility, acceptability and uptake outside 
of the clinical trial setting. Should the SWORD intervention proceed to implementation 
this will be the first evidence-based intervention for FCR to become widely available for 
Dutch cancer survivors.
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box 6. Recommendations
– Medical healthcare professionals should be aware of the prevalence of high 
FCR, its characteristics, available screening methods and the available options 
for psychological interventions and additional support services.
– First results of bCBT for FCR are promising. Options for implementation of this 
intervention should be explored.
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enGlIsH sUMMARY
Fear of cancer recurrence (FCR) is defined as the “fear, worry, or concern about cancer 
returning or progressing”. It has also been described as a “Sword of Damocles” that hangs 
over a patients’ head for the rest of his/her life. Some degree of FCR is considered normal 
and functional in cancer survivors; it prompts appropriate self-protective responses, such 
as staying alert for signs of a potential recurrence and adherence to medical regimens. 
However, for approximately 30-49% FCR becomes a chronic concern that detrimentally 
affects their wellbeing and daily functioning. It has also been reported to be one of the 
most frequently cited unmet needs by patients with breast, colon and prostate cancer 
survivors. High or clinical FCR tends to remain stable over time when no intervention is 
offered. Health care professionals acknowledge FCR to be a challenging problem and 
are unsure how to manage it best as there is no evidence based treatment available. FCR 
is therefore poorly addressed in clinical practice. The development and implementation 
of an evidence-based treatment for FCR is needed.
In the first part of this dissertation, three studies (chapter 2-4) were performed to get 
a better understanding of FCR in cancer survivors and partners, whereas the second part 
(chapter 5-7) reports findings from the SWORDY-study (Survivor’s Worries Of Recurrent 
Disease): a randomized controlled trial (RCT) that investigated the efficacy of blended 
cognitive behavior therapy in reducing high FCR.
In chapter 1 a general introduction to FCR was provided. The introduction showed that 
FCR research is currently plagued by definitional and assessment issues that have led 
to a strong diversity in the reported prevalence of moderate-to-high FCR rates across 
studies. It is not yet known what the distinctive clinical features of high FCR are and 
what factors (e.g. demographics or medical characteristics) place someone at risk for 
developing high FCR. Moreover, intervention studies for high FCR are scarce and form a 
priority matter. Professionals at the Radboudumc have therefore developed the SWORD 
intervention to tackle FCR in breast, prostate and colorectal cancer survivors. The 
SWORD intervention was developed as blended cognitive behavior therapy (bCBT) with 
5 face-to-face sessions and 3 e-consultations covering a three-month period. The inter-
vention is based on the theoretical framework by Lee-Jones (1997) where dysfunctional 
cognitions and behaviors are believed to be key factors in perpetuating FCR. The aim of 
the intervention was to reduce FCR severity by identifying and modifying dysfunctional 
cognitions and behaviors, and to equip cancer survivors with skills to better manage 
their own FCR.
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Part I: Understanding fCR in cancer survivors and partners
In chapter 2 the main aim was to investigate differences in FCR between colorectal 
cancer (n = 861), Hodgkin (n = 103), non-Hodgkin (n = 276), melanoma (n = 469), 
endometrial cancer (n = 688) and thyroid cancer (n = 218) survivors. Given that some 
cancers are associated with an objective higher risk of disease recurrence (for instance, 
colorectal cancer), it seemed plausible to assume that these would also experience 
more FCR than those with a low risk of recurrence (e.g. melanoma). However, we found 
that this was not the case as FCR did not significantly differ between the studied tumor 
types. We did find that a higher disease stage, shorter time since diagnosis, presence of 
comorbid conditions, a younger age and female gender were associated with higher 
FCR. Furthermore, Poorer emotional functioning, poorer mental health and, to a lesser 
extent, worse physical functioning were associated with more FCR. These findings add 
to the available literature that a number of medical (or objective) factors appear to be 
associated with FCR. However, results remain inconclusive as associations between 
medical factors and FCR have provided mostly inconsistent results. Only a younger age 
has almost consistently been identified as a predictor of FCR and there is increasing 
evidence that women report higher FCR than men.
Prostate cancer survivors remain an underserved group in psycho-oncology research. 
Prostate cancer is considered one of the most curable forms of cancer; most patients 
present with early stage disease and the five-year survival rate is nearly 100%. It is 
therefore often believed that FCR might be lower in this group than, for instance, in 
colorectal cancer survivors who have a worse prognosis. However, in chapter 3, a cross-
sectional study, we found that around third (36%) of PC survivors treated with curative 
intent reported high FCR. A percentage that is relatively comparable to percentages of 
high FCR in breast and colorectal cancer survivors (40% and 38%). These findings are in 
line with the findings from chapter 2 where FCR was found to be a universal concern 
across cancer types. Especially younger PC survivors and those treated with adjuvant 
radiotherapy were at risk for high FCR and the presence of high FCR was associated with 
a lower quality of life, more physical symptoms, higher distress and post-traumatic stress 
symptoms. While days around medical consultations and tests for prostate specific 
antigen (PSA) are considered tense times, we did not find that prostate specific antigen 
(PSA) level, time since last PSA test, or time until next PSA test were associated with 
an increase or decrease in FCR. Given the results from chapter 3, health care providers 
(urologists, radiotherapists and nurse specialists) should pay specific attention to FCR in 
this patient group and provide appropriate psychosocial care timely.
FCR not only affects the patient but also their partner. Because FCR has mainly been 
considered as a patient concern, studies on FCR in partners are scarce. In the cross-
sectional study described in chapter 4 we have therefore focused on FCR in partners 
of PC survivors (n = 168). Findings of this study illustrate that an equal proportion of 
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partners (35%) and patients (38%) experienced high FCR. Furthermore, patient FCR was 
significantly correlated with partner FCR (moderate strength relation) and was the stron-
gest contributor to partner FCR compared to demographics and patient characteristics. 
Partners with high FCR scored significantly lower on social functioning, emotional role 
functioning, mental health, general health and vitality than those with low FCR. These 
findings clearly illustrate that FCR is not only a patient concern but it also significantly 
affects their partners. Clinicians should be aware of partner FCR when delivering care to 
men with PC and future studies should further address this topic.
Part II: Managing fCR in cancer survivors
Based on part I of this dissertation we believe it is fair to say that high FCR is a common 
concern in cancer survivors and their partners (>30%) and is associated with a poorer 
wellbeing and worse functional status. The development of interventions to tackle FCR 
is thereby justified and should be a priority matter. Therefore, SWORD was developed in 
order to manage high FCR in cancer survivors.
In chapter 5 we presented the study protocol for the SWORD-study: a RCT to investi-
gate the efficacy of bCBT in reducing FCR severity. In this chapter several past, ongoing 
or planned FCR interventions by international research groups were discussed and the 
rationale and aim of SWORD were introduced. Two of the most novel aspects of SWORD 
are that the intervention was developed as individual bCBT rather than face-to-face 
therapy and that the target population included an equal ratio of both male and female 
cancer survivors. This chapter further described the development of the intervention 
which started with a needs assessment, followed by the development of the interven-
tion (manual, workbook and website), input from an advisory committee (patients 
and professionals), the website usability test and a pilot study. Key components of the 
intervention (psycho-education, cognitive restructuring and behavioral modification) 
and the study were described in great detail.
In Chapter 6 we described a classical, illustrative, explorative case study (n = 1) not 
purely aimed to define efficacy of the intervention, but rather to provide insight in the 
therapy process for NG: a 61-years old BC survivor with high FCR. NG was the first high 
fearful patient who was referred to the department of Medical Psychology and was 
therefore offered the intervention in its pilot phase. We found that perceived control 
over FCR increased during therapy (with a sharp increase after the third session) and FCR 
severity declined to a level of FCR similar to the normative BC population. This clinically 
significant improvement was still evident at the long-term follow-up assessments (6 
and 12 months post-therapy) and was supported by secondary outcomes; an increase 
in quality of life domains while distress, anxiety and post-traumatic stress symptoms 
(avoidance and intrusive thoughts) had declined after therapy. Qualitative evaluations 
with the patient, nurse specialist and therapist confirmed the quantitative findings. For 
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NG the therapy was feasible and acceptable. New insights gained were 1) that therapy 
should be tailored to meet a patients’ need (e.g. using relaxation vs. mindfulness exer-
cises) and 2) that partners should be offered to opportunity to participate in therapy as 
well as social support is an important perpetuating factor of FCR. These insights were 
implemented in the final treatment protocol as investigated in the SWORD-study.
After carefully designing and testing the intervention in a pilot study, a RCT was 
conducted in order to investigate the efficacy of bCBT for high FCR in cancer survivors. 
The results of this study have been reported in chapter 7. A total of 88 high fearful 
cancer survivors (6 months to 5 years post curative treatment) were randomly allocated 
to receive bCBT (n=45) or care as usual (CAU, n=43). All participants completed ques-
tionnaires prior to therapy (baseline assessment) and three months later (follow-up). 
For those in the intervention condition bCBT took place between baseline and follow-
up; those in the CAU condition did not receive bCBT. Primary study outcome was FCR 
severity and secondary outcomes included anxiety, depression, distress and quality of 
life. All analyses were based on intention-to-treat with last observation carried forwards 
to handle missing data at follow-up (6%). Sensitivity analysis for handling missing data 
confirmed robustness of our findings. Results showed that bCBT was significantly more 
effective than CAU in reducing FCR severity with a moderate-to-large effect size (d = 
0.76). Secondary outcomes supported our primary findings and showed an increase in 
quality of life whereby indices of anxiety, depression and distress showed a decrease. 
For those receiving bCBT, the proportion of cancer survivors with clinically significant 
improvement in FCR severity (29%) and self-rated improvement (71%) was significantly 
higher than proportions in the control group (0% and 32% respectively). To conclude, 
bCBT was found to have statistically significant and clinically important effects in reduc-
ing FCR severity in male and female cancer survivors.
Finally, in chapter 8, the findings of the studies presented in this dissertation were 
placed into a broader perspective and were discussed by major themes. Implications for 
future research and clinical practice were proposed.
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neDeRlAnDse sAMenvATTInG
Angst voor de terugkeer van de ziekte (in het Engels  “Fear of Cancer Recurrence”, afge-
kort FCR) wordt omschreven als “angst, zorgen of bezorgdheid dat de kanker terugkeert 
of zich verder uitbreidt”. Patiënten vergelijken FCR ook wel met het Zwaard van Damo-
cles dat hen figuurlijk boven het hoofd hangt voor de rest van het leven. Voor iemand 
die geconfronteerd wordt met de diagnose kanker is FCR een begrijpelijke en invoelbare 
emotie die niet prettig maar soms wel functioneel is. Het zorgt er bijvoorbeeld voor dat 
men alert blijft op lichamelijke veranderingen of symptomen die een mogelijk recidief 
indiceren. Bij een deel van de patiënten met kanker is deze angst echter dermate sterk 
aanwezig dat dit het dagelijks functioneren en psychisch welbevinden negatief beïn-
vloedt. Internationaal onderzoek laat zien dat dit bij ongeveer 30-49% van de patiënten 
het geval is. Niet alleen komt FCR vaak voor maar tevens wordt het als belangrijkste 
onvervulde behoefte aangemerkt. Daar komt bij dat FCR niet spontaan afneemt over 
tijd waardoor extra psychosociale ondersteuning voor een grote groep patiënten geïn-
diceerd is. Op dit moment is er echter nog geen eensgezindheid onder psychosociale 
hulpverleners over hoe FCR het beste behandeld kan worden. Het gevolg hiervan is dat 
therapeuten vaak terug grijpen op therapeutische tools waar zij het beste mee bekend 
zijn; met wisselende successen als resultaat. Het ontwikkelen en implementeren van een 
evidence-based behandeling voor FCR is daarom voor zowel de patiënt als de therapeut 
belangrijk.
Dit proefschrift is volledig gewijd aan FCR. In het eerste deel (Part I) zijn drie studies 
uitgevoerd (hoofdstuk 2 – 4) met als doel een helder beeld te krijgen van de kenmer-
ken en ernst van FCR in Nederlandse patiënten en hun partners. Het tweede deel (Part 
II) beschrijft de ontwikkeling en evaluatie van een psychologische behandeling van 
FCR (hoofdstuk 5-7). De SWORD-studie (Survivor’s Worries Of Recurrent Disease), een 
gerandomiseerd gecontroleerd onderzoek (RCT) naar het effect van blended cognitieve 
gedragstherapie (bCBT) op FCR, is in deel II uitgebreid beschreven.
In hoofdstuk 1 zijn recente wetenschappelijke ontwikkelingen en nieuwe klinische 
inzichten omtrent FCR besproken. Hierin komt duidelijk naar voren dat het onderzoek 
naar de prevalentie en kenmerken van FCR wordt bemoeilijkt door onenigheid tussen 
professionals over de definitie van FCR én onduidelijkheid over het meest geschikte 
meetinstrument om FCR in kaart te brengen. Het gevolg hiervan is een sterke diversiteit 
in de gerapporteerde prevalentie van FCR in wetenschappelijke publicaties. Daarnaast 
is het nog onduidelijk wat de belangrijkste klinische kenmerken van hoge FCR zijn en in 
welke mate demografische en medische variabelen hieraan bijdragen.
Op dit moment ontbreekt het aan een evidence-based behandeling voor FCR en is 
er slechts een handjevol interventiestudies gepubliceerd. Dit is voor het Radoudumc 
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een reden geweest om de SWORD interventie te ontwikkelen, een behandeling voor 
patiënten met borstkanker, prostaatkanker of darmkanker met hoge FCR. De SWORD 
interventie is ontwikkeld als een ‘blended care’ cognitieve gedragstherapie (bCBT) 
bestaande uit vijf face-to-face sessies met een psycholoog en 3 elektronische consulten 
(“chatsessies”) verspreid over een periode van drie maanden. Het theoretisch model 
onderliggende aan de interventie is het model van Lee-Jones (1997). Volgens dit model 
spelen disfunctionele gedachten en gedragingen een zeer belangrijke rol bij het in stand 
houden van hoge FCR. bCBT grijpt in op deze disfunctionele gedachten en gedrag, met 
als doel de angst te verminderen en de patiënt nieuwe vaardigheden bij te brengen 
zodat zij meer grip op FCR krijgen.
Deel I: Het in kaart brengen van fCR in patiënten met kanker en partners
Het doel van de cross-sectionele studie in hoofdstuk 2 was om de gemiddelde niveaus 
van FCR tussen de volgende zes patiëntengroepen met elkaar te vergelijken, patiënten 
met: colorectaalkanker (n = 861), Hodgkin (n = 103) en non-Hodgkin lymfoom (n = 276), 
melanoom (n = 469), endometrium kanker (n = 688) en schildklierkanker (n = 218). De 
veronderstelling was dat patiënten met een objectief slechtere prognose (die daarmee 
dus meer risico lopen op een recidief, o.a. patiënten met colorectaalkanker) meer FCR 
zouden rapporteren dan patiënten met een gunstigere prognose (o.a. melanoom). Dit 
bleek echter niet zo te zijn: het gemiddelde niveau van FCR was vergelijkbaar tussen 
alle hier bestudeerde patiëntengroepen. Wel bleek dat een verder gevorderd ziektesta-
dium, een kortere tijd nabij diagnose, de aanwezigheid van comorbiditeit, een jongere 
leeftijd en vrouwelijk gender geassocieerd waren met meer FCR. Met betrekking tot de 
relatie tussen FCR en kwaliteit van leven werd gevonden dat een slechter emotioneel 
functioneren, een slechter mentaal welbevinden en, in mindere mate, een verminderd 
fysiek functioneren tevens geassocieerd waren met meer FCR. Deze bevindingen komen 
overeen met wat er eerder al bekend was in de wetenschappelijke literatuur over FCR.
Ondanks dat prostaatkanker een van de meest voorkomende vormen van kanker bij 
mannen is blijft onderzoek naar het psychosociaal functioneren en het inzetten van 
psychosociale interventies bij deze patiëntengroep achter. Prostaatkanker wordt ook 
wel gezien als een van de best behandelbare vormen van kanker: de diagnose wordt 
vaak vroegtijdig gesteld en de meeste tumoren beperken zich bij diagnose nog lokaal 
tot de prostaat. Hierdoor is curatieve behandeling bij het merendeel nog een optie. Voor 
patiënten met prostaatkanker is de relatieve vijfjaarsoverleving nagenoeg 100% en een 
recidief kan vaak goed behandeld worden. De veronderstelling is daarom dat hoge 
FCR in patiënten met prostaatkanker minder prevalent is. In hoofdstuk 3 is daarom 
de prevalentie van hoge FCR in 288 curatief behandelde patiënten met prostaatkanker 
onderzocht in een cross-sectionele studie. In deze studie werd gevonden dat ongeveer 
een derde (36%) van de onderzochte groep last heeft van hoge FCR. Dit percentage is 
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vergelijkbaar met het percentage patiënten met borstkanker en darmkanker dat hoge 
FCR rapporteert (40% en 38%). Het ondersteunt tevens de bevinding uit hoofdstuk 2 
dat FCR een universeel probleem is onafhankelijk van prognose. Voornamelijk jonge 
patiënten met prostaatkanker, en patiënten die aanvullend werden behandeld met 
radiotherapie, rapporteerden meer FCR. Personen met hoge FCR rapporteerden op 
hun beurt een lagere kwaliteit van leven, meer fysieke klachten, meer distress en meer 
symptomen van posttraumatische stress dan patiënten met lage FCR. Ondanks dat 
routine prostaat specifiek antigen (PSA) onderzoek door patiënten wordt aangemerkt 
als een zeer spannende gebeurtenis is in hoofdstuk 3 geen relatie gevonden tussen FCR 
enerzijds en PSA-level, tijd sinds laatste PSA-test of tijd tot volgende PSA-test anderzijds. 
Uit dit hoofdstuk kan geconcludeerd worden dat FCR een significant probleem is voor 
patiënten met prostaatkanker en dat het belangrijk is voor zorgverleners (urologen, 
radiotherapeuten en verpleegkundigen) om specifiek aandacht te besteden aan dit 
probleem in deze patiëntengroep. Patiënten met hoge FCR dienen tijdig doorverwezen 
te worden voor gespecialiseerde psychosociale hulp.
Niet alleen patiënten maar ook partners kunnen FCR ervaren. Omdat FCR tot op heden 
vooral als een probleem van de patiënt werd beschouwd is er zeer beperkt onderzoek 
gedaan naar FCR in partners van patiënten met kanker. In hoofdstuk 4 hebben we in 
een cross-sectioneel onderzoek gekeken naar de prevalentie en kenmerken van FCR in 
partners van patiënten met prostaatkanker (n = 168). In deze studie werd gevonden dat 
een vergelijkbare proportie partners (35%) als patiënten (38%) hoge FCR rapporteert. Er 
was een significante samenhang tussen de hoogte van FCR zoals gerapporteerd door 
de patiënt en door de partner. Daarnaast bleek patiënt gerapporteerde FCR de beste 
voorspeller van partner gerapporteerde FCR. Partners die hoog scoorde op de FCR vra-
genlijst scoorde significant lager op sociaal functioneren, emotioneel rol functioneren, 
mentaal welbevinden en rapporteerde een lagere algemene gezondheidstoestand en 
minder vitaliteit dan partners met lage FCR. De bevindingen uit hoofdstuk 4 tonen aan 
dat FCR niet alleen een zorg voor de patiënt is, maar ook zeker voor de partners. De aan-
beveling is dan ook dat toekomstig onderzoek zich meer gaat richten op de belevenis 
van FCR in partners zodat ook zij de mogelijkheid krijgen om tijdig hulp voor omgang 
met FCR te zoeken.
Deel II: Het behandelen van fCR
De bevindingen van deel I van dit proefschrift tonen aan dat FCR een veelvoorkomend 
probleem is in patiënten met kanker en hun partners. Niet alleen is de prevalentie van 
hoge FCR substantieel (>30%) maar daarnaast gaat FCR gepaard met een verminderd 
emotioneel welbevinden en een slechtere functionele status. De ontwikkeling van een 
interventie om FCR te verminderen had daarom prioriteit. Om deze reden is de SWORD-
studie tot stand gekomen: een gerandomiseerd gecontroleerd onderzoek (RCT) waarin 
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de doelmatigheid van een blended cognitieve gedragstherapie (bCBT) op verminde-
ring van FCR is onderzocht. In hoofdstuk 5, het gepubliceerde studieprotocol van de 
SWORD interventie, is een samenvatting gepresenteerd met daarin een beschrijving van 
afgeronde, lopende en toekomstige FCR interventiestudies. In vergelijking met deze 
reeds beschreven studies heeft de SWORD interventie twee duidelijke vernieuwende 
aspecten, allereerst het feit dat de interventie is ontwikkeld om als blended care ingezet 
te worden (in plaats van face-to-face), en ten tweede dat de onderzoekspopulatie van 
SWORD bestaat uit andere patiëntengroepen. Het ontwikkelproces van de SWORD 
interventie bestond uit een behoefte-onderzoek (is er behoefte aan hulp voor FCR?), 
gevolgd door de ontwikkeling van de interventie zelf waarbij input en feedback van 
een leescommissie (patiënten, professionals) is gevraagd. Daarnaast hebben patiënten 
deelgenomen aan de usability testing van de website en de pilotstudie. Kerncompo-
nenten van de SWORD interventie zijn psycho-educatie, cognitieve herstructurering en 
gedragsverandering.
Meer informatie over hoe de interventie in de praktijk gebruikt kan worden staat 
beschreven in hoofdstuk 6. Dit hoofdstuk presenteert een klassieke, exploratieve case-
studie (n=1) die inzicht geeft in het therapeutisch proces voor een 61-jarige patiënte 
met borstkanker (NG). NG was de eerste patiënte die voor de SWORD-studie aangemeld 
werd en de interventie heeft doorlopen. Resultaten bij NG waren veelbelovend. De 
tussentijdse grip-op-angst metingen lieten zien dat de waargenomen controle over 
angst tijdens bCBT stapsgewijs is toegenomen (met een scherpe stijging na de 3e ses-
sie). Daarnaast bleek op de vragenlijstmetingen (direct na afronding van therapie) dat 
de ernst van FCR gedaald was tot een niveau vergelijkbaar met dat van niet verhoogd 
angstige patiënten met borstkanker. Deze klinisch significante verbetering was nog 
steeds duidelijk zichtbaar tijdens de metingen op 6 en 12 maanden na afronding van 
de behandeling. Niet alleen was er een significante vermindering in FCR, tevens was 
een verbetering zichtbaar in kwaliteit van leven, een vermindering van generieke angst, 
minder distress en rapporteerde NG minder symptomen van post-traumatische stress 
(vermijding en intrusieve gedachten). Deze kwantitatieve bevindingen (verkregen uit 
vragenlijstmetingen) werden ondersteund met kwalitatieve bevindingen uit evaluaties 
met NG zelf, haar verpleegkundige en de therapeut. Nieuwe inzichten die in deze case-
studie zijn opgedaan: 1) de therapie moet worden afgestemd op de behoefte van de 
patiënt (“tailored approach”) en 2) partners moeten ook de kans krijgen om de patiënt 
te vergezellen tijdens bCBT voor FCR. Deze inzichten zijn in het definitieve behandelpro-
tocol verwerkt alvorens met de RCT te starten.
In hoofdstuk 7 zijn de resultaten van de SWORD effectstudie (RCT) gepresenteerd. In 
totaal hebben 88 patiënten met hoge FCR aan de studie deelgenomen. Alle patiënten 
hadden de medische behandeling voor kanker reeds 6 maanden tot aan 5 jaar geleden 
afgerond. Na het invullen van vragenlijsten werden zij gerandomiseerd naar de inter-
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ventie groep (de groep die bCBT krijgt) of de controle groep (die ‘care-as-usual’ krijgt). 
Alle deelnemers aan het onderzoek hebben op baseline (T0, voor randomisatie) en drie 
maanden later (T1, follow-up) psychologische vragenlijsten ingevuld. Voor patiënten in 
de interventie groep vond bCBT plaatst tussen het T0 en T1. Patiënten in de controle 
groep kregen geen bCBT. De primaire uitkomstmaat van het onderzoek was ernst van 
FCR gemeten met de Cancer Worry Scale op T1. Secundaire uitkomstmaten waren onder 
meer: angst, depressie, distress en kwaliteit van leven. ANCOVA werd uitgevoerd om 
de scores van beide groepen op T1 met elkaar te vergelijken. Analyses waren allen 
op basis van intention-to-treat (ITT), waarbij last observation carried forwards (LOCF) 
werd toegepast om missende waarden op T1 in te vullen. Uit de resultaten bleek dat 
patiënten die bCBT hebben gehad na drie maanden (T1) een significant lager niveau van 
FCR rapporteerde dan patiënten in de controle conditie die geen behandeling hadden 
ontvangen, met een grote effect size (d = 0.76). Ook op de secundaire uitkomstmaten 
werden significante verschillen tussen de twee groepen gevonden: patiënten die bCBT 
hadden ontvangen rapporteerde een betere kwaliteit van leven, minder angst, minder 
depressieve symptomen en minder distress dan patiënten in de controle conditie op T1. 
Daarnaast liet de bCBT groep meer klinisch significante verbetering in FCR zien (29%) 
en rapporteerde ze frequenter een subjectieve verbetering in FCR (71%) dan personen 
in de controle conditie (respectievelijk 0% en 32%). Kortom, bCBT bleek een effectieve 
behandeling voor FCR met zowel statistisch significante als klinisch relevante effecten in 
een populatie van mannelijke en vrouwelijke patiënten met kanker.
In hoofdstuk 8 (de discussie) zijn de bevindingen uit eerder beschreven hoofdstuk-
ken in perspectief geplaatst en geïntegreerd in de bestaande internationale literatuur 
over FCR. Dit is gedaan aan de hand van verschillende prominente thema’s.
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Aan het onderzoek en de totstandkoming van dit proefschrift hebben velen bijgedra-
gen en zonder hen zou dit proefschrift niet zijn geworden tot wat het nu is. Er zijn enkele 
personen die ik in het bijzonder wil bedanken.
De deelnemers en deelnemende ziekenhuizen. Allereerst gaat mijn dank uit naar alle 
patiënten die tijd hebben vrijgemaakt om deel te nemen aan het invullen van de vra-
genlijsten, zitting hebben genomen in de leescommissie, een bijdrage hebben geleverd 
aan de ontwikkeling van het behandelprotocol of het testen van de website. Daarnaast 
gaat mijn dank uit naar alle betrokken artsen en verpleegkundigen: bedankt voor jullie 
inzet om van mijn onderzoek een succes te maken!
Mijn promotoren. Beste Judith, bedankt voor het vertrouwen dat jij de afgelopen jaren 
in mij hebt gehad. Zowel mijn persoonlijke als professionele ontwikkeling heeft hier-
door een enorme boost gekregen. Jij hebt mij gestimuleerd om het meeste uit mezelf 
en uit mijn onderzoeksprojecten te halen. De steun die ik van je heb gekregen toen ik de 
overstap naar de praktijk maakte heeft veel voor me betekend. Beste Anne, tijdens het 
vormgeven van het project en de voortgangsgesprekken wist jij altijd met een frisse blik 
naar de lopende zaken te kijken. Je feedback was zeer waardevol.
Mijn co-promotoren. Beste Marieke, ontzettend bedankt voor de prettige samenwerk-
ing die wij hebben gehad. Je kritische blik en rode pen waren soms gevreesd maar 
hebben mijn publicaties aanzienlijk verbeterd! Dear Belinda, it has been a true pleasure 
working with you. Thank you for showing me the perks of collaboration and for intro-
ducing me to many of your acquaintances and former colleagues.
sWoRD-support. Petra en Dennis. Bedankt voor jullie tijd, inzet en flexibiliteit. Ik kijk 
terug op een drukke (soms wat chaotische) periode met te allen tijde een fijne samen-
werking. Door de onvoorspelbaarheid van de inclusie heb ik soms jullie agenda’s vol 
gepropt met patiënten en de werkdruk flink opgevoerd zonder dat ik daar ooit gemop-
per over heb gehoord! (Oke, één keertje dan). Jacintha en Brenda, vooral bedankt voor 
de gezelligheid en jullie organisatorisch talent! Het randomiseren van patiënten was 
dankzij jullie toch altijd wel een klein feestje te noemen.
Mijn kamergenootjes. José, Sanne, Lynn, Annemiek, Harriët, Hanneke, Amilie, Juliane, 
Simone, Marloes, Eelke en Emiel. Het is onmogelijk om een saaie dag te hebben wan-
neer je een kamer deelt met jullie. Bedankt voor de gezelligheid, steun en het luisterend 
oor. Niet alleen was het fijn om even met jullie te sparren maar ook kon ik bij jullie naar 
hartenlust mopperen over de tegenslagen die je te verduren krijgt als promovenda. 
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Gelukkig heb ik velen van jullie al mogen uitzwaaien en voor de rest kom ik graag op 
korte termijn terug.
Mijn collega’s van het Radboudumc. Niet alleen van de afdeling Medische Psychologie 
maar ook zeker de afdeling Medisch Oncologie en het Centrum voor Mindfulness. Van 
harte bedankt voor de prettige werksfeer en collegialiteit! Beste collega’s van de onder-
zoeksgroep Psychosociale Oncologie, Journal Club, Trial Club en de Gammaraad: het is 
een deugd geweest om met jullie te werken en om van jullie te leren.
Mijn collega’s van het Máxima Medisch Centrum. Mijn liefde voor het werk als psy-
choloog in een ziekenhuis is bij jullie begonnen en gegroeid. Het is dan ook fantastisch 
dat ik nu weer in jullie gezelschap verkeer. Iedere dag ga ik met een lach op mijn gezicht 
naar het werk. Thanks!
Mijn familie. Lieve pap en mam, zonder jullie lag dit proefschrift vandaag niet op tafel. 
Al van kleins af aan hebben jullie mij mijn eigen keuzes laten maken en onvoorwaardelijk 
gesteund: zo ook tijdens mijn promotieonderzoek. Bedankt voor het luisterend oor en 
de veilige omgeving die jullie mij geboden hebben.
Lieve oma, wat ontzettend jammer dat jij dit moment niet meer mee kunt maken. Als er 
iemand trots op mij was, dan was jij het. Ik heb je beloofd om mijn proefschrift voor jou 
af te maken en zie hier het resultaat!
Mark en Katjana, bedankt voor de afleiding, overdosis aan onzin en flauwe humor die ik 
steeds weer van jullie te verwerken heb gekregen. Dat was een welkome afwisseling in 
periodes van drukte en stress.
Mijn vrienden. Bedankt dat jullie nooit aan me hebben gevraagd “Ben je nu nóg niet 
klaar met dat boekje?” Bedankt voor de oneindige steun en support: de etentjes, de 
avondjes weg en uitstapjes hebben mij goed gedaan!
Beste paranimfen, lieve Amilie, Sylvie en Meryem. Als vier-eenheid zijn we al heel wat 
jaartjes een bijzonder clubje. Fantastisch om jullie tijdens de verdediging naast me te 
hebben staan.
subsidieverstrekker. Dit proefschrift was niet mogelijk geweest zonder de financiële 
bijdrage van KWF Nederland die de SWORD-studie heeft gefinancierd.
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CURRICUlUM vITAe
Marieke van de Wal werd op 30 augustus 1988 geboren te Tilburg. In 2005 behaalde 
zij het HAVO diploma aan het Mill-Hill College te Goirle. Na het behalen van haar HBO 
propedeuse Toegepaste Psychologie op Fontys Hogescholen te Eindhoven (2006) en 
het afronden van wiskunde op VWO niveau heeft zij haar studie voortgezet aan de 
Universiteit van Tilburg. Na het aldaar cum laude afronden van de bachelor Psychologie 
& Gezondheid heeft zij aan dezelfde universiteit gekozen voor de tweejarige mastero-
pleiding Medische Psychologie. In het tweede jaar van haar opleiding heeft zij als psy-
choloog in opleiding haar klinische stage voltooid op de afdeling Medische Psychologie 
van het Máxima Medisch Centrum Eindhoven/Veldhoven. Haar onderzoeksstage voerde 
zij uit op de afdeling Medische Psychologie en Klinische Neuropsychologie van de 
Universiteit van Tilburg en richtte zich op subjectieve cognitieve klachten bij vrouwen 
met borstkanker. In 2011 is Marieke cum laude afgestudeerd en is zij in de functie van 
basispsycholoog blijven werken op de afdeling Medische Psychologie van het Máxima 
Medisch Centrum met als aandachtsgebieden oncologie, neuropsychologie en geriatrie.
De overstap naar de wetenschap werd in februari 2013 gemaakt toen zij door het 
Radboudumc werd aangesteld als promovenda op een onderzoeksproject naar de 
effectiviteit van blended cognitieve gedragstherapie op angst voor terugkeer van 
kanker. In de laatste maanden van haar promotieonderzoek heeft Marieke part-time 
de overstap gemaakt naar de klinische praktijk en is zij haar baan als onderzoeker bij 
het Radboudumc gaan combineren met de functie van basispsycholoog bij het Máxima 
Medisch Centrum. Sinds januari 2017 is zij bij laatstgenoemde in opleiding tot GZ-
psycholoog.
Fear of cancer recurrence (FCR) is the most 
commonly reported cancer survivorship concern 
and has been consistently associated with poorer 
quality of life. The studies in the ﬁ rst part of this 
thesis aimed to develop a better understanding of 
FCR in cancer survivors and their partners. 
The studies presented in the second part describe 
the development and evaluation of a psychological 
intervention for FCR.
Understanding 
and managing 
fear of cancer 
recurrence
